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Summary /Abstract 
 
Irreversible renal fibrosis represents the final common pathway of almost all chronic 
renal diseases and ultimately leads to end stage renal failure. Excessive accumulation 
of extracellular matrix proteins distinctively characterises this fibrotic process, which 
epithelial to mesenchymal transition (EMT) is thought to play a major role in.  
This thesis explored the role of miR-200b in preventing renal fibrosis with the focus 
of its role in EMT. miR-200b was found to be important player  in  maintaining the 
characteristics of epithelial cells by  regulating transcription factors Zeb1 and Sip1 in 
proximal tubular cells. Furthermore, a direct targeting and degradation mechanism of 
fibronectin mRNA by miR-200b was also identified. Thus, miR-200b is shown to be a 
master regulator of EMT and over-expression of this miRNA may have therapeutic 
implication in patients with chronic renal diseases. 
Followed by the discovery of molecular mechanisms underlying the protective effects 
of miR-200b in renal fibrosis, the focus of the study was shifted to the various 
delivery methods aiming targeted expression of miR-200b in renal proximal tubules 
in vivo.  The efficacy of gene delivery methods such as lentivirus mediated gene 
transfer, hydrodynamic injection, ultrasound microbubble mediated gene transfer and 
nanoparticles mediated gene uptake were investigated. Expression of the transgene 
was successfully detected in the kidney in lentivirus and ultrasound microbubble 
mediated gene transfer. Optimisation of each method is still in process aiming higher 
transfer efficiency.  
In the last chapter, the role of novel protein target PMEPA1 regulated by both miR-
200b and TGFβ was also investigated using in vitro fibrosis model. However, both 
over-expression and loss of function studies demonstrated no significant changes in 
the expression level of E-Cadherin, fibronectin and collagen IV suggesting its 
involvement in pathways other than EMT. 
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1 Chapter 1 Introduction  
1.1 Transforming growth factor beta (TGFβ) signalling and renal fibrosis  
1.1.1 TGFβ signalling and renal fibrosis 
Transforming growth factor beta1 (TGFβ1) and its downstream signalling pathways 
have been recognised as the key factor in the pathogenesis of renal fibrosis in all 
forms of nephropathy, including the most common cause of end stage kidney disease, 
diabetic nephropathy. It has been implicated in all facets of progressive kidney 
disease including glomerulosclerosis, tubulointerstitial fibrosis, infiltration of 
inflammatory mediators and activation of alpha smooth muscle actin (αSMA) 
positive myofibroblasts (Carew et al., 2012; Han et al., 2000; Hills and Squires, 
2011). BB rat and NOD mouse models with spontaneous diabetes mellitus show 
increased TGFβ1 mRNA levels within 3-7 days of the onset of hyperglycaemia 
(Sharma et al., 1996), while streptozotocin (STZ) induced rat models of diabetes 
mellitus demonstrate increased TGFβ1 and its type II receptor mRNA in the kidney 
within 3 days of successful induction (Sharma et al., 1996).  
 
1.1.2 TGFβ Family 
The TGFβ super family consists of four main subgroups of secreted proteins 
including the mullerian inhibitory substance (MIS) family, the inhibin/activin family, 
the bone morphogenic protein (BMP) family and the TGFβ family (Wrighton et al., 
2009).  The TGFβ family is comprised of five different isoforms all associated with 
development of various organs, with three being expressed in mammals. It is a 
pluripotential cytokine that modulates many fundamental biological processes from 
cell growth and differentiation to tissue repair and cell apoptosis (Bottinger and 
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Bitzer, 2002; Schmierer and Hill, 2007). Several intracellular signalling pathways 
and molecules respond to TGFβ1, including the small mothers against 
decapentaplegic (SMAD) signalling pathways and SMAD independent pathways 
such as mitogen activated protein kinases (MAPK), which encompasses p38, 
extracellular regulated kinase (ERK or p42/44), c-Jun N-terminal kinase/stress-
activated protein kinase (JNK/SAPK) and the PI3-K/Akt pathway.  
The TGFβ1 gene encodes a 390 amino acid precursor that is comprised of a signal 
peptide, the active TGFβ1 molecule and a latency associated peptide (LAP) (Hills 
and Squires, 2011). TGFβ1 is secreted as an inactive form and becomes activated 
only when it is proteolytically cleaved from the signal peptide and released from 
the LAP (Gentry et al., 1988). Environmental pH plays an important role in the 
release of the TGFβ1 from LAP, a process that marks the activation of TGFβ1 
(Ribeiro et al., 1999).  
 
1.1.3 TGFβ superfamily signalling 
1.1.3.1  TGFβ1 Signalling Pathway 
Following cleavage by plasmin, matrix metalloproteinase (MMP) -2, MMP9 or 
thrombospondin 1 (Kanwar et al., 2011), active TGFβ1 can bind to the TGFβ1 
receptor II of the heteromeric TGFβ1 receptor complex, which possesses 
serine/threonine kinase activity on the cell surface. Upon binding, the TGFβ1 
receptor II is phosphorylated and subsequently activates/phosphorylates the 
cytoplasmic domain of the TGFβ1 receptor I. This results in the downstream 
phosphorylation of the classic SMAD signalling molecules, SMAD2 and SMAD3, 
which are also called the receptor regulated SMADs or R-SMADs (Dennler et al., 
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1998; Hills and Squires, 2011; Itoh et al., 2003). Activated R-SMADs then form 
oligomeric complexes with SMAD 4, which is the common SMAD before 
translocation into the nucleus (Dennler et al., 1998). Inside the nucleus, the SMAD 
complex can regulate the transcription of target genes by binding directly or 
indirectly to the relevant area on DNA with various co-factors including collagen 1 
(COL1), plasminogen activator inhibitor (PAI-1), JunB, c-Jun and fibronectin (Leask 
and Abraham, 2004; Massague and Wotton, 2000; Padgett and Reiss, 2007; Rahimi 
and Leof, 2007; Shi and Massague, 2003; ten Dijke and Hill, 2004). The inhibitory 
SMADs, namely, SMAD6 and SMAD7 antagonise the R-SMAD phosphorylation by 
blocking their access to the TGFβ1 receptor I and/or promoting the degradation of 
the receptor complex (Lan, 2008; Li et al., 2002; Nakao et al., 2002; Park, 2005; Yan 
et al., 2009). SMAD7 is also modulated by the transcription factor nuclear factor κB 
(NFκB), inflammatory cytokines and their downstream signalling pathways (Marrero 
et al., 2006; Rhyu et al., 2005; Schiffer et al., 2000). These subsequently can activate 
the transcriptional factor activator protein 1 (AP1), which in turn increases 
transcription of effector molecules such as collagen and fibronectin (Hess et al., 
2004).  
AP1 can also form a complex with R-SMADs and bind to AP1 consensus 
sequences on the promoter of TGFβ1 target genes, suggesting cross talk between 
SMAD-dependent and SMAD-independent TGFβ signalling (Mulder, 2000; 
Ziyadeh, 2004). TGFβ1 activates another cytokine, connective tissue growth factor 
(CTGF), which is considered to play  an independent role in the pathogenesis of 
diabetic nephropathy (Schmidt-Ott, 2008) by promoting extracellular matrix (ECM) 
production, cell adhesion and collagen matrix contraction in mesangial and tubular 
cells (Lan, 2011a; Murphy et al., 1999).  
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Figure1.1 TGFβ signalling pathways and various signalling molecules involved. 
Adapted from (Kanwar et al., 2011) 
 
1.1.3.2 Bone Morphogenic Protein 7 (BMP7) 
BMP7, a member of the TGFβ superfamily, is highly expressed in distal tubular 
epithelia and podocytes (Gould et al., 2002; Mitu et al., 2007). BMP7 is considered 
to antagonise the profibrogenic effects of TGFβ1 (Chen et al., 2004), and has been 
shown to be renoprotective in STZ-induced diabetic mice overexpressing BMP7 
(Wang et al., 2006). Specifically, BMP7 overexpression reduces glomerulosclerosis 
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and tubulointerstitial fibrosis by down-regulating collagen and fibronectin 
expression and increasing podocyte survival. Thus, the balance of BMP7 and TGFβ1 
may play an important role in renal disease progression. 
 
1.1.3.3 Regulation of TGFβ Signalling 
The TGFβ signalling pathway is further complicated as co-repressor molecules such 
as the  Sloan-Kettering Institute proto-oncogene (Ski), Ski-related novel gene - non 
Alu-containing (SnoN), and TG-Interacting Factor (TGIF) have also been identified 
and shown to prevent gene transcription through inhibition of R-SMADs (Luo, 
2004). Significant down regulation of these co-repressors have also been observed in 
animal models of obstructive nephropathy and diabetes (Hills and Squires, 2011; 
Masszi et al., 2004). The SMAD ubiquitination regulatory factor 2 (Smurf2) has also 
been implicated in the pathogenesis of diabetic nephropathy by affecting the TGFβ-
SMAD signalling pathway via degradation of SMAD7 and co-repressors (Fukasawa 
et al., 2006; Tan et al., 2008; Yang et al., 2003). 
 
1.2 Renal fibrosis and Extracellular Matrix Production 
Excessive deposition of ECM is a key pathological process in the development of 
renal fibrosis. The production and degradation of ECM is dynamic and highly 
regulated under physiological circumstances. Degradation of ECM is largely 
determined by MMP activity, which in turn, is under the regulation of tissue 
inhibitors of MMPs (TIMPs). Loss of the regulation of MMPs and TIMPs ultimately 
tip the balance from repair to excessive accumulation of ECM (Hills and Squires, 
2011). Decreased levels of MMP2 and MMP3 along with increased expression of 
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TIMPs has been observed in STZ-induced rat models of diabetic nephropathy 
(Catania et al., 2007a), demonstrating a complex interaction between TGFβ1, MMPs 
and TIMPs, in addition to multiple additional factors in regulating net ECM 
accumulation. 
A large proportion of the studies trying to delineate the underlying pathology of 
renal fibrosis have focused on the pathophysiology of the glomerulus and its 
constituent cells. Increasing evidence suggests renal tubular preservation is key to 
limiting functional decline (Kanwar et al., 2011). Renal tubules comprise more than 
90% of the renal parenchymal mass and the degree of tubulointerstitial fibrosis 
correlates more closely with renal dysfunction than glomerular damage (Nath, 1992). 
Central to tubulointerstitial fibrosis is TGFβ1 which can exert a profibrogenic effect 
on the tubular cells but also drive an important process called epithelial to 
mesenchymal transition (EMT) that converts epithelial cells to ECM producing 
myofibroblastic cells.  
 
1.2.1 What is Epithelial to Mesenchymal Transition? 
EMT is an important biological process that converts polarised epithelial cells into 
migratory and invasive mesenchymal cells, which have significantly increased 
production of ECM, resistance to apoptosis and migratory ability. This process has 
been long recognised to play a crucial role in embryogenesis (Kalluri and Weinberg, 
2009).  Most adult organs utilise one or several waves of EMT in organ maturation, 
and conversely, mesenchymal to epithelial transition (MET) additionally modifies 
organogenesis and tissue repair (Kalluri and Weinberg, 2009; Nieto, 2011).  
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The initial observation of EMT can be dated to as far back as 1890 when the 
invasive ability of some morphologically different ductal epithelial cell breast 
tumours were described (Cajal, 1890). The term mesenchymal to epithelial 
transformation was not coined until 1968 and was later changed to epithelial to 
mesenchymal transition to highlight the potential reversibility of this process 
(Kalluri and Neilson, 2003b).  Later, Elizabeth Hay used a model of chick primitive 
streak formation to describe EMT, which states “Epithelial cells exhibit apico-basal 
polarity, and during the transformation of epithelium to mesenchyme, the 
transforming cells produce filopodia on their basal side followed by a new leading 
pseudopodium that is pushed out into the extracellular matrix. A mesenchymal cell 
has front end–back end polarity and forms only transient contacts with its neighbors” 
(Hay, 1995). Subsequently, the important links between EMT and cancer as well as 
organ fibrosis was established, and hence there has been significant scientific 
interest and progress in this field (Nieto, 2011).  
In this project, type 2 EMT was induced in an in vitro model by exposure to TGFβ1 
and in an in vivo model by unilateral ureteral obstruction to study the efficacy of 
using miR-200b to prevent renal fibrosis. Thus, type 1 and type 3 EMT will only be 
briefly discussed while type 2 EMT will be discussed in more depth. 
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Figure 1.2 Phenotypic and molecular markers during EMT. Adapted from (Kalluri 
and Weinberg, 2009) 
At the molecular level, multiple processes are involved in the initiation through to 
the completion of EMT. These comprise activation of transcription factors, 
expression of specific cell surface proteins, expression and reorganisation of 
cytoskeletal proteins, production of ECM degrading metalloproteinase as well 
alteration in microRNA (miR) expression profiles (Kalluri and Weinberg, 2009).  
EMT is a process that drives the formation of multi-layer and complex organs 
during development. However it is also a response to pathogenic signals such as 
tumorigenesis, hypoxia, and chronic inflammation (Ansieau et al., 2008; Wu et al., 
2009; Yang et al., 2008). EMT is activated under these conditions in different 
biological contexts and thus is classified into three discrete subsets (Kalluri and 
Weinberg, 2009; Zeisberg and Neilson, 2009).  
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Figure 1.3 Diagram illustrated differences between three different kinds of EMT in 
different biological contexts. Adapted from (Carew et al., 2012) 
 
1.2.2 Type 1 EMT 
Type 1 EMT is associated with implantation, embryo formation and organ 
generation. It produces mesenchymal cells at the completion of the process.  
EMT is involved from the beginning of embryogenesis and closely associated with 
implantation and placenta formation (Vicovac and Aplin, 1996), particularly the 
trophoectoderm cells, which later become the cytotrophoblast, undergo EMT in 
order to facilitate invasion of the endometrium and thereby secure placentation 
(Aplin et al., 1998; Bischof et al., 2006). 
The zygote undergoes gastrulation, which develops into three germ layers that 
ultimately generate all tissue types of the body. Initially a primitive streak in the 
epiblast layer is formed (Hay, 1990). The epithelial cells in the primitive streak 
express E-Cadherin and exhibit apical basal polarity. The epithelial-like cells of the 
epiblast undergo programmed changes to form the primitive streak from the lower 
extremity of the embryo to the head by expressing specific proteins associated with 
cell migration and differentiation (Thiery and Sleeman, 2006). 
The mesendoderm is formed after the primitive streak is generated, and the 
mesendoderm is then separated to form the mesoderm and endoderm via an EMT 
process (also known as Epiblast-mesoderm transition) (Hay, 1995). The mesoderm, 
which is between the epiblast and the hypoblast, eventually gives rise to primary 
mesenchyme (Hay, 2005).  Cells of the primary mesenchyme exhibit greater 
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migratory properties when compared with those of the epiblast and the hypoblast 
(Hay, 2005). 
During embryonic development, EMT drives  the formation of migratory neural 
crest cells from epithelial cells of the neuroectoderm (Duband and Thiery, 1982). 
Initially, the premigratory neural crest cells express genes such as sox, snail, slug 
and foxhead box D3, which then undergo EMT (Knecht and Bronner-Fraser, 2002; 
Sauka-Spengler and Bronner-Fraser, 2008). Consequently, they move out from the 
neural folds, become motile and migrate to different parts of the embryo, where they 
undergo further differentiation into different cell types such as the melanocytes.  
EMT occurring in the neural crest is triggered by similar signalling pathways to 
those involved with EMT associated with gastrulation, ie Wnts, FGFs, BMPs, c-Myb, 
and msh homeobox (Karafiat et al., 2007; Liem et al., 2000; Villanueva et al., 2002).  
BMP is a key inducer of the migratory property of neural crest cells. An inhibitor of 
BMP, Noggin, arrests EMT (Burstyn-Cohen et al., 2004; Sela-Donenfeld and 
Kalcheim, 2002).  Also, EMT in the neural crest will not occur unless E-cadherin 
and N-cadherin, the two cell adhesion molecules, are repressed (Thiery, 2003). EMT 
is integrally involved in later stages of embryogenesis, such as the endothelial-
mesenchymal transition (EndMT) that occurs during heart valve formation. These 
findings early in the recognition of EMT played a significant role in the subsequent 
understanding of type 2 EMT in renal fibrosis where similar molecular changes have 
been observed (Kalluri and Weinberg, 2009).  
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1.2.3 Type 3 EMT 
Type 3 EMT is involved in the epithelial cells transitioning to metastatic tumour 
cells and occurs in the secondary epithelia of cancerous tissues. It occurs in 
neoplastic cells that have previously undergone genetic and epigenetic changes, 
particularly when they affect oncogenes and tumour suppressor genes. Cancer cells 
undergoing Type 3 EMT may invade and metastasise, which clearly is associated 
with a poor prognosis (Carew et al., 2012; Kalluri and Weinberg, 2009).  
Many studies including in vivo mouse studies and in vitro cell culture experiments 
have identified that cancer cells can acquire a mesenchymal phenotype which render 
them an invasive capacity. These cells are normally found at the invasive front of the 
primary epithelial tumour and express mesenchymal markers such as αSMA, 
Fibroblast Specific Protein 1 (FSP1), vimentin and desmin (Yang and Weinberg, 
2008). It is thought that these cells are indeed the cells that eventually invade and 
metastasise (Brabletz et al., 2001; Fidler and Poste, 2008; Thiery, 2002).  
Many cytokines drive the activation of EMT, including, hepatocyte growth factor 
(HGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and 
TGFβ1. These cytokines drive the upregulation of  transcription factors including 
Snail, Slug, Zinc-finger E-box Binding homeobox 1 (ZEB1), Twist, Goosecoid, and 
FOXC2 (Jechlinger et al., 2002; Kokudo et al., 2008; Medici et al., 2008; Niessen et 
al., 2008; Shi and Massague, 2003; Thiery, 2002). Activation of these transcription 
factors lead to the downstream activation of signalling molecules and pathways 
including MAPK (p38, p42 and JNK) PI3K, Akt, SMADs, RhoB, β-catenin, 
Lymphoid Enhancer binding Factor (LEF), Ras, c-Fos and integrin signalling (Gupta 
et al., 2005; Hartwell et al., 2006; Mani et al., 2008; Mani et al., 2007; Taki et al., 
2006; Weinberg, 2008; Yang et al., 2006; Yang and Weinberg, 2008).  
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1.2.4 Type 2 EMT 
Type 2 EMT is associated with wound healing, tissue regeneration and fibrosis. This 
type of EMT is a repair mechanism that normally generates fibroblasts to replace and 
restore tissue integrity after inflammation and injury. During wound healing, 
keratinocytes at the border of the wound acquire an intermediate phenotype known 
as the “meta-stable” state or “partial EMT”, in which cells express both epithelial 
and mesenchymal markers. This allows these cells to migrate while still loosely 
attached to each other (Thiery et al., 2009). It appears that this state is controlled by 
Snail2 expression as its inactivation compromises wound healing whilst over-
expression accelerates the process (Arnoux et al., 2008).  
EMT ceases when the inflammation is mitigated in the case of wound healing and 
tissue regeneration. Persistent activation of EMT in response to inflammation leads 
to progressive organ fibrosis, as is observed in epithelial tissues such as kidney, liver, 
lung, and intestine (Kim et al., 2006; Potenta et al., 2008; Zeisberg et al., 2007a; 
Zeisberg et al., 2007b). 
 
1.2.5 Type 2 EMT in Chronic Kidney Disease 
One of the critical pathological changes in chronic kidney disease including diabetic 
nephropathy is tubulointerstitial fibrosis, in which excessive ECM proteins including 
collagen 1 and 4; laminin and fibronectin are deposited in the tubular interstitial 
space. The degree of tubulointerstitial fibrosis correlates with loss of renal function 
and the ultimate prognosis of the disease (Carew et al., 1994; Mason and Wahab, 
2003). The excessive accumulation of ECM is produced by several cellular sources 
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including activated myofibroblasts, the origin of which remains controversial (Badid 
et al., 2002; Powell et al., 1999; Roberts et al., 1997). Kalluri and Neilson 
demonstrated in mouse kidney fibrosis that 30% of fibroblasts are derived via EMT 
from tubular epithelial cells and 12% are derived from bone marrow (Kalluri and 
Neilson, 2003b).  In addition, about 35% of these fibroblasts are derived from 
endothelial cells normally residing in kidney via EndMT, while the remaining are 
thought to come from resident interstitial fibroblasts or other mesenchymal cells 
such as perivascular smooth muscle cells, pericytes and circulating fibrocytes 
(Zavadil and Bottinger, 2005). Nevertheless, type 2 EMT of epithelial cells 
contributes significantly to the pathogenesis of renal fibrosis.  
Type 2 EMT occurs in response to various injurious stimuli in the kidney including 
hypoxia, reactive oxygen species (ROS), advanced glycation end products (AGEs), 
profibrogenic cytokines and MMP elaboration, many of which are activated under a 
hyperglycaemic milieu. TGFβ1 represents the key candidate in the pathogenesis of 
renal fibrosis. Studies have demonstrated a critical role of the downstream signalling 
cascades of TGFβ1 such as the  SMAD and PI3K-Akt pathways in the induction of 
EMT in various epithelial cell lines (Bakin et al., 2000; Cano et al., 2000; Cho et al., 
2007; Kattla et al., 2008; Valcourt et al., 2005).  
Based on the phenotype and markers expressed, type 2 EMT can be divided into four 
stages.  
1. Loss of cell-cell adhesion  
2. De novo  synthesis of αSMA and actin reorganisation 
3. Disruption of tubular basement membrane 
4. Enhanced cell migration and invasion capacity 
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Figure 1.4 Four distinctive steps involved in type 2 EMT. adapted from (Liu, 2004) 
As a consequence of EMT, the epithelium is replaced with myofibroblasts that 
produce extracellular matrix, eventually lead to renal fibrosis and scaring.  
E-Cadherin is a adhesion molecule that is responsible for linking the epithelial cells 
into a highly coupled sheet under normal condition (Hills and Squires, 2011) and 
loss of E-Cadherin is one of the earliest changes in EMT resulting in dissociation of 
epithelial cells (Zheng et al., 2009). Most importantly, TGFβ1 is unable to initiate 
EMT without disrupting cell-cell adhesion suggesting a role for E-Cadherin in 
TGFβ1 mediated EMT. However, the mechanism of the loss of E-Cadherin initiating 
EMT remains unclear (Hills and Squires, 2011; Masszi et al., 2004). Recently 
several studies have demonstrated that the transcription factors ZEB1 and 2, 
regulated by TGFβ1, are able to down-regulate E-Cadherin suggesting a key 
involvement in the initiation of EMT (Gregory et al., 2008a; Korpal et al., 2008; 
Park et al., 2008).  
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1.2.6 Biomarkers of Type 2 EMT 
Though a large amount of evidence indicates that EMT plays an important role in 
generating myofibroblasts and thereby leading to the excessive deposition of ECM in 
chronic kidney disease (Kalluri and Neilson, 2003a; Liu, 2004; Okada et al., 2000; 
Zeisberg and Kalluri, 2004), in human renal fibrosis, the lack of robust methods and 
biomarkers identifying the transition and migration of epithelial cells under EMT as 
well as resulting mesenchymal cells remains the major hurdle defining the 
magnitude of EMT in fibrosis. A diverse array of biomarkers have thus been used to 
identify EMT and each subgroup has their own unique expression profile of markers, 
though some may overlap (Zeisberg and Neilson, 2009).  
Under normal conditions, tubular epithelial cells are separated from ECM by a layer 
of tubular basement membrane (Fan et al., 1999; Okada et al., 1997). During EMT, 
epithelial cell-derived fibroblasts enter the interstitium by breaking down the 
basement membrane and then they become active in ECM production. This is 
initiated by the down regulation of E-Cadherin and tight junction protein 1 (ZO-1), 
which are important adhesion proteins maintaining the structural integrity and 
polarity of epithelia (Kalluri and Neilson, 2003a; Yang and Liu, 2001).  The 
progressive change to OB-Cadherin from E-Cadherin had been observed in Type 2 
EMT and this had been used to monitor the development of Type 2 EMT (Strutz et 
al., 2002). Type 2 EMT has also been associated with Discoidin Domain Receptor 
tyrosine kinase 2 (DDR2) and subsequent up-regulation of MMP1 (Vogel et al., 
1997).   β-catenin is part of a complex of proteins that constitute adherens junctions 
and links cadherins to the cytoskeleton. It also participates in the transcriptional 
activation of EMT genes, in particular Snail1 (Bienz, 2005; Yook et al., 2006). It is 
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is thus used as a marker in all types of EMT (Kalluri and Neilson, 2003b; Kim et al., 
2002).  
De-novo synthesis of αSMA and reorganisation of the actin cytoskeleton marks the 
next phase of EMT, which is accompanied by the exchange of cytokeratin for 
vimentin filaments and activation of FSP1. FSP1 has been used as an early marker 
for Type 2 EMT. (Iwano et al., 2002a; Zeisberg et al., 2007a; Zeisberg et al., 2007c). 
Fibronectin is one of main constituents of ECM and can also function as a fibroblast 
chemo-attractant and promoter of fibroblastic differentiation (Yokoi et al., 2001). 
Laminin1, which is the major basement membrane protein, is down-regulated during 
EMT and again serves as a marker for Type 1 & 2 EMT (Zeisberg et al., 2002). 
However, many of these markers are non-specific. FSP1 is not specific to epithelial 
cells undergoing EMT, but is also expressed by endothelial cells, smooth muscle 
cells and inflammatory cells (Kalluri and Neilson, 2003b; Liu, 2004; Strutz et al., 
1995). Vimentin is controversial as it is expressed by other cells (Franke et al., 1978) 
while fibronectin can be produced from fibroblasts that have not been derived from 
EMT (Strutz et al., 2002; Zeisberg et al., 2001). αSMA represents the most 
commonly used marker in EMT,. However, heterogeneity of expression of this 
marker also exists (Masszi et al., 2004). Hence it is suggested that the combination 
of both vimentin and β-catenin be used to detect EMT in renal pathology (Galichon 
and Hertig, 2011).  
 
1.2.7 Models used in studying EMT and Renal Interstitial Fibrosis 
In terms of the models used to study renal fibrosis, the most convincing evidence 
that EMT contributes to human renal disease has come from studies of human renal 
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biopsies in patients with diabetes (Oldfield et al., 2001). However many cells have 
been used to study EMT in vitro, including primary cultures and cell lines from 
human and animal origin. Removal of ligands that induce type 2 EMT in some 
cultures restores epithelial cell phenotype in a process known as reversible scatter 
(Carew et al., 2012; Kalluri and Neilson, 2003b), suggesting plasticity and inter-
changeability associated with both the epithelial and myofibroblastic cells. Various 
cell lines with conditional knockout (KO) of key molecules involved in EMT, such 
as SMAD2, and SMAD3 have, allowed a better understanding of the pathways and 
potential therapeutic targets in EMT (Lan, 2011a). Studying EMT in in vivo models 
has been problematic due to the lack of specific biomarker(s) as discussed above. 
Hence cell-fate mapping, where reporter genes can be tracked in transformed cells, 
has been used to study its importance (Carew et al., 2012; Iwano et al., 2002b; Kim 
et al., 2006).  Diabetic animal models (mouse and rat), either spontaneous (db/db) or 
STZ induced, have been used to study hyperglycaemia induced EMT (Carew et al., 
2012). Mechanistically, EMT is consistent across many models of renal disease. 
Hence ureteric obstruction and sub-total nephrectomy models are frequently used to 
study tubular EMT (Ng et al., 1998; Yokoi et al., 2004) as renal injury occurs 
somewhat sooner in these models compared to diabetic nephropathy. In this project, 
unilateral ureteral obstruction (UUO) was used as a model of renal interstitial 
fibrosis. UUO was originally shown to induce renal interstitial fibroblast 
proliferation as well as epithelial transformation into active myofibroblasts (Nagle et 
al., 1973), along with increased expression of collagens and fibronectin (Sharma et 
al., 1993) in rabbit. This technique is now widely used to induce renal interstitial 
fibrosis in murine models (Chevalier et al., 2009a). Complete ligation of the ureter 
induces a rapid hemodynamic and metabolic change resulting in reduction in blood 
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flow and glomerular filtration rate in the obstructed kidney (Vaughan et al., 2004). It 
is followed by hydronephrosis, interstitial macrophage infiltration and tubular injury 
eventually leading to cell death (Docherty et al., 2006). The development of EMT 
and proliferation of fibroblasts contribute significantly to the excessive deposition of 
ECM and thus renal fibrosis (Chevalier et al., 2009b; Klahr and Morrissey, 2002). 
Further investigation into the UUO model has revealed the major pathways 
responsible for development of renal interstitial fibrosis. The infiltrating 
macrophages produce cytokines such as TGFβ1, which promotes tubular apoptosis 
and EMT. Transformed epithelial cells can then migrate out to the interstitium and 
actively produce ECM. Under TGFβ1 stimulation, local resident fibroblasts are 
activated and synergistically participate in the production of ECM. Tumour necrosis 
factor α (TNFα) is also secreted by infiltrating macrophages and is considered 
responsible for tubular death and subsequent development  of tubular atrophy 
(Chevalier et al., 2009b).  
1.3 Controversy of the role of EMT in renal fibrosis 
Even though the role of EMT in renal fibrosis is generally accepted and EMT is 
robustly observed in in vitro models where renal tubular cells were stimulated with 
TGFβ1, several studies raised the question whether this is truly what happens in vivo 
(Humphreys et al., 2010; Li et al., 2010). In these studies, labelled tubular cells (cell 
fate tracing) demonstrated no involvement of tubular cell EMT in contributing to 
renal fibrosis in UUO mice model. However, in another study, LacZ labelled tubular 
cells expressed both FSP-1 and LacZ at the same time in fibrotic tissue around tubules 
in a UUO mice model (Iwano et al., 2002a). Thus, more studies have to be carried out 
to end the controversy. 
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1.4 TGFβ Signalling and Diabetic Nephropathy 
Diabetic nephropathy is a devastating complication in patients with diabetes mellitus. 
Given it has clearly been associated with overexpression of TGFβ it is used as an 
illustrative form of nephropathy for the purpose of further discussion. Diabetes 
mellitus is a metabolic disorder induced by chronic hyperglycaemia, which causes 
dysfunction in multiple cells in the kidney, leading to progressive renal fibrosis and 
eventually renal failure. Diabetic nephropathy represents the single most common 
cause of entry into renal replacement therapy, ie dialysis and renal transplantation. 
Patients with diabetic nephropathy contribute up to 35% of patients with end stage 
renal disease (Fioretto and Mauer, 2007; Giunti et al., 2006; Schena and Gesualdo, 
2005; Susztak and Bottinger, 2006; Wolf, 2004). Type I and Type II diabetes are 
distinct in aetiology. However, the changes evoked by hyperglycaemia in the kidney, 
specifically, in the glomerulus, tubulointerstitium and vasculature are remarkably 
similar and virtually indistinguishable (Fioretto and Mauer, 2007). Initially, 
dysfunction of the glomerular capillaries induces the changes clinically manifesting 
as hyperfiltration and microalbuminuria (Wolf, 2004; Wolf and Ziyadeh, 2007). 
Subsequent changes include mesangial cell hyperplasia and hypertrophy, increased 
mesangial matrix and  thickening of the glomerular basement membrane, all of 
which together lead to Kimmelstiel-Wilson lesions in glomeruli (Mason and Wahab, 
2003; Wolf, 2004); tubular atrophy followed by thickening of the tubular basement 
membrane and interstitial fibrosis in the tubulointerstitium (Mauer et al., 1984).  As 
highlighted above, EMT is likely to play an important role in tubulointerstitial 
fibrosis causing excessive accumulation of ECM (Mason and Wahab, 2003; 
Nangaku, 2004; Zavadil and Bottinger, 2005). Vascular changes include 
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hyalinisation and thickening of both the afferent arterioles and interlobular arteries 
with widespread endothelial effacement (Kanwar et al., 2011).  
Even though various types of cells with different functions are present in the kidney, 
evidence suggests that they respond to hyperglycaemic insults by activating common 
intracellular signalling pathways, with minor variation (Kanwar et al., 2011). These 
signalling events include accentuated flux of polyols and hexosamines; generation of 
AGEs and ROS; activation of protein kinase C (PKC), TGFβ1, Janus kinase-signal 
transducer and activator of transcription (JAK-STAT) pathways and G protein 
signalling; abnormal cyclin kinases and their inhibitor levels; altered expression of 
ECM proteins and ECM degrading enzymes - metalloproteinases and their inhibitors 
(Brownlee, 2001; Catania et al., 2007b; Chung et al., 2003b; Inoguchi et al., 2003; 
Marrero et al., 2006; Mason and Wahab, 2003; Sharpe and Hendry, 2003; Tan et al., 
2007; Wolf, 2002; Ziyadeh, 2004). Furthermore, cross talk occurs at different levels 
of the signalling pathways, providing either positive or negative feedback that affects 
the net outcome in the disease process (Kanwar et al., 2011). The following figure 
adopted from Kanwar et al (Kanwar et al., 2011) summarises the cellular pathways 
activated under diabetic conditions. 
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Figure 1.5 Simplified diagram of various events involved in the pathogenesis of 
diabetic nephropathy. Adapted from (Kanwar et al., 2011). 
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1.4.1 Glucose Uptake and Its Role in Metabolic Pathways 
In kidneys, glucose is reabsorbed by the proximal tubular cells and this process is 
facilitated through various transporters on the cell surface including the basolateral 
active Glucose Transporters (GLUT)-1, GLUT-4, or the apical Sodium Glucose 
Linked Transporters, (SGLT)-1 and SGLT2, with SGLT2 being responsible for 
greater than 90% of renal glucose reabsorption (Brosius and Heilig, 2005). Under 
hyperglycaemic conditions, increased amounts of glucose are transported into 
tubular cells and channelled into different metabolic pathways which eventually lead 
to an inflammatory and fibrotic response. Accumulation of intracellular glucose is 
likely to play an important role in the early pathogenesis of diabetic nephropathy as 
inhibition of glucose transport by knockdown of GLUT-1 decreases the amount of 
fibronectin in mesangial cells under hyperglycaemic condition (Brosius and Heilig, 
2005).  
Intracellularly, glucose is converted to pyruvate by glycolysis.. During this process, 
glucose is phosphorylated to glucose 6-phosphate (G6-P) which then isomerises to 
fructose 6-phosphate (F6-P) before conversion to glyceraldehyde 3-phosphate (G3-P) 
(Kanwar et al., 2011). G3-P can then form glycerol phosphate, which is the precursor 
of diacylglycerol (DAG) - a signalling molecule accountable for the recruitment and 
activation of PKC (Quest et al., 1997). Under hyperglycaemic conditions, F6-P is 
diverted to hexamine biosynthesis, the end-product of which is uridine diphosphate 
N-acetylglucosamine – a precursor of matrix proteins such as proteoglycans 
(Schleicher and Weigert, 2000). The rate limiting enzyme in the hexamine pathway 
glutamine:fructose-6-phosphate-aminotrasnferase (GFAT), has been shown to 
modulate the activity of TGFβ1 and PAI-1 (Schleicher and Weigert, 2000).  
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Excess glucose can also be channelled into other metabolic pathways such as the 
polyol and myo-inositol pathways. The former results in an increase in oxidative and 
osmotic stress (Chung et al., 2003a), while the latter may be important in tubular 
‘health’, as the addition of myo-inositol to cultured proximal tubular epithelial cells 
normalises glucose induced proliferation and collagen synthesis (Ziyadeh et al., 
1991). 
 
1.4.2 Advanced Glycation End Products (AGEs) 
Synthesis of AGEs is initiated by non-enzymatic condensation of sugar and a free 
amino group, which form an unstable Schiff base. The Schiff base then undergoes an 
Amadori rearrangement, followed by a series of reactions. Dehydration and 
polymerisation eventually leads to the generation of macromolecular forms of AGEs 
(Kanwar et al., 2011; Schleicher et al., 2001). Under normal physiology, AGEs are 
produced at basal levels but are prominently increased under a chronic 
hyperglycaemic milieu (Jakus and Rietbrock, 2004). AGEs can activate multiple 
transcriptional and signalling pathways  including, but not limited to NFκB, PKC 
and MAPKs (Forbes et al., 2003; Thallas-Bonke et al., 2004) which subsequently 
regulate the expression of pro-fibrotic growth factors and cytokines such as TGFβ1. 
In the extracellular compartment, AGEs form by irreversibly linking glucose and 
ECM proteins such as collagen, fibronectin, laminin and proteoglycan (Thallas-
Bonke et al., 2004). This process may render these modified ECM proteins less 
susceptible to degradation by MMPs and allow excessive accumulation of ECM 
(Catania et al., 2007a). Notably, glycation of sulphated proteoglycans can reduce 
their electronegativity, thereby altering the charge-sensitive filtration properties of 
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the basement membrane, resulting in albuminuria (Brownlee, 1995; Kanwar et al., 
2011; Wautier and Guillausseau, 2001).  
AGEs also bind to receptors for advanced glycation endproducts (RAGE) on the cell 
surface and thereby modulate cellular function (Forbes et al., 2003; Jakus and 
Rietbrock, 2004). High concentrations of AGEs, either extracellular or intracellular, 
can also induce the production of ROS, which are likely to modulate NFκB and AP1 
activation  and downstream PKC and MAPK signalling (Jakus and Rietbrock, 2004; 
Schleicher and Weigert, 2000; Thallas-Bonke et al., 2004). Blocking of either AGE 
production or inhibition of its cellular action with soluble RAGE can partially 
reverse hyperglycaemia induced vascular complications (Mani et al., 2007). A recent 
report also looked at the effects of ingested AGE on renal diseases under diabetic 
conditions (Thallas-Bonke et al., 2013). A low AGE diet was given to STZ induced 
diabetic C57BL6 mice and RAGE-KO mice for 24 weeks. At the end the study, it 
was found that low AGE diet did not protect the diabetic C57BL6 mice from 
developing nephropathy, while diabetic RAGE-KO mice had reduced renal fibrosis 
measured by glomerulosclerosis,  tubulointerstitial expansion, TGFβ1 expression 
and  glomerular collagen 4 deposition (Thallas-Bonke et al., 2013).  These results 
indicate that, diabetic patients may be challenged by a significant AGE burden, both 
ingested and facilitated by hyperglycaemia. Blockade of RAGE can attenuate AGE 
induced renal diseases and suggests the utility of this strategy in ameliorating 
diabetic nephropathy.  
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1.4.3 Protein Kinase C  
Activated by multiple pathways, PKC influences a number of physiological and 
cellular processes including altered blood flow, capillary permeability, mesangial 
expansion and proteinuria (Kanwar et al., 2011). It is thought that these changes are 
mediated by the down-regulation of endothelial nitric oxide synthase (eNOS) and 
nitric oxide, as well as the subsequent up-regulation of endothelin 1 and vascular 
endothelial growth factor (VEGF) (Nakagawa et al., 2007). Furthermore, PKC 
induces the activation of TGFβ1 and PAI-1, which promote ECM production and 
decrease their degradation, as well as plasmalemmal NADPH, which increases 
oxidative stress (Carew et al., 2012; Thallas-Bonke et al., 2004). NFκB is also 
activated by PKC, resulting in an inflammatory response and a thrombotic 
angiopathy (Kanwar et al., 2011; Lee et al., 2003) Blocking PKC with ruboxistaurin, 
which targets the β1 and β2 isoforms of PKC, partially decreased diabetes induced 
renal damage in db/db mice, suggesting an important role of PKC in the 
pathogenesis of diabetic nephropathy (Koya et al., 2000). However this has not been 
substantiated in clinical trials. 
 
1.4.4 Reactive Oxygen Species  
The key ROS that induces renal pathology include superoxide anion (O2
-
), H2O2, 
hydroxyl radical and peroxynitrite (Djordjevic, 2004), which induce apoptosis and 
modulate the activation of angiotensin II (AngII) and TGFβ1 (Kanwar et al., 2011). 
Under physiological conditions, ROS are produced at basal levels to maintain 
cellular homeostasis, but are significantly increased in response to hyperglycaemia 
(Kanwar et al., 2011; Lee et al., 2003). They are generated predominantly via 
mitochondrial oxidative phosphorylation or via the NADPH-oxidase system (Gill 
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and Wilcox, 2006; Kang and Hamasaki, 2003; Li and Shah, 2003; Schrauwen and 
Hesselink, 2004). As previously discussed, ROS can be activated by several 
regulating molecules including AGEs and PKC. However, increasing evidence is 
showing a reciprocal relationship where ROS can induce the activity of ROS 
inducers, thus amplifying their signalling under hyperglycaemic conditions 
(Brownlee, 1995; Inoguchi et al., 2003; Kanwar et al., 2011; Wrighton et al., 2009). 
The “hunt and destroy” actions of these ROS are mediated by enzymes including 
cytoplasmic CuZn superoxide dismutase (CuZnSOD), mitochondrial manganese 
superoxide dismutase (MnSOD) and hemeoxygenase 1 (Catherwood et al., 2002; 
Koya et al., 2003). Over-expression of cytoplasmic CuZnSOD has been shown to 
reduce glomerular pathology in STZ induced diabetic db/db mice (Craven et al., 
2001; DeRubertis et al., 2004). Additionally, antagonising NADPH-oxidase 
decreased the expression of fibronectin in tubular and mesangial cells, demonstrating 
the potential of targeting ROS in the prevention or treatment of diabetic nephropathy.  
 
1.5 MicroRNA (miRNA) and Renal Fibrosis 
 
With the discovery of miRNA and their role in gene regulation, there is an explosion 
of studies suggesting an important role of miRNA in the pathogenesis of diabetic 
nephropathy. These miRNAs can be used as markers identifying EMT and renal 
fibrosis, or therapeutic targets in treating the disease. Thus, identification of these 
miRNAs and their molecular mechanisms in the initiation and progression of the 
disease become particularly important and naturally come to be the focus of this 
thesis. 
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1.5.1 MicroRNA and the Pathogenesis of Diabetic Nephropathy 
miRNAs are a group of endogenous, short non-coding RNA that are approximately 
22 base pairs (bps) in size. They play an important role in gene regulation and are 
usually associated with suppression of the target genes. 
 
1.5.2 Discovery of microRNA and its Biogenesis 
The first MicroRNA (miRNA) defined, lin-4, was described as a small non-coding 
RNA that is essential for postembryonic development in caenorhabditis elegans by 
Lee et al in 1993 (Lee et al., 1993). lin-4 was shown to down-regulate the protein 
translation of Lin-14 – a conventional protein coding gene. The authors 
demonstrated that lin-4 has several imperfect complementarity sites to the 3’ 
untranslated region (3’UTR) of lin-14, but was still able to bind to it, providing the 
first evidence of miRNA mediated gene regulation (Lee et al., 1993).  
It was not until 2000, that a second miRNA, let-7 was shown to be conserved across 
various species (Pasquinelli et al., 2000). Since then, there has been a rapidly 
growing interest in miRNAs, with increasing evidence to suggest that they regulate 
the majority of transcriptional or translational pathways in all organs. Importantly, 
miRNA dysfunction has been demonstrated to be associated with various diseases 
including diabetic nephropathy (Kato et al., 2009a; Lorenzen et al., 2011). As of 
August 2012, 21264 miRNA entries have been registered in miRBase 
(http://www.mirbase.org/), with the number growing daily. It is estimated that at 
least 60% of human protein coding genes expressed in the genome are regulated by 
miRNAs (usually inducing down-regulation) (Bartel, 2009; Friedman et al., 2009). 
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1.5.3 Biogenesis of microRNA 
miRNAs are first transcribed in the nucleus as long primary miRNAs by RNA 
polymerase and then processed into a  stem-loop structure, called precursor mRNA 
by RNase III (also named as Drosha), in a complex with DGCR8, a double-strand 
RNA-binding protein (Filipowicz et al., 2008; Kim, 2005). The precursor miRNA, 
which is approximately 70bp long, is then exported into the cytoplasm, in a process 
mediated by Exportin-5. When in the cytoplasm, it is further processed into a RNA 
duplex by a second RNase III family enzyme named Dicer (Filipowicz et al., 2008; 
Kim, 2005). After cleavage, the duplex unwinds and the functional strand also 
known as the mature miRNA is loaded onto the RNA –Induced Silencing Complex 
(RISC), consisting of several different functional subunits, namely, argonaute 2, 
Dicer and trans-activating response RNA-binding protein. (Filipowicz et al., 2008; 
Kim, 2005). The miRNA loaded RISC complex can then initiate gene repression via 
complementary binding to target mRNA 3’UTR. 
The following figure illustrates the biogenesis of miRNAs. 
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Figure 1.6 The biogenesis of miRNAs. Adapted from (Cullen, 2005) 
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1.5.4 mRNA repression mediated by miRNA 
miRNA functions as a guide for the complex to target mRNA. Upon binding with 
mRNA and based on the “seed sequence” complementarity, two modes of 
suppression of mRNA can then occur. “Seed sequences” are the key nucleotides 
normally 7bp in the mature miRNA that is critical for target recognition and 
inhibition (Bartel, 2009; Lewis et al., 2005).  In the case of perfect complementarity 
to target gene 3’UTR, the miRNA-RISC complex can then cleave the target mRNA, 
while translational repression is observed in imperfect complementarity (Bartel, 
2004; Chang and Mendell, 2007; Filipowicz et al., 2008; Zamore and Haley, 2005). 
A key property of miRNA is that due to the short length of seed sequence and ability 
to inhibit gene expression under imperfect complementarity, miRNA can target 
many mRNA targets, which is in contrast to single gene targeting observed with 
siRNA.  In addition, miRNA has also been implicated in mediating gene 
transcriptional repression by binding to the promoter region of the target (Kim et al., 
2008). Thus, miRNA can induce transcriptional inhibition, translational inhibition 
and target gene mRNA degradation to inhibit gene expression.   
 
1.5.5 miRNA involved in diabetic nephropathy  
To date, several miRNAs have been identified to play important roles in preventing or 
initiating renal fibrosis. They will be reviewed in the next few paragraphs.   
1.5.5.1 miR-192 
miR-192, along with miR-194, miR-204, miR-215 and miR216 are five of the most 
highly expressed microRNAs in the kidney (Sun et al., 2004). miR-192 is expressed at 
least 20-fold higher in the renal cortex than in the medulla in rat kidney (Tian et al., 
2008). Thus, miR-192 had been extensively studied in both in vitro and in vivo 
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models of diabetic nephropathy. However miR-192 is differentially regulated in each 
cell type at during the progression of real disease in multiple models of renal damage. 
 
1.5.5.1.1 Renal cortex  
Renal cortex from STZ-induced diabetic apoE knockout mice (a chronic 
hyperglycaemic and dyslipidaemic model which reliably develops physiological and 
pathological changes that reflect human disease) demonstrates  a significant reduction 
in miR-192 levels with an associated decrease in ZEB2 and increased fibrotic markers 
such as SMA, collagen 4 (COL4), CTGF, and fibronectin, (Wang et al., 2010a).  
However, systemic miR-192 knockdown in renal cortical tissue, using locked nucleic 
acid anti-miR-192 (LNA-anti-miR-192), demonstrated renoprotective effects in STZ 
induced diabetic c57BL/6 mice at two, twelve and seventeen weeks compared to 
control diabetic mice with similar levels of blood glucose. COL1A2, COL4A1, TGFβ, 
CTGF as well as fibronectin were decreased in kidney. Periodic acid schiff and 
masson trichrome staining confirmed the significant reduction in renal fibrosis in 
miR-192 knockdown mice (Putta et al., 2012). Physiological studies indicated a 
reduction in urinary albumin and decreased kidney/body weight ratio at 12 weeks, but 
not at 17 weeks when compared to control diabetic counterparts (Putta et al., 2012).    
Consistent with the above mentioned study, other models of renal fibrosis have shown 
an associated significant increase in miR-192. In a model of UUO studied at 5 days, 
mi-192 was increased 1.7 fold. (Chung et al., 2010).  
In a sub-total nephrectomy model of kidney disease in rat, increased miR-192 
expression was also observed  as early as 4 weeks and was higher at 8 weeks when 
the rats were sacrificed (Sun et al., 2011). Sun et al also confirmed SMAD3 was able 
to directly bind to the promoter region of miR-192 and this binding was decreased by 
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low dose paclitaxel – a anti-cancer drug which arrests the cell cycle in the G0-G1 and 
G2-M phases and induces apoptosis by  stabilising polymerised microtubules and 
maintaining microtubular assembly (Sun et al., 2011). Consistent with the above 
models miR-192 has also been found to be up-regulated in hypertensive and IgA 
nephropathy (Wang et al., 2010b, c). 
In contrast to the majority of findings cited above where renal cortical miR-192 is 
overexpressed in models of renal fibrosis and strategies to reduce miR-192 are 
renoproctive, biopsy samples from patients with established diabetic nephropathy 
demonstrated an inverse correlation of miR-192 level and the severity of 
tubulointerstitial fibrosis. Furthermore, decreased miR-192 correlates with a 
decreased estimated glomerular filtration rate (eGFR) (Krupa et al., 2010).  In this 
study, patients were divided into three groups according to their rate of reduction in 
eGFR in follow-up. Group 1 was defined as “Progressors” ie those in whom loss of 
eGFR was greater than 5ml/min per year, Group 2 “Non-progressors” ie those in 
whom loss of eGFR was less than 5ml/min per year, and Group 3 “Late presenters” ie 
those in whom  eGFR was less than  15ml/min at the time of biopsy. miR-192 levels 
(in pooled RNA samples) were significantly lower in the “late presenter” group 
compared to the other two groups. Expression levels from individual samples of each 
group demonstrated loss of miR-192 correlated with the decrease of eGFR, increased 
tubulointerstitial fibrosis and thus impairment of the kidney function (Krupa et al., 
2010). Hence it is likely that miR-192 expression varies with the stage of disease 
process, potentially being upregulated early in the development of nephropathy but 
becoming progressively diminished with progressive loss of functional renal tissue. 
Alternatively, production of miR-192 by the various cellular components in the renal 
cortex may predominate at different time points in the course of the disease. 
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1.5.5.1.2 Mesangial cells  
In both an insulin deficient (STZ induced) model of diabetes mellitus, studied  7 
weeks post-induction of diabetes, and  in an insulin resistant (db/db) model of 
diabetes studied at 10 weeks  of age, elevated miR-192 levels were demonstrated in 
the glomeruli (Kato et al., 2007).  In vitro  studies have shown that miR-192 is 
activated by TGF
the 3’UTR of ZEB2, which acts as an E-box repressor upstream of COL1A2 (Kato et 
al., 2007). MiR-192 also has been shown to down-regulate ZEB1 (Kato et al., 2007).  
Consistent with the known interdependent regulation of  microRNAs, a LNA-
modified antisense miR-192 decreased the expression of miR-192 itself and other 
miRs such as miR-141, miR-200b, miR-200c, which was reflected in the expression 
of fibrotic genes such as COL1A2, and COL4A1 in mouse mesangial cells (Kato et al., 
2011). Co-transfection of miR-192 with miR-200b in mouse mesangial cells increased 
COL1A2 promoter activity. However, overexpression of either miR alone has not 
been shown to influence fibrotic gene expression (Kato et al., 2011). 
 
1.5.5.1.3 Podocytes  
There is no current information regarding miR-192 in podocytes in diabetic 
concentrations (10ng/ml) show a trend to a decrease in miR-192. (Wang et al., 2010a). 
1.5.5.1.4 Tubules  
Tubular cells play an important role in maintaining fluid and electrolyte homeostasis. 
They  also contribute to the production and degradation of extracellular matrix in the 
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tubulointerstitium and dysregulation of this process leads to  tubulointerstitial fibrosis 
(Mason and Wahab, 2003). Thus understanding of the molecular architecture and 
signalling pathways involved in the pathophysiology of tubulointerstitial fibrosis is 
critical. MicroRNAs play a role in this process, identification and characterisation of 
these microRNAs will provide both targets for treatment and serve as biomarkers for 
prognostic purposes. 
There are no studies that have specifically studied tubular miRNA expression in in 
vivo models of diabetic nephropathy. In vitro studies, however, have simulated 
“diabetic” conditions by exposure to high glucose, or alternatively to TGF.  Krupa et 
al subjected the human proximal tubular cell line, HK-2 cells, to short term (48hr) 
exposure to high glucose, but that did not alter the miRNA expression profile (Krupa 
et al., 2010). They then exposed the cells to TGF
demonstrated decreased expression of miR-192 (Krupa et al., 2010). This finding was 
subsequently confirmed by Jenkins and colleagues  (Jenkins et al., 2012).  
Similar results were reported in rat epithelial cells. TGFβ (10ng/ml 10 days) 
decreased the expression of miR-192 in NRK52E cells. While over-expression of 
miR-192 increased E-cadherin expression in NRK52E cells pre-treated with TGFβ for 
10 days (Wang et al., 2010a). The decrease of miR-192 was reversed by the presence 
of TGFβ type I receptor kinase (ALK5) inhibitor, which blocks TGFβ receptor 
signalling, showing a direct regulation of miR-192 by TGFβ. These studies further 
demonstrated that hepatocyte nuclear factor (HNF) was able to bind to the promoter 
region of miR-192 and this promoter binding activity was down-regulated when 
exposed to TGFβ (10ng/mL). Knockdown of HNF with siRNA decreased miR-192 
expression (Jenkins et al., 2012). 
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Conversely, us
48 hr) increased miR-192 in NRK52E cells,  and over-expression of miR-192 
increased COL 1A1,  and COL 1A2, whereas transfection of anti-miR-192 decreased 
TGFβ induced up-regulation of collagen isoforms (Sun et al., 2011). Chung et al also 
showed TGFβ (2ng/ml, 12&24hr) increased miR-192 expression in NRK52E cells 
with this process independent of de novo protein synthesis (Chung et al., 2010). In 
keeping with the above studies demonstrating the interaction with the SMAD 
signalling pathways, over-expression of SMAD7 in NRK52E cells down-regulated 
TGFβ induced miR-192 (Chung et al., 2010). Overexpression of miR-192 in NRK52E 
for 24 hours increased COL1 with an additive effect on TGFβ induced COL1 
expression. As would be expected, knockdown of miR-192 demonstrated decreased 
COL1 and reversed TGFβ  induced collagen expression(Chung et al., 2010). 
These differences suggest a time and concentration dependent response of miRNAs in 
epithelial cells to TGFβ. This could also be due to the differences in the first wave 
response of genes activated directly by TGFβ and the secondary response subsequent 
to activation of multiple signalling pathways. 
Hence although the molecular mechanisms involved in regulation of miR expression 
may be similar, the expression of a particular miR may be very different in different 
cell types under similar conditions. Cell to cell differences may contribute 
significantly to the expression of tissue miR which needs to be further explored to 
understand the “controversies” in miR-192 expression patterns I disease states.  
 
1.5.5.2 miR-21 
miR-21 has been implicated in cardiac fibrosis (Thum et al., 2008) and in the 
regulation of expression of phosphatase and tensin homolog (PTEN), which plays an 
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important role in diabetic nephropathy (Meng et al., 2007). The phosphoinositide-3-
kinase/Akt pathway is activated by TGFβ (Ghosh Choudhury and Abboud, 2004; 
Kato et al., 2006; Mahimainathan et al., 2006) and in animal models of diabetic 
nephropathy (Kato et al., 2006; Mahimainathan et al., 2006; Nagai et al., 2005; Xin et 
al., 2007). Activation of this pathway has been associated with fibrotic responses such 
as increased expression of collagens and fibronectin (Ghosh Choudhury and Abboud, 
2004; Kato et al., 2009a; Runyan et al., 2004), cell hypertrophy (Mahimainathan et al., 
2006), cell survival and oxidative stress in mesangial cells (Kato et al., 2006).  PTEN 
antagonises the PI3K/Akt pathway, and thus shows protective properties (Salmena et 
al., 2008). Hence the relevance of miR-21 to renal fibrosis has been investigated.  
 
1.5.5.2.1 Renal Cortex  
Zhang et al demonstrated decreased miR-21 level in the cortex of the insulin resistant 
db/db mouse model. Over-expression of miR-21 in vivo, delivered by intraperitoneal 
injection of plasmid containing miR-21, decreased albuminuria (Zhang et al., 2009).  
Dey et al, however, showed elevated miR-21 expression in the renal cortex of the 
OVE26 type I diabetic mouse model  at three months of age with reduced PTEN  and 
increased pAKT and fibronectin expression (Dey et al., 2011).  Apart from the 
disagreement in the two types of diabetes models, the pro-fibrotic properties of miR-
21 in renal diseases have been recently highlighted. This study utilised miR-21 
deficient mice which not only were healthy and fertile without overt adverse effects 
but also had similar kidney gene expression profile compared to wild type (Chau et al., 
2012). However under diseased conditions, miR-21 positive mice developed 
significantly more interstitial fibrosis and epithelial injury when compared to miR-21-
/- mice in UUO and ischaemic reperfusion injury models. miR-21 was also shown to 
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be up-regulated in response to UUO and ischaemic reperfusion injury in mild type 
mouse kidney (Chau et al., 2012). In another study which used ultrasound micro-
bubble induced knockdown of miR-21 similarly suggested reduced miR-21 and 
inhibited the progression of renal fibrosis (reduced ECM deposition of α-SMA 
positive cells) in the UUO model (Zhong et al., 2011). Recently another study by 
Duffield’s lab further confirmed the pro-fibrotic role of miR-21 in kidneys and 
demonstrated the link between miR-21 and molecules involved in metabolic pathways 
such as Pparα (Chau et al., 2012). 
 
1.5.5.2.2 Tubular cells  
In proximal tubular epithelial cells, high glucose increased pre-miR-21 and miR-21 as 
well as PTEN. Knockdown of miR-21 in proximal tubular cells, as expected, inhibited 
high glucose induced protein synthesis and fibronectin expression (Dey et al., 2011). 
Zhong et al showed an increase of miR-
(2ng/ml) for either 12 or 24 hours. Knockdown of SMAD3 prevented 
iR-21 expression (Zhong et al., 2011).  Over-expression of miR-
and αSMA, while knockdown of miR-21  inhibited the expression of these fibrotic 
markers (Zhong et al., 2011). However, cell death was observed in both over-
expression and knockdown of miR-21, potentially due to the role of miR-21 in 
regulating cell proliferation and apoptosis (Frankel et al., 2008; Li et al., 2009; Zhou 
et al., 2010).  
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1.5.5.2.3 Mesangial cells  
Mesangial cells exposed to high glucose (25mM) show elevated miR-21 levels. This 
elevation is however reversed by stoping cellular glucose uptake through blockade of 
the glucose transporter Glut-1 (Dey et al., 2011; Heilig et al., 2006; Linden et al., 
2006). Knockdown of miR-21, inhibited high glucose induced fibronectin production 
(Dey et al., 2011). On the other hand, over-expression of miR-21 significantly 
increased protein synthesis in mesangial cells suggesting a role for miR-21 in 
mediating mesangial cell hypertrophy (Dey et al., 2011). Consistent with this finding, 
miR-21 had also been shown to inhibit mesangial cells proliferation and suppress 
PTEN expression under hyperglycemic condition. These studies, in combination, 
support the conclusion PTEN is a key target of miR-21 which may play an important 
role in maintaining kidney health (Zhang et al., 2009).  
 
1.5.5.2.4 Summary 
These early studies suggest that miR-21 as a pro-fibrotic miRNA is uniformly 
activated early in the kidney under hyperglycaemic conditions, is able to directly 
target PTEN and promotes renal fibrosis by driving the production of ECM proteins. 
It also responds to TGFβ signalling, where SMAD3 seems to play an important role in 
mediating the activation of miR-21. Thus, miR21 appears to be a good candidate as a 
target in preventing diabetic nephropathy, especially considering miR-21 knock-out 
cells have relatively normal physiology even though miR-21 induced cell apoptosis 
may need further investigation.   
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1.5.5.3 miR-200 family 
1.5.5.3.1 Whole kidney/tubular  
As discussed above, EMT is likely to play an important role in the pathogenesis of 
diabetic nephropathy. It allows epithelial cells to be converted into active 
myofibroblasts, which contribute significantly towards the deposition of extracellular 
matrix (Hills and Squires, 2011; Zeisberg and Duffield, 2010). Studies investigating 
the relevance of the miR-200 family to diabetic nephropathy were initially triggered 
by the observation that members of the miR-200 family prevented EMT in cancer 
cells by regulating ZEB protein expression. (Bracken et al., 2008; Gregory et al., 
2008a). Prolonged exposure to TGFβ has also been suggested to induce epigenetic 
changes in the miR-200 loci, resulting in altered expression of miR-200 (Gregory et 
al., 2011) and thus completing the negative feedback loop cycle.  
Wang et al reported TGFβ1 (10ng/mL, 72 hrs) decreases the expression of miR-200a, 
b, c, while both TGFβ1 and TGFβ2 down-regulate the expression of miR-200a in 
NRK52E cells (Wang et al., 2011). Over-expression of miR-200a down-regulated 
TGFβ induced SMAD3 activity as well as other markers of EMT such as ZEB1 and 
ZEB2 and PAI-1. They also demonstrated that miR-200a and miR-141 were able to 
directly bind to the 3’UTR of TGFβ2 and thus down-regulate the expression of 
TGFβ2. In vivo experiments confirmed that both miR-141 and miR-200a were 
decreased in an adenine-induced renal fibrosis animal model (Wang et al., 2011).  
Oba et al used the UUO model to study the role that the miR-200 family plays in renal 
fibrosis. Interestingly, all members of the miR-200 family were increased in a time 
dependent fashion following UUO, in association with reduced ZEB proteins, 
suggesting a positive compensatory response of the kidney to down-regulate fibrotic 
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proteins (Oba et al., 2010). Over-expression of miR-200b by intravenous injection of 
miR-200b precursor (0.5nM) before UUO reversed induction of ZEB proteins as well 
as COL1, 3 and fibronectin (Oba et al., 2010). 
However, Xiong et al showed contradictory data as they found in microarray analyses 
that miR-141 and miR-200a were decreased (days 3, 7, 14) along with a reduction in 
E-cadherin and increase in α-SMA and fibronectin in a similar UUO rat model. When 
exposed to TGFβ (5ng/ml, 12hr) the miR-200 family was however increased in 
NRK52E cells. Over-expression of any of the miR-200 family members prevented the 
TGFβ induced increase of α –SMA and fibronectin, and restored E-cadherin 
expression (Xiong et al., 2012). 
 
1.5.5.3.2 Mesangial cells 
 miR-200b and miR-200c had also been found to be increased in the glomeruli of both 
STZ-induced and db/db diabetic mice. TGFβ, as expected,  increased the expression 
of miR-200b, 200c, 192 by more than 2 fold in mouse mesangial cells (MMCs) (Kato 
et al., 2011). miR-200 family had been demonstrated to directly target ZEB1 ZEB2 
3’UTR in various cell types including NRK52E, HK-2 and MMCs (Gregory et al., 
2008a; Kato et al., 2011; Oba et al., 2010). COL4a1 expression induced by miR-192, 
200b mimic, as well as TGFβ can be reversed by miR-inhibitors in MMCs. 12 E-Box 
transcription factor binding sites which ZEBs can bind and suppress gene expression 
were identified on the promoter of COL4a1. Expression of the promoter activity was 
decreased by knocking down miR-200b. Co-transfection of miR-192, miR-200b 
increased COL1a2 promoter activity but the activity is clearly co-ordinated as no 
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single member is in isolation responsible for the increase in up-regulation of pro-
fibrotic genes (Kato et al., 2011). 
 
1.5.5.4 miR216/217 
1.5.5.4.1 Glomerulus/ Mesangial cells  
Kato et al identified two microRNAs, miR-216a and miR-217 that were activated in 
glomeruli of STZ induced and db/db diabetic mice, as well as by TGFβ in mesangial 
cells. Both miRs are located within the second intron of a non-coding RNA sequence, 
with several E-boxes being identified on the upstream promoter that are potentially 
regulated by ZEB proteins. Since TGFβ activates miR-192 and represses ZEB 
proteins, the question as to whether the activation of miR-216a/217 occurred through 
the action of miR-192 was addressed. Knockdown of miR-192 in the presence of 
TGFβ demonstrated reduced 216a/217, COL1a2 and increased ZEB2 mRNA while 
over-expression of miR-192 increased 216a/217. Knockdown of ZEB2 demonstrated 
a similar result, confirming that miR-192 plays a role in the regulation of these 
miRNAs. These investigators additionally identified PTEN to be a direct target of 
both miR216a and miR-217. Down-regulation of PTEN by the two miRs led to the 
activation of AKT, which resulted in mesangial cell survival and hypertrophy (Kato et 
al., 2009b). Additionally, miR-216 had also been shown to directly target Ybx1, a 
RNA-binding protein that may play a role in that activation of COL1a2 by interacting 
with transcription factors Tsc-22 and Tfe3 in mesangial cells (Kato et al., 2010).  
 
49 | P a g e  
 
1.5.5.5 miR-29 
The miR-29 family has been shown to play an important role in cardio-vascular health 
and down-regulation has resulted in cardiac fibrosis (van Rooij and Olson, 2009; van 
Rooij et al., 2008). Its role in renal disease is discussed below. 
 
1.5.5.5.1 Renal Cortex  
Long et al have shown that miR-29c is increased in db/db mice compared to their 
non-diabetic heterozygote control (db/m) littermates, while miR-29c anti-sense 
delivered intra-peritoneally in db/db mice resulted in reduced albuminuria and 
reduced renal fibronectin expression compared to mice treated with control 
oligonucleotides (Long et al., 2011). This result seems to challenge the previous 
findings on cardiac fibrosis. However, it was subsequently demonstrated that miR-29c 
was able to suppress Spry1 by directly targeting its 3’UTR.  Spry1 is an inhibitor of 
the Ras/MEK/ERK pathway (Kim and Bar-Sagi, 2004; Mason et al., 2006) and it may 
also negatively regulate the activity of RhoA and its downstream Rho Kinase activity 
through Wnt signalling pathways (Long et al., 2011; Miyoshi et al., 2004; Wang, 
2009; Wang et al., 2008b). Thus, by targeting Spry1, miR-29c positively promotes the 
progression of diabetic nephropathy. 
However, in a different study where a hyperglycaemic mouse model was also used, a 
a reduction of miR-29 was demonstrated. In an STZ-induced diabetic ApoE knockout 
mice model, miR-29a and c were decreased following 10 weeks of diabetes, which 
was associated with increased renal COL4 expression. In another model of advanced 
diabetic renal fibrosis, the uninephrectomised (UNx) STZ-diabetic rat model, 18 
weeks post induction of diabetes the renal cortex showed decreased level of miR-29a, 
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c again with increased COL1, COL4, fibronectin and laminin expression (Wang et al., 
2012b).  
Consistent with the Wang’s findings, mouse kidney subjected to ureteric obstruction 
showed decreased expression of all 3 members of the miR-29 family, when compared 
to the non-obstructed kidney. Over-expression of miR-29b in the kidney, as expected, 
partially prevented obstruction-induced renal fibrosis by reversing the elevated COL1 
and COL3. UUO in SMAD3 knockout mice showed increased miR-29a and miR-29b 
along with protection against renal fibrosis compared to wild type controls 
demonstrating a reno-protective property of miR-29b  (Qin et al., 2011).  
 
1.5.5.5.2 Proximal tubular cells and Fibroblasts 
miR-29a and miR-29c are 10 fold and 5 fold more abundant than miR-29b 
respectively in normal rat kidney (NRK52E) cells under control conditions. Du et al 
demonstrated that miR-29a, which is highly expressed in tubular cells (HK-2), was 
significantly down-regulated by high glucose (7days) and TGFβ (10ng/mL at various 
time points). miR-29a targets COL4a1 and COL4a2 directly for degradation in human 
cells (HK-2). (Du et al., 2010). In an in vitro epithelial cell model (NRK52E cells), 
TGFβ and high glucose (10ng/mL TGFβ and 25mM glucose, 3 days) decreased miR-
29a, miR-29b and miR-29c along with decreased E-cadherin and increased COL1 and 
COL4. Over-expression of all three members of miR-29 in NRK52E cells reduced 
COL1 and COL4 expression. In the same paper, the investigators also demonstrated 
that miR-29 (-a; -b; -c) decreased COL1 and COL4 via direct targeting of their 3’UTR 
(Burns et al., 2006; Wang et al., 2010a; Wang et al., 2012b).  
In NRK52E and MEF cells, miR-29b over-expression can reverse TGFβ (2ng/mL) 
induced COL1,COL3 expression while knockdown of miR-29b increased COL1, 
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COL3 and α –SMA independent of the presence of TGFβ. NRK52E and MEF cells, 
in which  SMAD3 had been silenced, showed similar results, indicating a possible 
negative regulation of miR-29 by TGFβ/SMAD. These cells also showed reduced 
COL1 and COL3 expression despite TGFβ (2ng/mL) incubation which is surprising 
given the multiple signalling pathways activated by TGFβ, again suggesting a central 
role of SMAD signalling in TGFβ induced renal fibrosis (Qin et al., 2011). In vitro 
experiments using NRK52E and MEF showed that miR-29b over-expression can 
reverse TGFβ (2ng/mL) induced COL1,COL3 expression, while knockdown of miR-
29b increased COL1, COL3 and α –SMA independent of the presence of TGFβ (Qin 
et al., 2011). 
 
1.5.5.5.3 Mesangial cells  
Consistent with findings in other cell types, TGFβ decreased all three members of 
miR-29 and increased COL1, COL3, COL4 mRNA expression in primary cultures of 
mouse mesangial cells. Over-expression of miR-29 (a,b,c) again as expected, 
decreased COL1 both at the mRNA and protein level (Wang et al., 2012b). 
 
1.5.5.5.4 Podocytes  
In accordance with Long’s findings in db/db mice where miR-29c was found to be 
increased, mouse podocytes exposed to 25mM glucose (24hr) also demonstrated 
increased miR-29c expression. Over-expression of miR-29c using lenti-virus 
mediated gene expression in mouse podocytes showed increased apoptosis, as 
evidenced by increased annexin-V-positive cells and increased caspase activity (Long 
et al., 2011). However, TGFβ (5ng/mL, 3 days) decreased miR-29b, and -c in 
conditionally immortalised human podocytes. Over-expression of all three members 
52 | P a g e  
 
of miR-29 in human podocytes decreased COL1, COL3 and COL4, as well as 
vimentin and αSMA mRNA expression (Wang et al., 2012b).  
 
1.5.5.6 miR-377 
miR-377 was found to be elevated in two mice models of diabetic nephropathy, 
namely, non-obese diabetic (NOD/Lt) mice and STZ induced C57BL/6 mice (Wang 
et al., 2008a). Both TGFβ (2ng/mL, 12hr) and high glucose (22.5 mM, 7 days) 
increased the expression of miR-377 in cultured human and mouse mesangial cells. 
Over-expression of miR-377 in these cells increased fibronectin but had no effect on 
COL4. Authors identified p21-activated kinase and superoxide dismutase, which 
enhance fibronectin production, as direct targets of miR-377 (Wang et al., 2008a). 
 
1.5.5.7 SMAD Knockout and miRNAs 
SMAD signalling pathway is central to TGFβ mediated renal fibrotic changes. 
Professor Lan’s group looked at miRNAs expression profiling using several SMAD 
knockout animal models and cell lines, providing invaluable data in understanding the 
interplay between SMADs and miRNAs. 
Knockdown of SMAD3 but not SMAD2 decreased TGF induced miR-192 expression 
in NRK52e cells and in mouse embryonic fibroblast (MEF) cells (Chung et al., 2010).  
These investigators further demonstrated  precipitation of the miR-192 promoter 
region containing 2 SMAD binding sites with anti-SMAD3 antibody in both human 
tubular epithelial cells (TEC) and MEFs, indicating the involvement of SMAD3 in 
regulating the expression of miR-192 (Chung et al., 2010). Again, miR-21 was found 
to be reduced in  SMAD3 knockout but not SMAD2 knockout  mice subjected to 
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UUO (Zhong et al., 2011).   Consistently, knockout of SMAD3 prevents TGF induced 
miR-21 expression in tubular cells and MEFs (Zhong et al., 2011).   
 
1.5.5.8 Conclusion 
 miRNAs are now considered to play key roles in regulating orchestrated gene 
expression in both health and disease. The differential expression of miRNAs in 
specific cell types at the various stages of the development of diabetic nephropathy, or 
in the presence of the pro-fibrotic cytokine TGFβ, suggest a time dependent 
regulation of miRNAs that is both context and time sensitive. The available studies 
suggest multiple biological processes involved in the pathogenesis of diabetic 
nephropathy could potentially be sophisticatedly regulated by miRNAs.  
However, controversies still exist in the expression profile of miRNAs observed in the 
kidney, such as miR-192. These differences may be explained by the different animal 
model or treatment conditions. More specific elucidation of miRNA expression in 
each type of cell in vivo is required, although this is technically challenging. It is not 
surprising that different cells respond differently to the same stimuli and differential 
changes observed in renal cortex might just be the average of all miRNAs expressed 
by different cells. Thus the absolute as well as the relative expression level of each 
miRNA in different cells is important in constructing the molecular basis of diabetic 
nephropathy.  
In terms of identifying targets of miRNAS, the in silicon prediction model provides a 
good starting point. The lack of a high-throughput methodology in identifying and 
verifying the miRNA and mRNA interactions remains a technical challenge, which 
limits our understanding of the regulatory roles mediated by miRNAs. Furthermore, 
the interaction between miRNAs themselves, add another level of complexity. Thus, 
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new approaches and technologies are likely to be required.  The following diagram 
summarizes the regulations of and by miRNAs reviewed in this thesis. 
 
Figure 1.7 MiRNAs involved in the regulation of genes of interest in the 
context of renal fibrosis. Central to this network is TGFβ.  
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1.6 Prostate Transmembrane Protein, Androgen Induced 
1.6.1 Background 
Prostate Transmembrane Protein, Androgen Induced (PMEPAI) which is also known 
as TMEPA1, STAG1 or ERG1.2 is a transmembrane protein that may play an 
important role in antagonising TGFβ1 signalling (Liu et al., 2011; Singha et al., 
2010). There is very little literature on this novel gene and thus more research is 
required to delineate the full spectrum of function of this gene. 
 
1.6.2 Discovery 
PMEPA1 was first identified as a novel gene that was up-regulated in response to 
activation of the nuclear androgen receptor in 2000. By examining multiple tissue 
using northern blots, it was found that PMEPA1 was expressed at highest levels in 
prostate tissue but also highly expressed in the kidney. Initial characterisation 
indicated the 252-amino-acid long protein contains a type Ib transmembrane domain 
coded by residues 9-25. (Xu et al., 2000). Later in 2001, Rae et al fully characterised 
the gene and found two PMEPA1 transcripts, 2.7 kb and 5 kb long, with identical 
coding regions but a variable 3’ UTR. PMEPA1 cDNA encodes a protein 287-
amino-acid long. However, two protein products of 36 and 39 kDa were observed. 
The PMEPA1 gene was mapped to chromosome20q13 between microsatellite 
markers D20S183 and D20S173 containing 4 exons and three introns (Rae et al., 
2001). In the same study, up-regulation of PMEPA1 was also observed in renal cell 
carcinoma using differential display polymerase chain reaction as well as stomach 
and rectal adenocarcinomas. Conversely, it was barely detectable in leukemia and 
lymphoma samples (Rae et al., 2001). Under normal conditions, it was 
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predominantly expressed in prostate tissue and at low levels in the ovary. (Rae et al., 
2001).  
 
1.6.3 Role in Prostate Cancer 
In 2003, the same group who first described PMEPAI demonstrated its interaction 
with human E3 ubiquitin-protein ligase (NEDD4), also known as neural precursor 
cell expressed developmentally down-regulated protein 4, which is involved in the 
ubiquitin-dependent proteasome-mediated protein degradation. PY motifs found in 
PMEPA1 are shown to interact with the WW domain in NEDD4 (Xu et al., 2003). 
PMEPA1 levels were decreased in advanced cases of prostate cancer, which is 
considered to be mediated through PMEPA1 induced cell growth inhibition, via 
interaction with NEDD4 and subsequent degradation (Xu et al., 2003). The same lab 
later discovered a negative feedback loop between PMEPA1 and the androgen 
receptor (Li et al., 2008). PMEPA1 is a direct transcriptional target of androgen 
receptor. Transient over-expression of PMEPA1 down-regulates androgen receptor 
protein levels, while knockdown of PMEPA1 leads to elevated levels of androgen 
receptor, as well as its target genes. The negative feedback on androgen receptor by 
PMEPA1 is thought be facilitated by the ubiquitination of androgen receptors and 
subsequent proteasome dependent degradation. A mutation in the PY motif impairs 
NEDD4 recruitment and thus abolishes androgen receptor ubiquitination (Li et al., 
2008). 
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1.6.4 PMEPA1 and TGFβ signalling 
In 2010, the pioneering work of Watanabe et al demonstrated an important role of 
PMEPA1 in TGFβ signalling.  (Watanabe et al., 2010). This study confirmed the 
existence of a negative feedback loop controlling the duration and intensity of TGF-
SMAD Signalling (Watanabe et al., 2010). Given the importance of this finding, and 
its potential role in preventing nephropathy, including diabetic nephropathy, details 
of this study will be discussed below. 
 
1.6.4.1 Induction of PMEPA1 by TGFβ1 
Induction of PMEPA1 expression by TGFβ1 is observed in many different cells. 
However it is still unclear whether PMEPA1 is activated directly by TGFβ1 or 
through its complex signalling pathways. To address this question cells were with 
cycloheximide for 1 hr to halt de-novo protein synthesis, followed by stimulation 
with TGFβ1 for 2 hr. PMEPA1 mRNA expression was found to be elevated, with a 
delayed increase in protein levels, suggesting PMEPA1 is a direct and early target of 
TGFβ1 signalling. BMP7, on the other hand, did not alter the expression of 
PMEPA1. Hence differential regulation occurs within the different members of the 
TGFβ superfamily. 
1.6.4.2 PMEPA1 interrupts TGFβ signalling pathways 
SMAD signalling, discussed earlier, is one of the main molecules involved in TGFβ 
signalling. Briefly to reiterate, TGFβ1 binds to TGFβ1 receptor II, which 
subsequently phosphorylates TGFβ1 receptor I. The activated TGFβ1 receptor I in 
turn, phosphorylates and activates SMAD2/3, which then forms the SMAD complex 
with SMAD4 and translocates into the nucleus for gene regulation. A luciferase 
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reporter with a SMAD only driven promoter was co-transfected with PMEPA1 with 
the presence of TGFβ1. PMEPA1 dose dependently inhibited luciferase activity 
implying inhibition of the SMAD signalling pathway. Furthermore, all three variants 
of human PMEPA1 registered in gene bank have been shown to block TGFβ1 
induced luciferase reporter activity. Co-transfection of constitutively active TGFβ1 
receptor I, FLAG tagged SMAD2 and PMEPA1 followed by immunoprecipitation of 
SMAD2 was undertaken. PMEPA1 significantly reduced phosphorylation of the 
pulled down SMAD2, which again confirms the findings.  
A gain of function study by the over-expression of PMEPA1 in NMuMG cells 
prevented the expression of TGFβ1 direct target gene PAI-1. In an immortal human 
keratinocyte line (HaCaT) cells, TGFβ1 activated genes, such as cyclin-dependent 
kinase inhibitors and JunB, were also decreased, while TGFβ1 suppression of c-Myc 
was rescued by PMEPA1 over-expression. Loss of function with PMEPA1 
knockdown again demonstrated prolonged and intensified SMAD2 and SMAD3 
phosphorylation. 
 
1.6.4.3 PMEPA1 and SMAD proteins 
Using co-immunoprecipitation of SMAD followed by detection with anti-PMEPA1, 
the investigators demonstrated PMEPA1 can physically bind to unphosphorylated 
SMAD2 and SMAD3, but not SMAD1, 4 and 7. Incubation with activated SMAD2 
and TMEPA1 in vitro suggested PMEPA1 binds equally well to both phosphorylated 
and unphosphorylated SMAD2, though no result for SMAD3 result was shown. 
Furthermore, PMEPA1 has been shown to disrupt the binding between SMAD2 and 
SMAD4 before translocation to the nucleus..  
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It was hypothesised that the PY domain presented in PMEPA1 is responsible for the 
inhibition of TGFβ signalling. However, a mutated PMEPA1 lacking the PY motif 
preserved its ability to inhibit TGFβ signalling. Interestingly, a PMEPA1 mutant 
lacking the transmembrane domain and mislocalised in cytoplasm could also inhibit 
TGFβ signalling. Thus a distinct mechanism of inhibition must be present. Deletion 
analysis narrowed the functional region responsible for inhibition of TGFβ1 to 
Asn
171
 to Ser
204
 residues of PMEPA1, while PMEPA1 with residues from 1 to 171 
failed to interact with SMAD2. After examining the region, a Pro-Pro-Asn-Arg 
(PPNR) peptide sequence was found to be similar to the SMAD interaction motif 
originally identified in the Milk and Mixer transcription factors (Randall et al., 2002). 
Site specific mutagenesis was again used to modify PPNR to 4 alanine residues in 
PMEPA1, where upon interaction with SMAD2 was subsequently lost. A fusion 
protein consisting of a 20 amino acid residue, including the putative SMAD binding 
region and Green Fluorescence Protein (GFP), was constructed and was shown to 
interact with SMAD2, while the 4 alanine mutant had no binding capacity, further 
proving the direct interaction between PMEPA1 and SMAD2.  
1.6.4.4 PMEPA1 Competes with SARA for SMAD2 Binding 
SMAD Anchor for Receptor Activation (SARA) is a protein that aids the recruitment 
of SMAD2 to the TGFβ1 receptor complex and mediates the interaction with 
SMAD2 via its SMAD binding domain (Tsukazaki et al., 1998). There is a 
significant similarity between the sequences of the SMAD binding domain in SARA 
and PMEPA1 (Randall et al., 2002). It has been demonstrated that over-expression 
of SARA affected PMEPA1 –SMAD2 interaction while the vice versa was also true 
as over-expression of PMEPA1 abrogated SARA-SMAD2 interaction. Thus, 
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PMEPA1 competes with SARA for SMAD2 binding and consequently prevents 
SMAD2 activation by TGFβ1 receptors. 
 
1.6.5 Subsequent investigation of PMEPA1 in models of disease 
Since the link between PMEPA1 and TGFβ1 signalling has been established and its 
inhibitory role described, there is a growing interest in PMEPA1 and its role in 
various disease models. 
The same group who identified the TGFβ1 inhibitory role of PMEPA1 investigated 
the regulation of PMEPA1 gene itself (Nakano et al., 2010). It was found that the 
PMEPA1 promoter was under the synergistic regulation of both TGFβ1-SMAD and 
Wnt/β-catenin/T Cell Factor (TCF) 7L2 signalling. A TGFβ1 – responsive TCF7L2-
binding element (TTE) was found in intron 1 of the PMEPA1 gene. TCF7L2 can 
bind to TTE and initiate gene regulation. Mutagenesis of this TTE binding site 
abolished TGFβ1 and TCF7L2 responses, indicating the important role of TCF7L2 
in the regulation of PMEPA1 (Nakano et al., 2010). 
More recently, PMEPA1 has been shown to suppress p21 transcription in androgen 
receptor negative prostate cells and promote cell proliferation. This is thought to be 
mediated via up-regulation of c-Myc, indicating PMEPA1’s role in cell cycle 
regulation (Liu et al., 2011).  
Thus, the mode of action of PMEPA1 can be summarised in the following diagram: 
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Figure 1.8 Mechanism of PMEPA1 in inhibiting TGFβ1 signalling.  
 
1.6.6 PMEPA1 and Diabetic Nephropathy 
TGFβ1 and downstream SMAD signalling play an important part in the pathogenesis 
of all forms of progressive kidney disease, including and importantly, diabetic 
nephropathy. The discovery of the link between the inhibitory role of PMEPA1 and 
TGFβ1 signalling added a new piece of information to the existing body of 
knowledge regarding the SMAD signalling pathway and its regulation of 
downstream genes.  Targeting TGFβ1-SMAD mediated profibrogenic genes by 
PMEPA1 provides a potential therapeutic strategy in preventing and delaying 
progression of renal disease, including diabetic nephropathy. 
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1.7 Summary and Statements of aims 
The aims of the thesis were: 
1. To evaluate the role of miR-200b in preventing renal fibrosis, in vitro 
and in vivo.  
For the in vitro component of the study, TGFβ1 was used to induce cellular 
‘fibrotic’ responses and drive epithelial to mesenchymal transition in the human 
proximal tubular cell line (HK-2). The role of miR-200b in preventing these 
changes was studied by examining the ECM proteins and EMT markers such as 
collagen, fibronectin, α-SMA, vimentin and ZEB proteins. Important signalling 
pathways and molecules activated to drive these pathological changes were also 
examined, for example, the MAPKs and SMADs were studied using western 
blotting. It was determined that miR-200b was able to strongly suppress the 
production of fibronectin and successfully prevented EMT, whereas the latter 
was thought to be due to the  suppression of ZEB1 and ZEB2 transcription 
factors. Molecular mechanisms behind the miR-200b mediated fibronectin 
suppression was also studied and determined to be direct targeting of  the 
fibronectin 3’UTR by miR-200b. 
For the in vivo studies, examining the role of miR-200b in preventing renal 
fibrosis, lentivirus, nanoparticle and ultrasound microbubble mediated gene 
transfer technology were carried out and applied to mice subjected to UUO. 
Given that TGFβ1 is well recognised to play a central role in all models of renal 
fibrosis, this model was undertaken prior to the future study of mi-200b in a 
long term model of diabetic nephropathy. The efficacy of miR-200b in 
modifying UUO induced renal fibrosis was then studied. Immunohistochemistry 
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was used to examine the profibrogenic and EMT markers. Alternative miRNA 
delivery systems for in vivo applications and their efficacy will also be 
investigated. 
 
2. Role of PMEPA1 in preventing TGFβ1 induced changes. 
PMEPA1 has been implicated in a process which antagonises TGFβ signalling 
by targeting R-SMADs. In this study, the role of PMEPA1 in preventing TGFβ1 
induced fibrosis in the renal context was examined by experimentally inducing 
loss and gain of function of PMEPA1 in HK-2 cells. siRNA mediated silencing 
and plasmid mediated gene over-expression were used. Markers of EMT induced 
by the TGFβ1-SMAD pathway such as E-Cadherin and vimentin, and of cell 
cycle regulation ie p21 were studied to evaluate the importance of PMEPA1 in 
mediating TGFβ1-SMAD signalling and downstream effects in renal tubules.   
65 | P a g e  
 
2 Chapter 2 Materials and Methods 
2.1 Cell Culture 
2.2 Immortalised Human Kidney Proximal Tubular Cell Line (HK-2)  
HK-2 cells from American Type Cell Collection (ATCC) are the main cells used in 
this PhD project to model renal tubular cell pathology. They are derived from PTCs 
originating from normal adult human renal cortex and immortalised by transduction 
with human papillomavirus (HPV16) E6/E7 genes (Ryan et al., 1994). HK-2 cells 
have been widely used as a robust substitute of the primary kidney proximal tubular 
cells in in vitro experiments studying renal pathology in laboratories around the world 
including our own (Qi et al., 2006; Wong et al., 2011) 
HK-2 cells were grown in Keratinocyte-Serum Free Medium (KSFM) (Life 
Technologies, USA) supplemented with 5ng/mL recombinant EGF and 0.05mg/mL 
bovine pituitary extract in various culture vessels including 10cm petri dishes, tissue 
culture plate and tissue culture flasks. Cells were incubated at 37
o
C in 5% CO2 and 95% 
air. The medium was refreshed every 48 hrs until confluent.  
When cells were confluent, trypsin-EDTA (containing 0.25% (w/v) trypsin) was used 
to detach cells from the culturing vessel. Trypsin was then diluted 10 fold with 
complete KSFM and cells were spun down at 123G and subsequently washed twice 
with complete KSFM. HK-2 cells were then plated at the desired density for 
immediate experimental use or frozen for longer term storage in liquid nitrogen.  
 
2.2.1 Human Embryonic Kidney 293T Cell Line (HEK293T) 
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HEK293T cells also known as 293T cells was created by transfecting a sub-line of 
adenovirus-immortalized human embryonic kidney cells (HEK) with a gene encoding 
the SV40T-antigen and a neomycin resistance gene. The cell line is competent for 
replication of vectors carrying the SV40 origin of replication.  This allows for greater 
amplification of transfected plasmids and extended temporal expression of the desired 
gene products  
(http://www.hpacultures.org.uk/products/celllines/generalcell/detail.jsp?refId=120220
01&collection=ecacc_gc) (Graham et al., 1977).  In addition, the easy ‘transfectabilty’ 
also made this cell line a popular model for viral packaging and molecular studies.  
HEK293T cells were grown in Dulbecco's Modified Eagle Medium (DMEM) with 
25mM D-glucose supplemented with 10% Fetal Calf Serum (FCS) in various culture 
vessels including tissue culture plates and flasks. Cells were incubated at 37
o
C in 5% 
CO2 and 95% air. The medium was refreshed every 48 hrs until confluent.  
When cells were confluent, trypsin-EDTA (containing 0.25% (w/v) trypsin) was used 
to detach cells from the culturing vessel. Trypsin was then diluted 10 fold with 
DMEM (10% FCS) (Life Technologies, USA) and cells were spun down at 123G and 
subsequently washed twice with DMEM (10% FCS). HEK293T cells were then 
plated at the desired density for immediate experimental use or frozen for longer term 
storage in liquid nitrogen.  
 
2.3 RNA Extraction and Reverse Transcription 
2.3.1 Total RNA Extraction and Reverse Transcription 
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Total RNA was extracted using a GenElut Mammalian Total RNA Miniprep Kit 
(Sigma, MO, USA). Cells (<7 million cells) subjected to relevant experimental 
conditions were lysed by incubation with 350 μL lysis solution containing β-
mercaptoethanol (1%, v/v) in the culture vessel for 2 minutes. The crude lysate was 
transferred to a filtration column and spun at 14,000 g for 2 min to remove cellular 
debris and shear DNA. 350 μL 70% ethanol was added to the filtrate and mixed 
thoroughly. The lysate/ethanol mixture was transferred to a GenElute Binding 
Column and centrifuged at 14,000 g for 15 s followed by removal of the filtrate. The 
binding column was washed once with 500 μL wash solution 1 and twice with 500 μL 
wash solution 2 (included in the kit, ingredient unknown). RNA was eluted with 50 
μL elution solution and quantitated using a NanoDrop ND-1000 Spectrophotometer 
(Thermo Fisher Scientific, USA). The quality of RNA was confirmed by the 
measurement of the A260/280 ratio. Typically, the ratio of an optimal sample falls 
between 1.8 and 2.2. RNA was used immediately or stored at -80
o
C. 
The extracted RNA was treated with DNAse to remove traces of DNA contamination 
carried over from RNA extraction that may interfere with the downstream real-time 
PCR (qPCR) analysis. For each RNA sample, 1 μg RNA, 1 μL 10x DNAse buffer 
(Life technologies, USA) and 1 μL DNAseI (Life technologies, USA) were added to 
an RNAse free PCR tube and the final volume was made up to 10 μL with RNAse-
free water. The reaction mix was incubated at room temperature (22
 o
C) for 15 min 
followed by the addition of 1 μL 25mM EDTA (Life technologies, USA) and 
incubated at 65
 o
C for 5 min to inactivate the DNAse enzyme. 
2 μL of the DNAsed RNA was used as the template in cDNA synthesis in the 
SuperScript VILO cDNA Synthesis Kit (Life technologies, USA). RNA template was 
mixed with 2 μL 10X SuperScript enzyme mix, 4 μL 5X VILO reaction mix and 12 
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μL RNAse-free water and then incubated at 25 oC for 10 min, 42 oC for 60 min and 85 
o
C for 5 min. The resulting cDNA was used immediately or stored at -20
 o
C. 
 
2.3.2 MicroRNA Extraction and Reverse Transcription 
2.3.2.1 Trizol Extraction of total RNA including microRNA 
1mL Trizol reagent (Life technologies, USA) was added to the cells (cells cultures in 
a 6-well plate) in a fume hood before being transferred to a fresh eppendorf tube. The 
homogenized lysate was incubated at room temperature for 5 min before the addition 
of 1 μL glycogen and 200 μL chloroform (Sigma, MO, USA).  The mixture was 
vortexed and incubated at room temperature for an additional 2-3 min before being 
centrifuged at 12,000 g for 15 min at 4
o
C. Three layers were evident: a lower red, 
phenol-chloroform phase containing protein, an intermediate phase (genomic DNA), 
and an aqueous phase containing RNA. The aqueous phase was transferred to a fresh 
ultracentrifuge tube and RNA was precipitated by the addition of 800 μL isopropanol 
and incubated at -80
o
C for 20 min. The mixture was then centrifuged at 12,000 g for 
30 min at 4
o
C followed by the removal of the supernatant. Precipitated RNA was 
washed with 1 mL 75% ethanol by inverting 3-4 times followed by centrifugation at 
12,000 g for 15 min at 4
O
C. Ethanol was removed and RNA was allowed to air dry 
briefly (5-10 min) followed by re-suspension  in 20 μL RNAse-free water. The RNA 
concentration was quantified using the NanoDrop ND-1000 Spectrophotometer. 
microRNA was DNAse treated in a similar way as total RNA described in above 
section. 
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2.2.2.2 MicroRNA Extraction with mirPremier microRNA Isolation Kit  
MicroRNA was also extracted using a column based mirPremier microRNA Isolation 
Kit (Sigma, MO, USA).  Cells (<3 million cells) subjected to relevant experimental 
conditions were lysed by incubation with 350 μL lysis solution containing 245 μL 
microRNA lysis buffer and 105 μL binding solution supplemented with 3.5 μL β-
mercaptoethanol (1%, v/v) in the culture vessel for 5 minutes. The crude lysate was 
transferred to a filtration column and spun at 14,000 g for 2 min to remove cellular 
debris and shear DNA. 385 μL 100% ethanol was added to the filtrate and mixed 
thoroughly. The lysate/ethanol mixture was added to a GenElute Binding Column and 
centrifuged at 14,000 g for 30 s followed by removal of the filtrate. The binding 
column was washed once with 700 μL 100% ethanol and twice with 500 μL wash 
solution 2. microRNA was dried by centrifugation at 14,000 g for 30 seconds before 
being eluted with 30 μL elution solution and quantified using the NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific, USA). The quality of microRNA was 
confirmed by the measurement of the A260/280 ratio. microRNA was used immediately 
or stored at -80
o
C. 
 
2.3.2.2 MicroRNA Reverse Transcription  
MicroRNA Reverse Transcription was performed using the miScript System (Qiagen, 
USA). MicroRNA (50ng-200ng) was mixed with 4 μL 5xmiScript, 1 μL miScript 
reverse transcriptase mix and the total volume made up to 20μL with RNAse-free 
water. The mixture was then incubated at 37ºC for 60 min followed by 95ºC for 5 min. 
The resultant cDNA was used immediately or stored at -20
 o
C. 
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2.2.2.4 MicroRNA PCR (Sybr Green Based) 
The relative expression of microRNA was determined by Sybr Green based PCR that 
amplifies reverse transcribed microRNA using one universal primer and one 
microRNA specific primer. Reverse transcribed microRNA was diluted 50 folds in 
water and used as template in PCR. in details 
 
2.4 Polymerase Chain Reaction (PCR) 
Semi-quantitative PCR was performed to assess relative changes in gene expression 
in different samples. Gene specific primers were designed using Roche Universal 
ProbeLibrary Assay Design (www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000) and verified using BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Internal controls, such as β-Tubulin, actin 
and RPL4 were used to ensure equal concentration of cDNA in concurrent PCRs. The 
number of amplification cycles in PCR was determined from the linear portion of the 
PCR cycle and was performed with increasing numbers of cycles.  
The primers were diluted to 10 mM with 10 nM Tris-HCL. The final PCR mix 
contained 2 μL cDNA, 1x PCR buffer, 2.5mM MgCl2, 0.5 mM dNTP, 0.1 mM of 
each forward and reverse primers, 1.25U Platinum Tad DNA polymerase (Life 
Technologies, USA) and RNAse-free water up to 25 μL. 
The following conditions were used to amplify genes of interest 
Initial denaturation:   94
 o
C  5 min 
3 step cycling 
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 Denaturation   94
 o
C  30 s 
Annealing   Variable  30 s 
Extension   72
 o
C  30 s 
Final extension  72
 o
C  10 min 
Amplicons and molecular markers (Fermentas, Canada) were electrophoresed through 
a 1.2% (w/v) agarose gel at 90V and visualised by GelGreen staining (Jomar 
Diagnostics, South Australia). Digitised images were obtained using an ultra-violet 
transilluminator (Bio-Rad, USA) and analysed with QuantityOne software (Bio-Rad, 
USA).  
 
2.5 Real-time PCR 
2.5.1 mRNA PCR 
Real-time PCR was performed using SYBRGreenER (Life Technologies, USA). 
cDNA, synthesised using a SuperScript VILO cDNA synthesis kit diluted 50X with 
DNAse-free water to be used as template in real-time PCR. 2 μL of the diluted cDNA 
was mixed with 10 μL SYBRGreenER qPCR Supermix Universal, 0.4 μL each of 10 
μM forward and reverse primer and 7.2 μL water. Amplification was performed using 
the Corbett Rotor Gene 3000 (Qiagen, USA) in the following profile with 
fluorescence captured at the end of each extension step. 
Initial denaturation:   95
 o
C  10 min 
3 step cycling for 40 cycles 
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 Denaturation   95
 o
C  10 s 
Annealing   60
 o
C  15 s 
Extension   72
 o
C  20 s 
The melting curve was obtained at the end of each run by ramping the temperature 
from 72 
o
C to 95 
o
C at the rate of 1 degree per 3.91 s.  
 
2.5.2  microRNA PCR 
Real-time PCR was performed using Qiagen miScript Primer Assays (Qiagen, USA). 
Synthesised cDNA was diluted 50X with DNAse-free water to be used as the 
template in real-time PCR. 2 μL of the diluted cDNA was mixed with 10 μL SYBR 
Green PCR master mix, 2 μL of each 10 x forward and universal primer and 4 μL 
water. Amplification was performed using the Corbett Rotor Gene 3000 (Qiagen, 
USA) in the following profile with fluorescence captured at the end of each extension 
step. 
1. Initial denaturation:   95 oC  15 min 
2. 3 step cycling for 40 cycles 
a. Denaturation  95
 o
C  15 s 
b.Annealing   55
 o
C  30 s 
c.Extension   70
 o
C  30 s 
The melting curve was obtained at the end of each run by ramping the temperature 
from 72 
o
C to 95 
o
C at the rate of 1 degree per 3.91 s. 
 
73 | P a g e  
 
2.6 Protein extraction and Quantitation 
Cells exposed to relevant experimental conditions were washed 3X with ice cold 1X 
Phosphate Buffer Saline (PBS) (136 mM NaCl, 2.68 mM KCL, 10.14 mM Na2HPO4, 
1.76 mM KH2PO4). Ice cold protein lysis buffer (50 mM Tris HCl, 150 mM NaCl, 5 
mM EDTA 9pH7.4), 1% Triton X-100. 0.1% sodium dodecyl sulphate (SDS), 
1%NP40, 1X PhosSTOP Phosphatase Inhibitor Cocktail (Roche, USA), 1X cOmplete, 
Mini Protease Inhibitor Cocktail (Roche, USA) were then added to the cells and left 
to incubate for 30 min at 4
 o
C. The cells with lysis buffer were scraped off the culture 
vessel before being transferred to a chilled microcentrifuge tube and incubated for 
another 30 min on ice. Lysate was subjected to a sonication water bath with 5s on, 5 s 
off alternate sonication cycles for 5 min with minimum sonication power output 
followed by centrifugation at 20,800g for 20 min at 4
o
C. The supernatant was 
collected and used immediately or stored at -20
 o
C. 
 
2.7 Western Blotting 
Cell lysate was mixed with 6X Laemmli sample buffer (0.35 M Tris HCl (pH 6.8), 10% 
SDS, 30% glycerol, 0.175 mM Bromophenol Blue, 6% (v/v) β-mercaptoethanol) and 
heated at 95
o
C for 10 min. Samples were then resolved on a SDS-PAGE gel and 
transferred to a Hybond nitrocellulose membrane (Amersham Pharmacia Biotech, 
Bucks, UK). The blots were blocked for 1 hr with Tris Buffered Saline (15.35 mM 
Tris HCl, 0.5 M NaCl) with 0.2% Tween (TTBS) and 5% skim milk or Bovine serum 
albumin (BSA) (pH7.4) before being incubated with primary antibody overnight at 
4
o
C. The nitrocellulose membrane was then washed three times with TTBS (1X 15 
min, 2X 5 min) and incubated with Horse Radish Peroxidase (HRP) labelled 
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secondary antibody for 1 hr at room temperature. Another three washes with TTBS 
(1X 15 min, 2X 5 min) were applied to the membrane, which was then developed 
using the ECL chemiluminescence detection method (Amersham Pharmacia Biotech, 
Bucks, UK). The image was captured and digitised using Las3000 (Fuji Film Life 
Science, Japan) and analysed using Multi Gauge software (Fuji Film Life Science, 
Japan). 
 
2.8 Transient Transfection with microRNA and/or Plasmid 
Transfection was successfully carried out using the Lipofectamine2000 transfection 
reagent (Life Technologies, USA). Cells were seeded onto a 6 well plate 24 hr prior to 
the transfection at 50% confluence. On the day of transfection, nucleic acids and 
Lipofectamine2000 were diluted with Opti-MEM Reduced-Serum Medium (Life 
Technologies, USA) before being mixed together and incubated to create the 
transfection complex. The cells were washed with Opti-MEM Reduced-Serum 
Medium before the transfection complex was carefully added in a drop wise fashion. 
Transfection complex was removed 5 hr post transfection and replaced with complete 
medium. Experimental protocols were commenced the following morning. 
 
2.9 Plasmid Cloning 
Plasmid cloning involves the enzymatic restriction digestion of both the plasmid 
cloning vector and insert before ligation of the two. Unless otherwise stated for 
specific experiments, 2 μg of DNA (applies to both plasmid and insert vector) was 
digested with the first restriction enzyme and purified with QIAquick PCR 
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Purification Kit (Qiagen, USA). The recovered DNA was digested with the second 
restriction enzyme and again purified. The recovered insert DNA fragment was then 
quantitated for use in experiments. The recovered plasmid cloning vector was further 
treated with shrimp alkaline phosphatase (Promega, USA) to remove the 5  ´phosphate 
groups on the DNA backbone to prevent auto-ligation of the linearized DNA. The 
purified vector DNA was then mixed with the insert DNA in the ratio of 1:3 in the 
presence of 1X ligation buffer and T4 ligase (Life Technologies, USA) and incubated 
at 4
o
C overnight. A negative control tube was included without the addition of the 
insert DNA. The ligation mix was diluted 10 fold and 2 μL of the diluted ligation mix 
was used to transform competent cells.  
50 μL MAX Efficiency DH5α Competent Cells (Life Technologies, USA) were 
removed from the -80
 oC freezer and thawed on ice. 2 μL of the diluted ligation mix 
was added to the competent cells, followed by gentle tapping on the side of the tube. 
The mixture was then incubated on ice for 30 min and heat shock treated at 42
 o
C for 
30 s. The mixture was incubated on ice again for 2 minutes before the addition of 200 
μL S.O.C. Medium (Life Technologies, USA) and then incubated on an orbital shaker 
for 30 min at 225rpm at 37
 oC. 50 μL of the competent cells were spread onto an agar 
plate containing 50 μg/mL ampicillin (Sigma, USA) and incubated overnight at 37 oC. 
Clones were picked and grown in 1-5 mL Luria-Bertani (LB) broth containing 50 
μg/mL ampicillin at 37 oC. 
 
2.10  PCR product clean up 
PCR purification to remove salt and protein as well as other contaminants was carried 
out using a QIAquick PCR Purification Kit (Qiagen, USA). 5 volumes of Buffer PB 
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were added to 1 volume of the PCR sample and mix, followed by the addition of 10 
μL 3M sodium acetate. The mixture was transferred to a QIAquick column and 
centrifuged for 60 s. The column was washed twice with 750 μL Buffer PE and dried 
by centrifugation for 1 min. The DNA was then eluted in 50 μL Buffer EB or pure 
water.   
 
2.11 Nucleotide Removal 
The QIAquick Nucleotide Removal Kit (Qiagen, USA) was used to remove 
nucleotides enzymatically digested from a DNA sequence as well as other 
contaminants. 10 volumes of Buffer PN was added to 1 volume of the reaction sample 
and mixed. The mixture was transferred to a QIAquick column and centrifuged for 
60s. The column was washed twice with 750 μL Buffer PE and dried by 
centrifugation for 1 min. The DNA was then eluted in 50 μL Buffer EB or pure water.   
 
2.12 Plasmid Extraction 
2.12.1  Plasmid Miniprep 
Plasmid minipreps were carried out using QIAprep Spin Miniprep Kits (Qiagen, USA) 
from 1-5 mL culture in LB broth grown overnight. Bacterial cells were harvested by 
centrifugation at 4000 g for 15 min at 4°C.  The resulting bacterial pellet was 
resuspended in 250 μL Buffer P1containing RNAse A. 250 μL Buffer P2 was then 
added and mixed thoroughly by vigorously inverting the sealed tube 4–6 times before 
the addition of 350 μL Buffer P3. The tube was then mixed immediately and 
thoroughly by vigorously inverting 4–6 times followed by centrifugation at 17,900 g 
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for 10 min. The supernatant containing plasmid DNA was collected and transferred to 
a QIAprep spin column before centrifugation at 17,900 g for 60. The column was then 
washed with 500 μL Buffer PB and 750 μL Buffer PE and eluted with 50 μL Buffer 
EB (10 mM Tris HCl, pH8.5). The eluted plasmid was then quantitated using 
Nanodrop and used immediately or stored at -20°C. 
 
2.12.2  Plasmid Maxiprep 
Plasmid miniprep was carried out using QIAGEN Plasmid Plus Maxi Kits (Qiagen, 
USA) for up to 200 mL culture in LB broth grown overnight. Bacterial cells were 
harvested by centrifugation at 5,000 g for 30 min at 4°C.  The resulting bacterial 
pellet was resuspended in 8 mL Buffer P1containing RNAse A. 8 mL Buffer P2 was 
then added and mixed thoroughly by vigorously inverting the sealed tube 4–6 times 
followed by incubation at room temperature for 3 min. 8 mL Buffer P3 was then 
added before the mixture was mixed and transferred to a filtration syringe. The 
mixture was then incubated at room temperature for 10 min and filtered. The filtrate 
containing plasmid DNA was collected and mixed with 5 mL Buffer BB before being 
transferred to a binding column.  A vacuum was created to draw the solution through 
the binding column, which was then washed with 700 μL Buffer ETR and 700 μL 
Buffer PE. Plasmid DNA was eluted with 400 μL Buffer EB. The eluted plasmid was 
then quantified using Nanodrop and used immediately or stored at -20°C.  
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2.13 Luciferase Assay 
Luciferase assays were carried out using the Dual-Luciferase Reporter Assay System 
(Promega, USA). Cells subjected to relevant plasmid transfection and experimental 
protocols in 12-well plates were washed with ice-cold PBS twice before 250 μL 1X 
passive lysis buffer was added to each well. The culture plate was placed on MixMate 
shaker (Eppendorf, USA) and gently shaken at 700 rpm for 15 min at room 
temperature. 20 μL lysate was transferred to each well of the 96-well luminometer 
compatible plate, which was then transferred to a luminometer for luciferase activity 
reading. Each sample was done in three technical triplicates.  
While in the luminometer, 50 μL Luciferase Assay Reagent II (prepared by 
resuspending Luciferase Assay Substrate in 10 mL Luciferase Assay Buffer II) was 
injected into each well and firefly luciferase activity was recorded for the next 10 s. 
50 μL 1X Stop & Glo Reagent was then added (prepared by mixing 1 volume of 50X 
Stop & Glo Reagent with 50 volumes of Stop & Glo Buffer) and renilla luciferase 
activity was recorded.  
 
2.14 Site Directed Mutagenesis 
Site directed mutagenesis was used to change 4bp in the 3’UTR of fibronectin mRNA 
to verify the binding ability of miR-200b to this region. The detailed methods are 
described in Materials and Methods section of Chapter 3. 
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2.15 Animal Handling 
C57BL6 mice were used during this PhD project to study the role of miR-200b in 
preventing unilateral ureteral obstruction induced renal fibrosis. The Royal North 
Shore Hospital Animal Care and Ethics Committee approved ethics with approval 
number 1203-008A.  Mice were bred in Kearns Facility located at level 3 of the 
Kolling Building. 6-8 week old mice were ordered and placed in the assigned holding 
shelf for Renal Research Lab. 2 weeks was given for mice to adapt to the new 
environment before the commencement of any treatment. Sufficient food and water 
was given to the mice throughout the whole experiment. Pseudo-virus or 
nanoparticles (according to different treatment group) containing miR-200b gene 
were injected through the tail vein when the mice were anaesthetised by 2% 
isoflurane gas (mixed with 1 part oxygen, 2 parts nitrogen) inhalation. A second 
injection of the same dosage was given 2 days after the first injection to ensure the 
expression of miR-200b. Expression of red fluorescent protein (fluorescent protein 
was co-expressed with miR-200b on the same vector) was examined using an in vivo 
imaging system in mice anaesthetised 2-3 days post injection to confirm positive 
transduction. 
On the day of performing UUO, mice were anaesthetised by 2% isoflurane gas (mixed 
with 1 part oxygen, 2 parts nitrogen) inhalation before immobilised onto a surgical 
pad. The region lateral to the abdomen (where kidneys lie beneath) was shaved and 
cleaned using Alcowipes (70% isopropanol). A vertical incision (~1-1.5 cm) was 
made at shaved area.  The left ureter was isolated and ligated twice (proximal and 
distal of the ureter) with surgical silk line. Sham-operated control mice had their 
ureter manipulated but not ligated. The incision wound was then sutured using a 
surgical silk line and mice were given intra-peritoneal buprenorphine (0.03 – 0.05 
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mg/kg) for pain induced by surgery. The mice were returned to cage after the surgery 
and kept under a heating lamp for 20 minutes. Infection and signs of stresses 
including pilo-erection, arching back, sunken face and weakness of the mice was 
observed closely daily. Mice were sacrificed 7 days after UUO and urine (from 
bladder), blood (from heart) and organs were harvested for analysis. 
 
2.16  Live Animal Imaging  
Anaesthetised mice were immobilised (limb immobilisation using tape) onto the 
platform fitted with adaptors for isoflurane gas, provided in the in vivo imaging 
device, and the mice were kept anaesthetised. Fluorescence was detected and X-ray 
scans of the skeleton were also obtained. The two images were then superimposed to 
illustrate the location of fluorescence.  Mice were then returned to their respective 
cages. 
 
2.17 Mouse Organ Harvesting 
Mice were anaesthetised using 2% isoflurane (mixed with 1 part oxygen, 2 parts 
nitrogen) and immobilised onto a surgical pad. A vertical incision was made to expose 
the internal organs. Bladder urine was collected followed by blood drawn from the 
left ventricle. 15 mL PBS was used perfuse the mice by gently pushing it through the 
left atrium. Organs were then collected. Samples for RNA/DNA and protein analysis 
were snap frozen in liquid nitrogen while samples reserved for immunohistochemistry 
were placed in 4% paraformaldehyde overnight before being transferred to 70% 
ethanol. 
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2.18 RNA extraction from tissue  
Once harvested, tissue samples were snap frozen in liquid nitrogen and stored in a -
80
0
C freezer until extraction. The miRNeasy Micro Kit (Qiagen, USA) was used to 
extract both mRNA and miRNA from the tissue samples. On the day of extraction, 
700 μL QIAzol Lysis Reagent was added to the sample, which was then homogenised 
for 20s using the Qiagen TissueRuptor (Qiagen, USA). The homogenised tissue was 
then incubated at room temperature for 5 mins before the addition of 140 μL 
chloroform and mixed by vigorous shaking for 15 s. The homogenate was allowed to 
settle at room temperature for 2-3 mins and centrifuged at 12,000 g for 15 mins at 4
0
C. 
350 μL of the upper clear aqueous phased was transfer to a fresh tube followed by the 
addition of 525 μL 100% ethanol.  The solution was mixed and transferred to into an 
RNeasy MinElute column in a 2 mL collection tube before being centrifuged at 
10,000g for 15s. The flow through was discarded and 700 μL Buffer RWT was added 
to the tube.  
 
2.19 Stable Cell Line Construction 
During this PhD, a stable cell line that constantly over-expresses PMEPA1 was 
constructed to study its role in preventing cellular fibrosis. The detailed materials and 
methods were outlined in the relevant sections of Chapter 5 of this thesis. 
 
2.20  Statistical Analysis 
All relative quantitation was expressed as percentage of the control value (100% or 1). 
Experiments were performed at lease in triplicate in a minimum of 3 different culture 
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preparations. Results were expressed as mean ± standard error mean (SEM) with n 
reflecting the number of culture preparations. Statistical comparisons between groups 
were made by analysis of variance (ANOVA) with pairwise comparison made using 
unpaired t-test. Analysis was performed with the software package Graphpad, version 
5.0 (Prism, USA). P values < 0.05 were considered significant. 
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3 Chapter 3 MiRNA-200b represses transforming growth factor beta1-
induced EMT and fibronectin expression in kidney proximal tubular cells  
 
3.1 Introduction 
miRNAs comprise a large family of small noncoding RNAs that have emerged as key 
post-transcriptional regulators of gene expression in mammals, plants, and protozoa. 
In mammals, miRNAs are predicted to control the activity of more than 60% of all 
protein-coding genes (Friedman et al., 2009) and regulate almost every cellular 
process (Bartel, 2009; Fabian et al., 2010). miRNAs regulate protein synthesis by 
base-pairing to 3’UTR of target mRNAs. TGF-β1 plays a key role in cell 
proliferation, differentiation and apoptosis, predominantly, but not exclusively 
through SMAD signalling pathways, which are key signalling pathways downstream 
of ligands of the TGF-β superfamily. TGFβ1 is considered to be a key driver of 
epithelial to EMT during which, epithelial cells are converted to active myofibroblasts. 
Excessive extracellular matrix proteins, including fibronectin, are produced by these 
myofibroblasts and hence they contribute significantly to renal tubulo-interstitial 
fibrosis. As alluded to above, the SMAD signalling pathway activated by TGFβ1 is a 
key pathway responsible for the downstream activation of TGFβ1. Once activated, the 
SMAD complex translocates into the nucleus and initiates transcription of genes 
relevant to renal fibrosis. In addition, signalling molecules such as phospho-ERK and 
phospho-p38 MAPK, activated by angiotensin II and AGEs as well TGFβ1, can also 
promote EMT by either interacting with the SMAD proteins or through non-SMAD 
dependent pathways. TGFβ1 additionally activates plasminogen activator inhibitor-1 
(PAI-1) (Clouthier et al., 1997; Ghosh and Vaughan, 2012; Han et al., 2010; Li et al., 
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2006). PAI-1 is a potent inhibitor of urokinase/tissue type plasminogen activator 
(uPA/tPA), which regulates the activity of MMPs. Since MMPs are involved in 
proteolytic degradation of matrix proteins, such as collagen and fibronectin, a 
reduction in PAI-1 expression will up-regulate MMPs and thus down-regulate the 
expression of fibronectin (Ghosh and Vaughan, 2012; Nagase and Woessner, 1999; 
Visse and Nagase, 2003). TGFβ1 is also known to regulate a wide array of cellular 
functions through non-SMAD pathways, which are activated directly by ligand 
occupied receptors to reinforce, attenuate, or otherwise modulate downstream cellular 
responses. These non-SMAD pathways include various branches of the MAP kinase, 
Rho-like GTPase, and phosphatidylinositol-3-kinase/AKT signalling pathways (Hills 
and Squires, 2011; Lan, 2011b). In 2008, pioneering work performed by Gregory et al 
demonstrated miRNA-200b, a member of the microRNA-200 family, to be a key 
miRNA in regulating EMT by targeting ZEB1 and ZEB2 transcription factors using 
protein tyrosine phosphatase Pez (PTP-Pez) over-expressing Madin Darby canine 
kidney (MDCK) epithelial cells, an immortalised model of distal tubular cells 
(Gregory et al., 2008a). Subsequently the miRNA-200b pre-cursor/mature form was 
shown to prevent renal tubulointerstitial fibrosis in a mouse model of UUO, and to 
prevent TGFβ1 induced increases in ECM production in in vitro models of rat tubular 
epithelial cells (NRK52E) (Xiong et al., 2012) respectively.  It has been well 
substantiated that TGFβ1 down-regulates the expression of miRNA-200b (Gregory et 
al., 2008a; Korpal and Kang, 2008; Korpal et al., 2008; Park et al., 2008). However, 
the role of miRNA-200b in preventing renal pathology by virtue of proximal tubular 
cytoprotection and the molecular mechanisms involved remain unclear. 
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3.2 Specific Materials and Methods  
3.2.1  Cell culture 
The immortalised human kidney proximal tubule cell line (HK-2) purchased from 
American Type Culture Collection (ATCC) was used in this study and maintained in 
keratinocyte-SFM (Invitrogen). Cells were plated and grown over night to reach 
approximately 50% confluence and then transfected with 25nM/L miRNA-200b 
(Thermo Scientific) using Lipofectamine 2000 (Invitrogen) transfecting reagent 
according to the manufacturer’s instructions. A 25nM/L non-specific miRNA (Qiagen) 
served as a negative control of miRNA transfection. Twenty-four hours after 
transfection, cells were exposed to 0.5ng/mL TGFβ1 (Sigma-Aldrich) or control 
conditions for 48 hours. Total RNA was extracted using Trizol Reagent (Invitrogen) 
and total protein was prepared using cell lysis buffer and sonication. Cell morphology 
was observed by phase contrast microscopy. 
 
3.2.2 Reverse transcription –polymerase chain reaction & Real-time PCR 
Extracted total RNA was DNase I treated, and cDNA was synthesized from 1μg total 
RNA using Superscript VILO cDNA synthesis kit (Invitrogen). mRNA level was 
determined by real-time PCR using  SYBR GreenER qPCR Supermix (Invitrogen) on 
Corbett Rotor-Gene 3000 (Qiagen). The results were analysed and Ct values were 
determined by comparing the results to a standard curve produced by serial dilutions.  
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3.2.3 Quantitation of miRNA  
miRNAs in total RNA were polyadenylated by poly(A) polymerase and converted to 
cDNA by reverse transcriptase using miScript Reverse Transcription Kit (Qiagen). 
MiRNA level was determined by real time PCR using miScript SYBR Green PCR Kit 
(Qiagen). U6 was used as the internal control of miRNAs. 
 
3.2.4 Western Blotting 
As described above, HK-2 cells were plated in 10 cm-tissue culture dishes overnight 
and transfected with synthetic 25nM miRNA-200b (Thermo Scientific). Twenty-four 
hours after transfection, cells were exposed to 0.5ng/mL TGFβ1 or control conditions 
for 48 hours. Cells were then lysed in ice-cold lysis buffer, sonicated and the protein 
concentration was measured (Bio-Rad). Equal amounts of total protein (45μg) were 
prepared in 2x sample buffer and denatured at 95
o
C for 5 minutes. Samples were 
loaded and resolved by SDS-polyacrylamide gel electrophoresis. Protein was 
transferred onto a nitrocellulose membrane (GE Health) and non-specific binding was 
blocked by incubating with 5% skim milk for 2 hours at room temperature and probed 
with anti-E-Cadherin (BD Biosciences), anti-Fibronectin (Millipore), anti-phospho 
p38, anti-phospho p42/44, anti-phospho-SMAD2, anti-phospho-SMAD3 (Cell 
Signalling) antibody overnight at 4
o
C. The membrane was washed and probed with 
corresponding secondary antibodies for 2h at room temperature. The membrane was 
washed after secondary antibody probing and subjected to enhanced 
chemiluminescence (ECL) (GE Health) according to the manufacturer’s instructions. 
Fluorescence was read and digitised using LAS4000 (Fuji Film) and analysed by 
Multi-gage software (Fuji Film). 
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3.2.5 Plasmid construction 
The construction of Luciferase reporter vectors for miRNA-200b target and for 
3’UTR of fibronectin was performed according to the instructions (pMIRNA-
REPORTER, Ambion). Complementary DNA fragments containing the putative 
miRNA-200b target site within the 3’UTR of human fibronectin mRNA were 
amplified by PCR (the primers: sense, 5’- ATCGGAGCTC CACAGCTTCT 
CCAAGCATCA -3’ and antisense, 5’- ATCGAAGCTT TGGCTGCATA 
TGCTTTCCTA -3’) with flanking Hind III and Sac I restriction enzyme digestion 
sites. The amplified DNA fragment was cloned into the Hind III and Sac I sites 
downstream of firefly luciferase gene in pMIRNA-Reporter system (Applied 
Biosystem).  
A mutant with fibronectin 3’UTR identical to the wild type sequences, apart from 4bp 
in the seed region, was generated as a negative control. Desired mutations were 
introduced by amplifying pMIRNA plasmid containing fibronectin 3’UTR using 
mutated primer pairs (the primers: sense, 5’- 
GTATTCAATACCGCTCAACGGTTTAAATGAAGTGATTC-3’ and antisense, 5’- 
GAATCACTTCATTTAAACCGTTGAGCGGTATTGAATAC-3’). The mutated 
plasmid was transformed into DH5α competent cells and mutation was confirmed by 
sequencing.  
 
3.2.6 Fibronectin promoter reporter assay & Luciferase assay of 3’UTR of 
fibronectin 
HK-2 cells were seeded in 24-well plates overnight prior to transfection. 200ng of 
pMIRNA reporter plasmid containing 3’UTR or mutated 3-UTR of fibronectin or 
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empty pMIRNA reporter plasmid along with renilla luciferase plasmid were co-
transfected with 25nM miRNA-200b (Thermo Scientific) or All-star non-specific 
siRNA (Qiagen) using Lipofectamine 2000 (Invitrogen). Cells were collected 48 
hours post transfection and luciferase activity was assayed using the Dual-Luciferase 
reporter assay system (Promega). Firefly luciferase activity was normalized to renilla 
luciferase activity. All experiments were performed in triplicate with data from 5 
independent experiments. 
 
3.2.7 Statistical Analysis 
Each experiment was repeated at least 4 times and results expressed as mean ± SEM. 
ANOVA and unpaired t-tests were used for statistical comparison. Analysis was 
performed using Graphpad version 5 (San Diego CA). P values less than 0.05 were 
considered significant. 
 
3.2.8 Optimisation of various techniques described in this chapter 
Numerous efforts had been put into the optimisation of the technique and construction 
of the materials necessary for the experiments describe in the previous chapter. In this 
chapter, these will be discussed in detail so mistakes made may be avoided by others 
in the future. 
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3.2.8.1 Initial Construction of Fibronectin 3’UTR 
The predicted miR-200b binding sites with 5’ and 3’ restriction enzyme overhangs 
were ordered as sense and anti-sense single stranded DNA (Sigma Aldrich, USA). 
The sequences were:  
Fibronectin 3’UTR miR-200b binding site 1 Sense with SpeI at 5’: 
CTAGTCGAAGTATTCAATACCGCTCAGTATTTTAA 
Fibronectin 3’UTR miR-200b binding site 1 anti-Sense with HindIII at 5’: 
AGCTTTAAAATACTGAGCGGTATTGAATACTTCGA 
Fibronectin 3’UTR miR-200b binding site 2 Sense with SpeI at 5’: 
CTAGTTATTTATCAATTTTTCCCAGTATTTTTATAA 
Fibronectin 3’UTR miR-200b binding site 2 anti-Sense HindIII at 5’: 
AGCTTTATAAAAATACTGGGAAAAATTGATAAATAA 
Reverse sequence of the corresponding sequences were also ordered to serve as a 
control sequence. The sequences of reverse sequences were: 
 Fibronectin 3’UTR miR-200b binding site 1 reverse sequence Sense with SpeI at 5’: 
CTAGTCGAAAAATACTGAGCGGTATTGAATACTAA 
Fibronectin 3’UTR miR-200b binding site 1 reverse sequence anti-Sense HindIII at 5’: 
AGCTTTAGTATTCAATACCGCTCAGTATTTTTCGA 
Fibronectin 3’UTR miR-200b binding site 2 reverse sequence Sense with SpeI at 5’: 
CTAGTTATTTATCAATTTTTCCCAGTATTTTTATAA 
Fibronectin 3’UTR miR-200b binding site 2 reverse sequence anti-Sense HindIII at 5’: 
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AGCTTTATAATTTATCAATTTTTCCCAGTATTTTAA 
 
3.2.8.2 DNA Annealing 
The sense and anti-sense sequences (complementary oligonucleotides) were annealed 
into double stranded DNA. The complimentary oligonucleotides of equal molar 
amount (20 μL of 200 μM of each oligonucleotide) were mixed with 50 μL 10x 
annealing buffer (100 mM Tris-HCl, pH 7.5, 1 M NaCl, 10 mM EDTA) and 410 μL 
water before being heated to 95
o
C on a dry bath. The mixture was then allowed to 
cool to room temperature on the dry bath for oligonucleotide annealing. The annealed 
DNA was resolved on an agarose gel to verify the size.  
 
3.2.8.3 pMIR Lucifrease Reporter plasmid preparation  
The annealed sequences of fibronectin 3’UTR were to be inserted into the 3’UTR 
position of luciferase gene in the pMIR-REPORT Luciferase plasmid (Life 
Technologies, USA) (Figure3.1). The regulation of these sequences is reflected by the 
changes in the activity of luciferase gene product.   
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Figure 3.1:  The vector map of pMIR-REPORT Luciferase plasmid. 
The vector plasmid was subjected to a 2 step restriction enzyme digestions to create 5’ 
and 3’ overhangs. Briefly, 2μg of vector plasmid was mixed with 2μL 10x Buffer, 1 
μL SpeI restriction enzyme (NEB, USA) and titrated up to 20μL with water. The 
mixture was incubated at 37
o
C for 2 hr followed purification again to remove protein, 
salts and cleaved DNA fragments. The eluted DNA was mixed with 2μL 10x buffer, 
2μL HindIII restriction enzyme (NEB, USA) and made up to 20μL with water. The 
mixture was incubated at 37
o
C for 1 hr and purified. The linearised plasmid, with 
sticky ends at both 5’ and 3’ regions, was then treated with shrimp alkaline 
phosphatase (Promega, USA) to remove the 5  ´ phosphate groups on the DNA 
backbone to prevent auto-ligation of the linearized DNA using the method outlined in 
Chapter 2. The resulting DNA was purified and eluted in water prior to cloning. 
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3.2.8.4 pMIR Luciferase plasmid construction with annealed fibronectin 3’UTR 
The annealed fibronectin 3’UTR sequences and pMIR-REPORT luciferase plasmid 
vector, both with sticky ends were then ligated together at a 3:1 molar ratio (insert 
DNA to vector DNA). 100 ng pMIR-REPORT luciferase plasmid was mixed with 
1.62 ng fibronectin 3’UTR sequences in the presence of 1 μL 10x ligation buffer, 1 
μL of T4 DNA ligase (NEB, USA) and water to 10 μL. The mixture was then 
incubated at 4
o
C overnight. A negative control was also setup but without the addition 
of the insert DNA. 2 μL of the ligation mix was used to transform 50 μL of DH5α 
chemically competent E. coli cells (Life Technologies, USA) using the methods 
described in chapter 2. The transformed E.coli from both positive and negative tubes 
were plated onto agar plates containing 100 μg/mL ampicillin and incubated at 37 oC 
overnight. 
 
3.2.8.5 Colony Selection  
The number of colonies on each plate were counted and compared. It was considered 
successful only when positive plates had significantly more colonies than negative 
plates. However, there were equal numbers of colonies on both positive and negative 
plates (20+ for each plate). 2 colonies from the positive plate were picked and grown 
in 5 ml LB broth containing 100 μg/mL ampicillin and incubated 37 oC overnight at 
225rpm in a shaking incubator. Plasmid was extracted from each sample using 
QIAprep Spin Miniprep Kit (Qiagen, USA) according to manufacturer’s instruction 
described in Chapter 2. 2μg of plasmid was double digested with SpeI and HindIII 
and it was expected that the positive clone would display a 35bp DNA fragment when 
resolved on the agarose gel together with the linearised plasmid vector. However, no 
fragment was observed on the gel. 
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Two modifications to the selection procedure were subsequently made. Firstly, 
bacterial cells were cracked open to release plasmid DNA instead of miniprep. 
Secondly, PCR amplification of the MCS was used to identify positive clones instead 
of restriction enzyme double digestion.  
Briefly, colonies on the agar plate were picked and resuspended in 10 μL of water 
before incubation at 95
o
C for 10 min. The crude extract was chilled on ice for 2 min 
before centrifugation at 12,000 x g for 20 min. The supernatant was removed to a 
fresh tube without disturbing the pellet. 2 μL of the supernatant was used as template 
in PCR to amplify MCS using the method described in Chapter 2. The primer pair 
used to amplify MCS was:  
pMIR-MCS-F: 5’-CCAACACACAGATCCAATGAA-3’ 
pMIR-MCS-R: 5’-CCTCATAAAGGCCAAGAAGG-3’ 
10 more colonies from each transformed E.Coli  plates were screened.However no 
positive clone was identified (Figure 3.2). 
A 
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B 
 
Figure 3.2 Colony screening for positive clones. Ligated plasmid vector was used to 
transform 50 μL chemical competent cells and colonies formed were screened using 
PCR. A. Agarose gel separation of amplified MCS for binding site 1. Lane 1: Control 
pMIR plasmid. Lanes 2-11 colonies subjected to screening. B. Agarose gel separation 
of amplified MCS for binding site 1 reverse sequence. Lane 1: Control pMIR plasmid. 
Lanes 2-11 colonies subjected to screening. 
Several other combinations of conditions for ligation including various insert DNA to 
vector DNA ratio (1:1, 3:1, 6:1, 10:1) at various ligation temperature (4
o
C, 16
o
C and 
22
o
C)  were also tested. However, no positive clone was identified.  
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3.2.8.6 Other ligation approaches 
It was thought that the insert DNA might be too short for insertion, thus longer DNA 
fragments containing the putative miR-200b binding site on fibronectin 3’UTR were 
amplified using the method outlined in the previous chapter. 
 
3.2.8.7 First Approach of Site Directed Mutagenesis 
The QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, USA) was 
employed to mutate the core binding site for miR-200b on the fibronectin 3’UTR. 
Mutagenic primer pairs that are complementary to each other were designed using 
web based software provided by Agilent Technologies. The sequences of the designed 
mutagenic primers were: 
g107a_t108c_a109g_t110g:  
5’-
TGTTCTGCTTCGAAGTATTCAATACCGCTCAACGGTTTAAATGAAGTGATT
CTAAGATTTGGTTTG-3’ 
g107a_t108c_a109g_t110g_antisense:  
5’-
CAAACCAAATCTTAGAATCACTTCATTTAAACCGTTGAGCGGTATTGAAT
ACTTCGAAGCAGAACA-3’ 
 
20 ng of plasmid containing the original miR-200b binding site was mixed with 5 μL 
10x reaction buffer, 125 ng of each mutagenic primer 1 μL dNTP mix and filled to 50 
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μL with water before the addition of 1 μL PfuUltra HF DNA polymerase (Agilent 
Technologies, USA). PCR was then performed using the following thermo profile: 
1. Initial denaturation:   95 oC  30s  
2. 3 step cycling for 18 cycles 
a. Denaturation  95
 o
C  30 s 
b.Annealing   55
 o
C  60 s 
c.Extension   72
 o
C  8 min 
The resulting PCR product was resolved on an agarose gel. However, no PCR product 
of the expected size was observed (Figure 3.3).  
 
Figure 3.3 Site-Directed Mutagenic PCR did not amplify the desired plasmid. 
Mutagenic primers, designed using software provided by Aligent Technologies, were 
used together with PfuUltra Site-Directed Mutagenesis Kit to introduce a 4bp 
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mutation in miR-200b binding site. Lane 1: pMIR plasmid containing miR-200b 
binding site (1 μg). Lane 2: Mutagenic PCR using pMIR plasmid containing miR-
200b binding site as template. 
 
A second mutagenic PCR using exactly the same conditions except annealing at 50
o
C 
was performed to increase the chance of successfully getting a PCR product. However, 
no product was observed (Figure 3.4).  
 
Figure 3.4 Site-Directed Mutagenic PCR with annealing temperature of 50
o
C did not 
amplify the desired plasmid. Lane 1: pMIR plasmid containing miR-200b binding site 
(1 μg). Lane 2: Mutagenic PCR using pMIR plasmid containing miR-200b binding 
site as template with annealing temperature of 50
o
C. 
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Another proof-reading enzyme namely AccuPrime Pfx DNA Polymerase (Life 
Technologies, USA) was used to perform the mutagenic PCR. 20 ng of plasmid 
containing original miR-200b binding site was mixed with 22.55 μL 10x AccuPrime 
Pfx Supermix, 125 ng of each mutagenic primer and filled to 50 μL with water. PCR 
was then performed using the following thermo profile: 
 
1. Initial denaturation:   95 oC  5 min  
2. 3 step cycling for 35 cycles 
a. Denaturation  95
 o
C  15 s 
b. Annealing   50-60
 o
C 30s 
c. Extension   68
 o
C  8 min 
PCR products were then resolved in an agarose gel (Figure 3.5). 
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Figure 3.5 Site-Directed Mutagenic PCR using AccuPrime Pfx DNA Polymerase with 
three different annealing temperatures did not amplify the desired plasmid. Annealing 
temperature is indicated at the top of each lane. 
 
A shorter version of the mutagenic primers was designed by truncating several 
nucleotides on each side (3 at 5’ end and 6 at 3’ end) of the existing mutagenic 
primers. The sequences of new mutagenic primers were: 
Mutation S sense: 5’- 
GTATTCAATACCGCTCAACGGTTTAAATGAAGTGATTC-3’ 
Mutation S antisense: 5’- 
GAATCACTTCATTTAAACCGTTGAGCGGTATTGAATAC-3’ 
Two PCR were performed using either AccuPrime Pfx DNA Polymerase (Figure 
3.6A) or PfuUltra Site-Directed Mutagenesis Kit (Figure 3.6B) at various annealing 
temperatures and 35 cycles. The PCR products were resolved on an agarose gel 
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Figure 3.6: AccuPrime Pfx DNA Polymerase successfully amplified pMIR with 
fibronectin 3’UTR using mutagenic primers while the PfuUltra Site-Directed 
Mutagenesis Kit did not amplify pMIR. A. Mutagenic PCR carried out using 
AccuPrime Pfx DNA Polymerase. Lane 1: 2 μg pMIR plasmid containing miR-200b 
binding site. Lane 2: 200ng pMIR plasmid containing miR-200b binding site. Lane 3: 
PCR with annealing temperature of 50
 o
C. Lane 4: PCR with annealing temperature 
of 55
o
C. Lane 5: PCR with annealing temperature of 60
 o
C. Lane 6: PCR with 
annealing temperature of 65
o
C. B. Mutagenic PCR carried out using Platinum Pfx 
DNA Polymerase. Lane 1: 2 μg pMIR plasmid containing miR-200b binding site. 
Lanes 2-5:  PCR with annealing temperature of 50
 o
C, 55
o
C, 60
 o
C, 65
 o
C. 
 
To select the best annealing temperature, an annealing temperature gradient PCR was 
performed. All conditions were kept exactly the same as for the previous PCR except 
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annealing temperature, which ranged from 65
o
C to 50
 o
C.  The PCR products were 
then resolved on an agarose gel (Figure 3.7). 
 
Figure 3.7: Gradient mutagenic PCR amplification using AccuPrime Pfx DNA 
Polymerase. Lower annealing temperature demonstrated higher PCR efficiency. Lane 
1: 2 μg pMIR plasmid containing miR-200b binding site. Lanes 2-9: Gradient PCR 
product with varying annealing temperature. 50 μL PCR product was loaded into 
each well.  
 
Thus, another PCR was carried out using an annealing temperature of 50
o
C and 18 
cycles of amplification. However, the PCR product resolved on agarose gel 
demonstrated a low quantity of amplified DNA (Figure 3.8). 
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Figure 3.8 18 cycles of amplification yielded a low quantity of DNA, which was 
insufficient for transformation. Lanes 1 & 2: Product of mutagenic PCR. 50 μL PCR 
product was loaded into each well.  
 
PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies, USA) was then used 
to carry out the site-directed mutagenesis, as it had high PCR fidelity and robustly 
amplified ‘difficult to amplify’ DNA fragments. To carry out the PCR using PfuUltra 
II Fusion HS DNA Polymerase, 20 ng of plasmid containing the original miR-200b 
binding site was mixed with 5 μL 10x reaction buffer, 1 μL of each mutagenic primer 
(10mM), 1.25 μL dNTP mix (10 mM) 1 μL PfuUltraII Fusion HS DNA polymerase 
and filled to 50 μL with water. PCR was then performed using the following thermo 
profile: 
1. Initial denaturation:   95 oC  2 min  
2. 3 step cycling for 18 cycles 
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a. Denaturation  95
 o
C  20 s 
b. Annealing   55
 o
C  50 s 
c. Extension   72
 o
C  2 min 15 s 
3. Final Hold   72 oC  3 min 
The PCR product was then resolved on an agarose gel (Figure 3.9). 
 
Figure 3.9 18 cycles of amplification using PfuUltra II Fusion HS DNA Polymerase 
yielded much higher quantity of DNA than AccuPrime Pfx DNA Polymerase.  Lanes 1: 
1 μg pMIR plasmid containing miR-200b binding site. Lanes 2-4: Product of 
mutagenic PCR using PfuUltra II Fusion HS DNA Polymerase with different 
annealing temperatures indicated. 50 μL PCR product was loaded into each well.  
 
PCR product was then DpnI treated to digest the heavily methylated parental strand. 1 
μL DpnI restriction enzyme was added to the PCR product and incubated for 1 hr at 
37
 o
C. 
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To achieve maximum transformation efficiency due to the low amounts of DNA, the 
DpnI treated PCR product was crudely purified and concentrated by mixing with 500 
μL 1-butanol before vortexing for 10 s. The mixture was then centrifuged at 12,000 
rpm for 10 min to precipitate DNA, which was then resuspended in 10 μL water. 5 μL 
of the concentrated DNA was added to 50 μL ElectroCompotent cells in a chilled 
electro-cuvette (Bio-Rad, USA) and electrically shocked to transfer the DNA into the 
competent cells. 500 μL SOC media was used to resuspend the cells, which were then 
incubated for 1 hr at 37
 o
C on a shaker rotating at 225 rpm. Cells were then plated 
onto an agar plate containing 100 μg/mL ampicillin and incubated at 37 oC overnight. 
100+ colonies were observed and 3 colonies were picked, minipreped and sent for 
sequencing using either of the following primers depending on the direction of 
sequencing desired. 
pMIR-MCS-F: 5’-CCAACACACAGATCCAATGAA-3’ 
pMIR-MCS-R: 5’-CCTCATAAAGGCCAAGAAGG-3’ 
For sequencing, 800 ng of plasmid DNA was mixed with 1 μL sequencing primer (10 
μM) and filled up to 12 μL with water. Samples were then sent to Australian Genome 
Research Facility (AGRF) for sequencing. The sequencing results were analysed 
using FinchTV (PerkinElmer, USA) and BLAST against the original sequence to 
assess if the mutagenesis was successful. 2 of the 3 of the colonies picked contained 
the mutation.  
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3.3 RESULTS  
3.3.1 miRNA-200b over-expression suppressed TGFβ1 -induced EMT and 
fibrotic responses of HK-2 cells 
To examine the role of miRNA-200b on TGFβ1-induced EMT of kidney proximal 
tubular cells, HK-2 cells were transfected with miRNA-200b or nonspecific miRNA, 
and 16hrs later were incubated with or without TGFβ1 for 48 hours. As shown in 
Figure 3.10, transfection of mature miRNA-200b increased miRNA-200b level 150 
fold in HK-2 cells measured by quantitative real-time PCR. HK-2 cells under control 
conditions (Panel A) showed a typical epithelial cuboidal shape with a cobble stone 
morphology, whereas HK-2 cells transfected with non-specific miRNA in the 
presence of TGFβ1 (Panel B) appeared elongated and spindle shaped, indicating a 
typical morphological change of EMT. However HK-2 cells transfected with 
miRNA-200b (Panel C) retained epithelial cell morphology (Figure 3.11). 
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Figure 3.10 Transfection efficiency of miRNAs with HK-2 cells using Lipofectamine 
2000 
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Figure 3.11 HK-2 cells maintained epithelial cell characteristics when transfected 
with miR-200b and treated with TGFβ1.   
 
To further confirm the effect of miRNA-200b on TGFβ1-induced EMT, E-Cadherin 
expression was examined. MiRNA-200b increased E-Cadherin mRNA by 17 fold 
compared to cells transfected with non-specific miRNA in the presence of 0.5ng/mL 
TGFβ1 (Figure 3.12A) (P<0.01). The protein level of E-Cadherin was also increased 
5 fold (P<0.05) in miRNA-200b transfected cells compared to non-specific miRNA, 
showing a similar pattern of change induced by TGFβ1 and miRNA-200b (Figure 
3.12B).  
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3.12A 
 
 
 
 
 
 
 
3.12B 
 
 
 
 
 
 
 
Figure 3.12 miR-200b restored TGFβ1 induced down-regulation of E-Cadherin. 
P*<0.05. 
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The expression of transcription factors ZEB1 and ZEB2 were then measured. 
MiRNA-200b reduced ZEB1 by 1.7 fold (P<0.05) and ZEB2 by 1.4 fold (P<0.05) 
(Figure 3.13A & 3.13B) in the presence of TGFβ1 confirming the protective role of 
miRNA-200b against EMT.   
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3.13A 
 
 
 
 
 
 
 
3.13B 
 
 
 
 
 
 
 
Figure 3.13 miR-200b suppresses transcription factors ZEB1 & ZEB2 expression.   
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As fibronectin is a key extracellular matrix protein and cells induced to EMT by 
TGFβ1 are major producers of fibronectin, the effect of miRNA-200b on TGFβ1-
induced fibronectin was examined. TGFβ1 significantly increased both mRNA (2 
fold, P<0.05) (Figure 3.14A) and protein (2.5 fold, P<0.05) (Figure 3.14A B) levels 
of fibronectin in HK-2 cells compared to control (P<0.01) but the stimulatory action 
of TGFβ1 on fibronectin was reversed in cells transfected with miRNA-200b 
compared to cells exposed to non-specific miRNA (2.5 fold reduction in mRNA 
(P<0.001) and 5 fold reduction in protein level (P<0.05)).  Secreted fibronectin was 
also found to be reduced 9 fold (P<0.0001) by miRNA-200b in the presence of 
TGFβ1 when compared to non-specific miRNA (Figure 3.14AC). Other extracellular 
matrix proteins such as COL1A1 (p<0.001), COL3A1 (p<0.001) and COL4A1 
(p<0.001) were also reduced at least 2 fold by miR-200b in the presence of TGFβ1. 
Unexpectedly, PAI-I mRNA was found to be increased 2.5 fold by miRNA-200b 
compared to non-specific miRNA when exposed to TGFβ1 (Figure 3.15).   
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3.14A 
 
 
 
 
 
                                   
3.14B                                                                   3.14C 
 
 
 
 
 
 
 
Figure 3.14 miR-200b reduced fibronectin level in the presence of TGFβ1.  
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Figure 3.15 miR-200b increased PAI-1 mRNA expression in the presence of TGFβ1.  
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The changes induced by miR-200b were correspondingly tested in the absence of 
TGFβ1 to further confirm the results. Again, miR-200b significantly elevated the 
expression of E-Cadherin and reduced the expression of fibronectin, COL4A1, 
ZEB1 and ZEB2 in HK-2 cells compared to non-specific microRNA. COL1A1 and 
COL3A1 mRNA appeared to be reduced after miR-200b transfection. However, this 
did not reach statistical significance. 
 
3.3.2 The effect of miRNA-200b over-expression on phosphorylation of SMAD 
2 & 3 in HK-2 cells 
To examine whether miRNA-200b modifies TGFβ1 induced fibronectin expression 
through inhibition of SMAD signalling, phosphorylation of SMAD2 and SMAD3 
were measured by Western blotting. As shown in Figure 3.16, over-expression of 
miRNA-200b did not reduce the phosphorylation of SMAD 2 (Figure 3.16A) and 
SMAD 3 (Figure 3.16B) compared to nonspecific miRNA transfection in the presence 
of TGFβ1. Paradoxically miRNA-200b further increased the phosphorylation of 
SMAD 2 by 1.9 fold (P>0.05).  
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Figure 3.16  miR-200b did not suppress the SMAD signaling pathway activated by 
TGFβ1.  
 
3.3.3 The effect of miRNA-200b over-expression on non-SMAD signalling 
pathways in HK-2 cells 
To examine whether miRNA-200b reduces fibronectin through inhibition of non- 
SMAD pathways, the phosphorylation of p38 and ERK1/2 were measured by Western 
blotting. As shown in Fig.8, over-expression of miRNA-200b did not reduce the 
phosphorylation of p38 (Figure 3.17A) and p42/44 (Figure 3.17B) compared to 
nonspecific miRNA transfection in the presence of TGFβ1. In keeping with the 
observed increase in phosphorylated SMAD expression, miRNA-200b unexpectedly 
increased the phosphorylation of p38 and p42/44 MAPK. 
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Figure 3.17: miR-200b increased the phosphorylation of p38 and p42/44 MAPK.  
 
 
3.3.4 miRNA-200b binds the 3’UTR of fibronectin (FN) mRNA thereby 
suppressing fibronectin expression. 
 
The data clearly demonstrate that miRNA-200b reduced TGFβ1-induced fibronectin 
(Figure3.14) independent of TGFβ1 signalling pathways (Figure3.15-3.17). To 
examine whether miRNA-200b suppresses the fibronectin gene promoter activity, 
promoter reporter assays were conducted. As shown in Figure 3.18, nonspecific 
miRNA or miRNA-200b was co-transfected with basal pGL3 or pGL3-FN luciferase 
reporter plasmid and luciferase activity was measured 48hrs later. Overexpression of 
miRNA-200b did not significantly reduce the promoter activity compared to 
nonspecific miRNA transfection.  
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Figure 3.18 miR-200b did not significantly alter the promoter activity of fibronectin 
gene.  
 
We next explored the possibility of a direct targeting mechanism of miRNA-200b to 
FN 3’UTR. In silicon searching predicted a possible binding site for miRNA-200b 
on the 3’UTR of FN which had a 7-mer overlap. A 163bp fragment on FN 3’UTR 
containing the putative miRNA-200b binding site was amplified and then cloned 
into the 3’UTR position of the luciferase gene in pMIRNA reporter plasmid. A 
control reporter plasmid, differing by only 4bp in the core miRNA-200b binding 
region was also constructed using site directed mutagenesis. The reporter plasmids 
were then co-transfected separately with 25nM miRNA-200b. Luciferase activity 
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was measured 48hr post transfection. The miRNA-200b ‘mimic’ was able reduce 
luciferase activity by 67% (P<0.001) compared to the control values (Figure 3.19). 
This confirms the direct targeting of FN mRNA by miRNA-200b binding to the 
3’UTR region.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 miR-200b targets fibronectin gene directly via targeting its 3’UTR.  
 
3.4 DISCUSSION  
In this study, we demonstrated the efficacy of using miRNA-200b to prevent TGFβ1 
induced EMT and extracellular matrix production in human proximal tubular 
epithelial cells. MiRNA-200b robustly elevated E-cadherin while suppressing 
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fibronectin and collagen expression. These studies further defined that mature 
miRNA-200b was able to directly target the fibronectin mRNA 3’UTR region. Since 
a significant reduction was observed in both mRNA and protein levels, it is more 
likely miRNA-200b initiated mRNA degradation rather than translational repression 
upon binding. These findings suggest miRNA-200b may modify the development of 
tubular fibrosis and may provide therapeutic benefits in preventing progressive 
kidney disease, independent of modification of classical TGFβ1 signalling pathways. 
Interestingly and importantly, miRNA-200b did not reduce, and paradoxically 
enhanced SMAD and MAPK signalling pathways downstream of TGFβ1 receptor 
activation. It is well known that TGFβ1 modifies cellular function via downstream 
signalling through SMAD (Qi et al., 2007) or non- SMAD pathways (Moustakas and 
Heldin, 2005, 2009). It has been reported that SMAD 3 mediates TGFβ1 -induced 
fibronectin expression in mesangial cells (Isono et al., 2002). Conversely a blocker 
of ERK signalling, PD98059, blocks TGFβ1 -induced fibronectin expression in rat 
glomerular mesangial cells (Inoki et al., 2000). It has also been reported that 
selective inhibition of both SMAD 3 phosphorylation (SB-431542) and p38 MAPK 
kinase phosphorylation (SB-203580 and SB-202190) inhibits TGFβ1-induced 
fibronectin expression (Laping et al., 2002). Our findings of miRNA-200b 
paradoxically stimulating downstream TGFβ1 signalling pathways are consistent 
with the observed elevation in PAI-1 expression. PAI-1 has been shown robustly to 
be linked to kidney fibrosis and activated by TGFβ1 and downstream SMAD 
signalling pathways (Ghosh and Vaughan, 2012). Activation of PAI-1 blocks the 
degradation of extracellular matrix proteins and thus the excessive deposition. These 
data are consistent with miRNA-200b operating through a mechanism independent 
of TGFβ1 signalling and yet regulating EMT and renal fibrosis.  
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EMT has recently been categorized into three subtypes (Wang et al., 2010a; Zeisberg 
and Neilson, 2009): Type 1 in embryogenesis, Type 2 in epithelial or endothelial 
cells transitioning to resident tissue fibroblasts and Type 3 in epithelial carcinoma 
cells transitioning to metastatic tumour cells. Although the role of miRNA-200b in 
cancer cell related Type 3 EMT has been well documented (Gregory et al., 2008a; 
Gregory et al., 2008b; Park et al., 2008; Paterson et al., 2008), its role in renal 
fibrosis related to Type 2 EMT has not been previously reported. Our findings 
suggest that EMT is likely to be similarly regulated by miRNA-200b in Type 2 EMT, 
as has been reported in Type 3 EMT. E-Cadherin is under the control of several 
transcriptional repressors including ZEB1, ZEB2, which bind to E-boxes in the 
promoter regions of E-Cadherin (Perez-Moreno et al., 2001; Thiery and Sleeman, 
2006). E-Cadherin is an important determinant for the maintenance of the epithelial 
phenotype, with its loss being an important early initiator of EMT. Two reports, 
using luciferase gene assays where 3’UTR sequences of ZEB1 or ZEB2 gene were 
cloned into the 3’UTR position of a luciferase gene (Gregory et al., 2008a; Park et 
al., 2008) have identified ZEB1 and ZEB2 as direct targets of miRNA-200b. In PTP-
Pez over-expressing MDCK and 4TO7 Mammary Carcinoma Cell Line, miRNA-
200b inhibits the expression of the E-box-interacting transcription factors ZEB1 and 
ZEB2 allowing enhanced E-Cad transcription (Bracken et al., 2008; Gregory et al., 
2008b; Korpal and Kang, 2008; Korpal et al., 2008). The miRNA-200 families have 
also been shown to prevent EMT in response to TGFβ1 in PTP-Pez stably 
transfected MDCK (Gregory et al., 2008a).  Hence our findings of increased E-
cadherin and reversal of morphological changes of EMT in association with 
reduction in ZEB1 and ZEB2 expression in the presence of miRNA-200b are 
consistent with these findings.  
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As the gene promoter activity generally determines the transcription efficiency, we 
examined whether miRNA-200b reduces fibronectin expression through inhibition 
of its promoter activity, using promoter reporter assays. However, miRNA-200b did 
not reduce the promoter activity of fibronectin in kidney proximal tubular cells 
compared to non-specific miRNAs. MiRNAs target mRNA transcripts and suppress 
their expression by either translational repression or mRNA degradation. Several 
articles have demonstrated direct mRNA targeting and suppression by miRNAs in 
kidney cells (Bartel, 2009; Carthew and Sontheimer, 2009; Kim et al., 2009). For 
example, miRNA-192 and miRNA-200b were shown to directly target ZEB2 and 
ZEB1 respectively in mesangial cells (Kato et al., 2011; Kato et al., 2007). MiRNA 
target scanning indicated that 3’UTR of fibronectin is a potential target of miRNA-
200b.  We confirmed that miRNA-200b directly targets the 3’UTR of fibronectin 
leading to instability of the mRNA and/or inhibition of protein translation, which are 
well documented consequences of miRNA (Bartel, 2009; Carthew and Sontheimer, 
2009). 
Recently, it was reported that the miR-29 family is able to target collagen expression 
via direct targeting of their 3’UTR (Wang et al., 2012b). Once more, reduction in 
collagens and increases in TGFβ signalling suggested a miRNA network where miR-
200b may promote the expression of miR-29 family and subsequent inhibition of 
collagen expression. 
 
The regulation of fibronectin protein expression in kidney disease is important, not 
only because of the direct effect of ECM protein accumulation on renal interstitial 
fibrosis, but also because fibronectin, in particular, is actively involved in both 
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cellular and extracellular signalling pathways, acting as a ligand for signalling 
pathways that lead to fibrosis (Wight and Potter-Perigo, 2011). Hence, targeting 
components of the extracellular matrix to limit fibrosis and direct the wound-healing 
process toward reestablishment of a healthy equilibrium (Frantz et al., 2010) is likely 
to be critically important.  
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4 Chapter 4 In vivo expression of miR-200b and its role in obstructive 
nephropathy 
4.1 Specific Background and Aims 
In Chapter3, the role of miR-200b in in vitro models of renal fibrogenesis was 
described. It was found that miR-200b was able to prevent TGFβ induced proximal 
tubular cell epithelial to mesenchymal transition, as well as elevation of extracellular 
matrix proteins. However, the roles of miR-200b in preventing tubule-interstitial 
fibrosis in “in vivo” models still need to be elucidated. Thus, this project was 
designed to study the effects of systemic over-expression of miR-200b in kidney 
fibrosis, developed as a consequence of obstructive nephropathy. 
In order to achieve over-expression of miR-200b in the kidney of mice, lentivirus 
mediated gene transfer was used. Plasmid containing pre-miR-200b was packaged 
into lentivirus before being transferred via tail vein injection into mice to induce 
systemic infection. Upon infection, lentivirus inserts the copy of pre-miR-200b driven 
by the CMV promoter into the genome of the infected cell, leading to persistent 
expression of miR-200b.  
UUO is one of the most commonly used animal models to study the pathophysiology 
of renal fibrosis (Dendooven et al., 2011). Hydrostatic pressure induced by this 
technique results in marked renal hemodynamic and metabolic changes that promote 
tubular injury, cell apoptosis and necrosis and interstitial macrophage infiltration. 
Interstitial fibroblast proliferation and myofibroblast transformation leads to the 
excessive deposition of ECM and causes progressive loss of the functional renal 
parenchyma (Cachat et al., 2003; Chevalier et al., 2009a; Dendooven et al., 2011; 
Schreiner et al., 1988; Sharma et al., 1993; Vaughan et al., 2004). This technique was 
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used in this study to induce progressive renal fibrosis in experimental animals, which 
has common features in all models of nephropathy, including diabetic nephropathy 
(Chevalier et al., 2009a; Dendooven et al., 2011; Kanwar et al., 2011).  
The specific aims were 
1. To evaluate the effectiveness of miR-200b in preventing molecular and 
histological evidence of fibrosis in C57BL/6 mice with ureteric obstruction. 
2. To evaluate the role of miR-200b in preventing EMT in C57BL/6 mice with 
ureteric obstruction. 
3. To evaluate the efficacy of different systems in delivering miRNA to the 
kidney. 
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4.2 Specific Materials and Methods  
4.2.1 Viral Packaging  
Plasmid containing pre-miR-200b (pCDH-CMV-miR-200b-EF1-RFP) was co-
transfected with packaging plasmids into HEK293T cells. The packaging plasmids 
consist of three individual plasmids that encode all the necessary proteins to produce 
lentivirus. The supernatant containing lentivirus was then harvested, purified and 
concentrated before tail vein injection into mice.  
Specifically, 4.5 million HEK293T cells were seeded into a T75 tissue culture flask 
(Nunc, USA) 18 hr before transfection in the presence of 13.5 mL DMEM with high 
glucose (4.5 g/mL) supplemented with 10% foetal calf serum (FCS) (The complete 
formulation can be found at 
http://www.invitrogen.com/site/us/en/home/support/Product-Technical-
Resources/media_formulation.45.html).  Prior to transfection, 11.25 μg pPACKH1 
HIV lentivector packaging plasmid (SBI, USA) and 2.25 μg pCDH-CMV-miR-200b-
EF1-RFP were diluted in 1.35 mL Opti-MEM reduced serum medium (Life 
Technologies, USA) before the addition of 27 μL X-tremeGENE HP DNA 
Transfection Reagent. The mixture was incubated at room temperature for 15-20 min 
to form the transfection complex.  1.35 mL transfection complex was then added in a 
drop wise manner to HEK293T cells in the T75 tissue culture flask. 48 hr post 
transfection, supernatant containing packaged lentivirus was removed and 10 mL 
fresh DMEM (4.5 g/mL D-glucose, 10% FCS) was added. The removed supernatant 
was centrifuged at 2500 rpm for 5 min to remove cell debris before the addition of ¼ 
volumes of the 5x PEG-it virus precipitation solution (SBI, USA). The mixture was 
then incubated overnight at 4
o
C and then centrifuged at 1500 g for 30 min to 
precipitate the lentivirus. The precipitated virus was resuspended in 1/40 original 
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volume (of supernatant) in sterile PBS. A second collection of supernatant was 
performed 24 hr after the addition of medium. The collected supernatant was purified, 
concentrated, resuspended in PBS and combined with the first collection.  
 
4.2.2 Viral Titre Determination 
4.2.2.1 Transduction of Cells 
HK-2 cells were seeded at 2.5x10
5
 per well in a 6-well plate 24 hr before lentiviral 
transduction.  On the day of transduction, 2 mL 10-fold serial dilution over a range of 
1x10
-2
 to 1x10
-6 
was prepared and 1 mL of each lentiviral dilution was added to each 
well of the 6-well plates. The cells were incubated at 37
o
C for 48 hr with 5% CO2 
before being subjected to flow cytometry. 
The viral titre was calculated using the formula: 
 
Titre = ((F × Cn) /V) × DF 
 
F: The frequency of RFP-positive cells determined by flow cytometry;  
Cn: The total number of target cells infected.  
V: The volume of the inoculum.  
DF: The virus dilution factor. 
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4.2.2.2 Flow Cytometry Analysis 
Cells were exposed to 1 mL TrypLE Express (Life Technologies, USA) to detach 
from culturing vessel and neutralised with 2 mL DMEM supplemented with 10% FCS. 
The cells were then pelleted and washed twice with 2 mL ice-cold PBS before being 
analysed by flow cytometry for red fluorescent protein (RFP) expression. 
 
4.2.3 Lentivirus Delivery to Mice 
All animal work was carried out with the approval of the Royal North Shore Hospital 
Animal Care and Ethics Committee (ACEC application number: 1203-008A). 
C57BL/6J mice were obtained from the Kearns Animal Facility and were allowed to 
acclimatise before being subjected to experimentation. 5x10
6 
pseudo-lentivirus, 
containing either non-specific control sequences or miR-200b, were injected into each 
mouse via the tail vein under anaesthesia using 2% isoflurane gas (mixed with 1 part 
oxygen, 2 parts nitrogen). The RFP co-expressed was detected by In-Vivo FX PRO in 
vivo imaging machine (Carestream, NY, USA) to visualise the distribution and 
relative intensity of lentiviral transduction. A second injection with equal amount of 
lentiviral particles as the first injection was carried out 48 hrs after the first injection 
to boost the transduction.  
 
4.2.4 Unilateral Ureteral Obstruction  
48 hr post lentivirus injection, mice (n=7) were anaesthetised with 2% isoflurane gas 
(mixed with 1 part oxygen, 2 parts nitrogen) inhalation and immobilised onto a 
surgical pad. The left or right lateral flank (renal angle) was shaved and cleaned using 
isopropyl alcohol wipes.  
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An incision (1-2 cm) was made by a scalpel to expose the kidney. The left ureter was 
then ligated at two points with surgical silk line. The incision point was subsequently 
sutured using a surgical silk line and cleaned using isopropyl alcohol wipe. The mice 
were given analgesia (Buprenorphine 0.03 – 0.05 mg/kg IP) for pain induced by 
surgery. 
5 days post operation, mice were sacrificed by pericardiectomy under 2% isoflurane 
anaesthetic and organs including the obstructed and unobstructed kidneys, lungs, heart 
and liver from both non-specific miR and miR-200b lentivirus transduced mice were 
harvested.  Blood was also collected.  
 
4.2.5 Total RNA Extraction 
Both mRNA and miRNA were extracted from mouse kidney, lung, heart and liver 
tissue using Qiagen miRNeasyMini Kit (Qiagen, USA).  About 25 mg tissue was cut 
from frozen kidney cortex on dry ice and placed in a 2 mL eppendorf tube with 2 
tungsten carbide beads (3 mm diameter) (Qiagen, USA) and 700 µL QIAzol Lysis 
Reagent. The mixture was then homogenised on a Retsch MM301mixer (Retsch, 
Germany) at 1000 oscillations per minute for 3 min. Tungsten carbide beads were 
removed and homogenised solution was incubated at room temperature for 5 min 
before the addition of 140 μL chloroform. Mixture was thoroughly mixed for 15 s and 
incubated at room temperature for a further 3 min before centrifugation at 12,000 g 
for 15 min at 4
oC. 350 μL of the upper aqueous phase was transfer to a fresh tube and 
mixed with 525 μL 100% ethanol. 700 μL of the mixed sample was loaded onto an 
RNeasyMini spin column and centrifuged at 10,000g for 15s. Flow through was 
discarded and the column was washed once with buffer RWT, and twice with buffer 
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RPE. Columns were dried by centrifugation at 10,000 g for 2 mins and total RNA was 
eluted with 50 μL RNAse free water.   
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4.3 Results 
4.3.1 Packaging efficiency  
The vector used for miR-200b delivery also contained RFP gene and thus transfection 
efficiency could be conveniently checked by the fluorescence emitted by RFP. Cells 
were examined under fluorescent microscope for RFP expression (Excitation at 560 
nm and emission at 593 nm). 
 
4.3.2 Lentiviral Transduction 
5 μL concentrated lentivirus (1:40) was used to transduce HEK293T cells in a T75 
tissue culture flask to confirm the infectivity of lentivirus packaged before titering. 
Lentivirus successfully transduced HEK293T cells (Figure. 4.1) and thus were 
subjected to titering.  
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Figure 4.1 HEK293T cells express RFP 48 hr after lentivirus transduction. HEK293T 
cells were seeded at approximately 2x10
6 
cells per T75 tissue culture flask 24 hr 
before transduction. 5μL concentrated lentivirus (1:40) were used to transduce 
HEK293T cells in one tissue culture flask. The cells were observed under florescent 
microscope 48 hr post lentiviral transduction for RFP expression. 
 
4.3.3 Animal welfare during experiment 
The animals subjected to this experiment were closely monitored for any signs of 
stress. Specific monitoring items include signs of dehydration, sunken face, diarrhoea, 
pilo erection, arching back, weakness and surgical wound inspection. No signs of 
adverse effects were observed during and after the 2 lentiviral injections. Signs of 
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fatigue and weakness were observed immediately after the surgery to induce UUO. 
However, they resolved within 3 post-operative days.  
 
4.3.4 Viral Integration in vivo-Preliminary Study  
In a preliminary experiment, one of the two mice was injected with approximately 10 
million lentiviral particles, while the other served as control. Both mice were 
sacrificed and imaged 5 days post-injection. Total body imaging showed no 
noticeable fluorescence (Figure 4.2). However, when removed from body and imaged 
ex vivo, the liver demonstrated the most significant amount of fluorescence (Figure 
4.3). RNA was extracted from liver and kidney sample for detection of RFP mRNA. 
The lack of detection of fluorescence using whole body imaging was considered to be 
due to the level of RFP expressed and the autofluorescence observed from the fur. 
The result showed strong expression of RFP in both liver and kidney in the mouse 
injected with lentivirus (Figure 4.4).  Hence proof of concept was confirmed.  
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Figure 4.2 Total body imaging of mice for RFP detection. The mouse injected with 
control lentivirus was on the left hand side while the one injected with miR-200b 
lentivirus was on the right hand side. Stripes showed high fluorescence in the middle 
are tapes used to immobilise the mice. 
  
Control Mouse 
Lentivirus  
Injected Mouse 
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Figure 4.3 Imaging of individual organs for detection of RFP expression. Mouse 
injected with saline (Control) and mouse injected with 10 million lentiviral particles 
were sacrificed 5 day post injection. Organs were removed and imagined for RFP 
detection. 
  
Figure 4.4 Lentivirus successfully transduced cells in the liver and kidney in vivo. 
Mice were injected with 10 million lentiviral particles carrying RFP or with saline, 
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which served as a mock control. Liver and renal cortex were harvested and analysed 
for RFP expression (PCR).  
 
4.3.5 Further study – miR-200b Transduction 
After optimisation of the lentivirus injection, a further study aiming to evaluate the 
role of miR-200b in preventing renal fibrosis in vivo was carried out. 7 mice were 
divided into two groups, namely, non-specific miRNA control group (4 mice) and 
miR-200b transduction group (3 mice) and subjected to lentivirus injection. All mice 
demonstrated RFP mRNA expression and thus viral integration into genome (Figure 
4.5). However, 2 of the 3 mice injected with miR-200b containing lentivirus had very 
low expression of RFP.  
 
Figure 4.5 RFP expression in renal cortex of mice injected with lentivirus. Each 
mouse was injected with 2 x 5 million lentiviral particles. UUO was performed 24 hr 
after the second injection. RFP was amplified using conventional semi-quantitative 
PCR and resolved on 1% agarose gel. All mice demonstrated RFP expression in the 
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kidney. Positive control: PCR amplified from RFP containing plasmid. Negative 
control: water, Control mouse: mice injected with lentiviral vectors carrying non-
specific sequence, miR-200 O/E mouse: mice injected with lentiviral vectors carrying 
mir-200b  sequence.  
 
4.3.6 miR-200b reduced ECM and EMT markers 
4.3.6.1 PCR Analysis 
Several fibrotic markers were tested using real-time PCR to evaluate the reno-
protective effects of miR-200b in vivo. UUO itself induced significant changes in all 
genes tested when compared to the control kidney (Figure 4.5). No apparent changes 
were detected when comparing non-specific miR transduced group and miR-200b 
transduced group in the ligated kidney (Figure 4.6A). However, the low level of 
expression of RFP in two of the experimental animals transduced with miR-200b may 
have masked the effects of miR-200b. Thus, result was analysed again by comparing 
the control mice samples to the high RFP expressing mouse sample transduced with 
miR-200b (Figure 4.6B). Data indicated that miR-200b may lower COL1, COL3 and 
fibronectin as observed in the in vitro model, while αSMA and vimentin were also 
slightly decreased. However, more biological repeats are required to validate the 
changes.  
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Figure 4.6 Real-time PCR analysis of kidney cortex from mice transduced with miR-
200b. Each mouse was injected with 5 million lentiviral particles per injection per 
day for 2 days. UUO was performed 24 hr after the second injection. Mice were 
sacrificed 5 days post UUO and kidney cortex was harvested. Gene expression was 
examined and normalised to actin. A. data from 4 control mice were compared to 3 
miR-200b transduced mice. B. data from 4 control mice were compared to one miR-
200b transduced mouse with high RFP expression. P value is greater than 0.05 for all 
comparisons due to the small sample size.  
 
4.3.6.2 Masson Trichrome stain and Periodic acid-Schiff stain (PAS) 
Masson trichrome and PAS staining were also performed on the renal cortex collected. 
The cortex tissue was sectioned and stained by Anatomical Pathology in Royal North 
Shore Hospital, St Leonards, NSW. UUO induced severe tubulo-interstitial fibrosis, 
as indicated in the Masson Trichrome staining. However, fibrosis was reduced in the 
ligated kidney transduced with miR-200b when compared to non-specific miRNA 
(Figure 4.7). Interestingly, in the unligated kidney, miR-200b appeared to reduce the 
amount of normal extracellular matrix proteins.  UUO, as expected, also induced 
more severe tubular lesions (Figure 4.8) without affecting the glomeruli (Figure 4.9). 
The Masson Trichrome stained slides from the ligated kidneys were blindly graded by 
Dr. Jason Chen (pathologist). The result is shown below in Table 4.1. The data 
suggest that miR-200b transduced kidneys (5,6,7) had an average lower score than the 
non-specific miRNA transduced kidney. 
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Figure 4.7 UUO induced severe renal interstitial fibrosis which was potentially 
reversed by miR-200b. Kidney cortex was harvested and stained with Masson 
trichrome. Images were taken at 200x magnification. A: unligated kidney transduced 
with non-specific miRNA. B: unligated kidney transduced with miR-200b. C: ligated 
kidney transduced non-specific miRNA. D: ligated kidney transduced with miR-200b. 
200x 
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Figure 4.8 UUO induced severe tubular lesions. Kidney cortex was harvested and 
stained with PAS stain. Images were taken at 200x magnification. A: unligated kidney 
transduced with non-specific miRNA. B: unligated kidney transduced with miR-200b. 
C: ligated kidney transduced non-specific miRNA. D: ligated kidney transduced with 
miR-200b. 
 
200x 
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Figure 4.9 UUO induced little pathology in the glomerulus. Kidney cortex was 
stained with PAS stain. Images were taken at 400x magnification. A: unligated kidney 
transduced with non-specific miRNA. B: unligated kidney transduced with miR-200b. 
C: ligated kidney transduced non-specific miRNA. D: ligated kidney transduced with 
miR-200b. 
 
 
 
 
 
 
 
400x 
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Mouse 
Number 
miRNA 
Transduced 
Masson Trichrome 
Score 
1 non-specific severe 
2 non-specific Moderate 
3 non-specific Severe 
4 non-specific Moderate 
5 miR-200b Mild to Negative 
6 miR-200b Mild to Negative 
7 miR-200b Moderate 
 
Table 4.1: Masson Trichrome score of ligated kidneys transduced with either non-
specific miRNA or miR-200b, determined by pathologist Jason Chen in Royal North 
Shore Hospital in a single blinded fashion. Despite little RFP expression observed, 
there was a significant reduction in tissue pathology. 
 
4.4 Discussion 
In this study, we examined the role of miR-200b in preventing tubulo-interstitial 
fibrosis. We successfully induced progressive renal fibrosis using the UUO model. 
The pathology induced by UUO was mainly limited to tubules and the interstitial 
areas, while glomeruli were unaffected. This provided us a good model for studying 
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the interventions impacting on the development of progressive tubulo-interstitial 
fibrosis.  
In the preliminary test with lentiviral carrying non-specific miRNA, we successfully 
demonstrated the over-expressed RFP in mouse kidney after systemic delivery. RFP is 
used as a qualitative marker for successful transduction due to the lack of RFP gene in 
c57bl/6 mice genome. However, in the following study, a significant reduction in 
transduction efficiency was observed in miR-200b carrying lentivirus when compared 
to the ones carrying non-specific miRNA. Thus, the number of mice with high RFP 
expression in the miR-200b transduced group was limited to one. This may be due to 
intra-muscular leakage of lentivirus during injection or mouse to mouse variation in 
integrating the cargo gene. This discrepancy could be further explained by the 
secondary structure formed by miR-200b. As it is delivered in the pre-miR-200b 
format, it forms a short hairpin loop structure which may hinder the integration of the 
gene. This phenomenon was also observed by another colleague when she was trying 
to transduce a human breast cancer cell line using miR-200b carrying lentivirus. This 
significantly restricted the interpretation of results. Though the real-time PCR result 
showed a trend of reduction in the expression of matrix proteins in the successfully 
transduced mouse, more mice numbers will be required to achieve statistical 
significance to verify the finding. Interestingly, there was an improvement in 
histological severity of tubulointerstitial pathology in all 3 miR-200b transduced mice 
independently of transfection efficiency. Recent studies suggest that miRNA can 
indeed travel from one organ to another in by packaging them into small vesicles with 
lipid-bilayer (Katsuda et al., 2014). Due to the high transduction rate in liver, miR-
200b could be produced there and transported to the kidney and thus have an effect. 
Improvements including using more lentivirus with higher titer could be carried out to 
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improve the expression of miR-200b in kidneys. Furthermore, more localised 
lentiviral delivery such as retrograde infusion through the ureter, intrarenal artery/vein 
infusion and intraparenchymal injection could also be tried in order to improve the 
gene transfer efficiency in kidney. Indeed, other studies using these methods have 
shown significant increase of  delivered gene products (Gusella et al., 2002a)  
(Gusella et al., 2002b). The localised delivery concentrates lentivirus in kidney and 
reduced the level of unwanted transduction in other organ and thus reduced the off-
target effects. However, these methods are much more technical challenging and may 
cause damage to kidney itself during the procedure. They are highly unlikely to have 
future clinical applicability. 
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5 Chapter 5 Nanoparticle mediated gene delivery: 
5.1 Introduction  
Since the discovery of RNA interference (RNAi) in Caenorhabditis elegans (Fire et al., 
1998), plants and mammalian cells (Hamilton and Baulcombe, 1999) in the late 1990s, 
there has been an exponential increase in the study of these short RNA species aiming 
to develop not only new strategies for disease treatment, but also new methods for 
researchers to switch off genes of interest. Indeed, RNAi has become a powerful tool 
and is now an integral part of modern molecular biology lab methodology. Meanwhile 
the first RNAi based drug Kynamro, which targets apolipoprotein B mRNA, the gene 
responsible for homozygous familial hypercholesterolemia (Merki et al., 2008), was 
approved by the FDA in 2013 
(http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm337195.htm).  
 
5.1.1 Challenges  
RNAi mechanism can be initiated by the double strand RNA (dsRNA) such as siRNA, 
miRNA and shRNA (Wang et al., 2011).  They are all processed and loaded onto 
mRNA in a similar fashion as described. Despite the initial bright prospects, the 
application of RNAi relies on efficient and specific delivery of these dsRNA to the 
desired target cells or tissues. Hurdles still need to be overcome to ensure these 
requirements are met. 
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5.1.1.1 Stability and Bioavailability  
Unmodified dsRNA, even though relatively stable (Hickerson et al., 2008), are prone 
to serum nuclease degradation after systematic delivery. Degradation could further 
trigger the innate immune response, hence rendering the therapy ineffective (Layzer et 
al., 2004). (Jackson and Linsley, 2010; Nguyen et al., 2012). In addition to 
degradation, systemically delivered dsRNA has been shown to preferentially 
accumulate in the kidney, where it is excreted rapidly due to its small size (~14kda for 
a 23bp dsRNA) (Alexis et al., 2008; Guo et al., 2010). However, this trait may be 
appealing for delivery of dsRNA into kidney proximal tubular cells if functional 
integrity remains, dsRNA is too large and hydrophilic to diffuse through the 
phospholipid bilayer of cell membranes (Whitehead et al., 2009).   
 
5.1.1.2 Off-target Effects 
Non-specific off-target effects induced by RNAi had been observed when siRNA 
affected gene expression via 3’UTR regulation with imperfect complementarity 
(Birmingham et al., 2006; Jackson et al., 2006). Conversely, saturation of miRNA 
machinery may be caused by unintentional accumulation, which may also trigger non-
specific off-target effects (Wang et al., 2011). 
 
5.1.1.3 Immune Response 
In addition to the activation triggered by degraded dsRNA, intact dsRNA can also 
induce immune responses. It is thought that the dsRNA can interact with RNA-
binding proteins, such as toll-like receptors and protein kinase receptors, which in turn 
initiate type I interferon mediated immune responses (Deng et al., 2014).  
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Furthermore, the immune response can be activated in a sequence specific manner 
(Hornung et al., 2005) and the severity is also believed to positively correlate with the 
length of delivery dsRNA (Deng et al., 2014). 
Though viral vectors such as lentivirus and adenovirus had been extensively used to 
deliver the genes both systemically and locally (Kootstra and Verma, 2003; Verma 
and Weitzman, 2005), they still pose a high risk of severe immunological responses as 
well as increased susceptibility to certain types of cancer (Check, 2005; Hacein-Bey-
Abina et al., 2003; Raper et al., 2003; Raper et al., 2002). Thus, much attention has 
been diverted to the development and characterisation of safer, non-viral delivery 
systems including naked dsRNA, conjugate delivery systems, lipid nanoparticles, 
polymeric nanoparticles, ultrasound microbubble mediated gene transfer and more. 
Ideally, these delivery systems should (a) increase the stability of cargo dsRNA, (b) 
evade the immune system, (c) be physiologically inert, (d) avoid/intended renal 
clearance depend on the application, (e) reach target tissue and facilitate cell entry, 
and (f) efficiently incorporate the dsRNA onto RNAi machinery (Kanasty et al., 2013). 
Some of these innovative methods will be briefly described. 
 
5.2 in vivo Gene  Delivery Methods 
The clinical application of knowledge of miRNA involves the transfer and over-
expression of exogenous genetic material to the host somatic cells, a procedure also 
called gene therapy. Gene therapy requires the right amount foreign gene(s) to be 
delivered precisely to the desired cell type(s) without causing any adverse effects. 
Gene therapy in the kidney, particularly targeting the proximal tubular cells, is 
challenging, because the kidney is a well differentiated organ with different 
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compartments that work together to maintain homeostasis in the body. In this chapter, 
non-viral mediated gene deliveries such as nanoparticles mediated gene transfer and 
ultrasound microbubble mediated gene transfer were explored.  
 
5.2.1.1 Chemical Modification of the Base 
One of the strategies that are adopted by virtually all dsRNA delivery methods is the 
chemical modification of the dsRNA backbone (Kanasty et al., 2013). This can either 
be the replacement of phosphodiester bonds with phosphothioate bonds or the 
boranophosphate bond shown as 5.1a or chemical modification of the 2’-sugar, 
commonly 2’-O-methyl, 2’-O-methoxyethyl, 2-fluoro and locked nucleic acid shown 
in 5.1b (Kanasty et al., 2013). These modifications augment dsRNA’s resistance to 
nuclease degradation and thus increase their serum stability while maintaining their 
silencing effects (Amarzguioui et al., 2003; Braasch et al., 2003). However, extensive 
modification may also lead to increased cytotoxicity and loss of silencing activity 
(Amarzguioui et al., 2003; Czauderna et al., 2003). Thus careful modification of 
dsRNA is required to achieve the optimal balance between silencing and nuclease 
resistance. 
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Figure 5.1 Common modifications of dsRNA for increased serum stability. (a) 
phosphodiester replacement: original, phosphothioate, boranophosphate. (b) 2’-
sugar modification: 2’-O-methyl, 2’-O-methoxyethyl, 2’-fluoro and locked nucleic 
acid (LNA). Picture adapted from Advanced Delivery and Therapeutic Applications of 
RNAi (Kun Cheng (Editor), May 2013).  
 
5.2.1.2 Direct Conjugation 
One of the most straight forward systems is the direct conjugation of cargo dsRNA 
with a targeting molecule. The first dsRNA conjugates that showed great delivery 
efficacy were linked to cholesterol or other lipophilic molecules (Soutschek et al., 
2004; Wolfrum et al., 2007). Later, other types of simple conjugate links with 
antibody, aptamer, and peptide (such as cell penetrating peptide) or even inorganic 
ligands that bind to a specific surface molecule on the target cell, have also been 
developed (Kanasty et al., 2013). These conjugate systems have well defined structure 
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and properties, which may be advantageous when compared to other more complex 
systems (Kanasty et al., 2013). The size of these systems is relatively small and thus 
may benefit dsRNA delivery to the PTCs as the pore size of glomerular filtration 
barrier is approximately 8nm (He and Carter, 1992; Wartiovaara et al., 2004). 
However, the pore size can be as large as 40 nm under diseased state allowing bigger 
particles to be filtered.  This is crucial in the design of complex multifunctional 
delivery systems targeting the luminal membrane of PTCs, as the difficulty in 
functionalisation and characterisation of these systems increase exponentially as they 
become smaller and smaller in size (Haraldsson and Jeansson, 2009).  
 
5.2.1.3 Nanoparticles Mediated Gene Delivery 
Complex multi-functional nanoparticle delivery systems have also been designed and 
developed for dsRNA in vivo delivery. Compared to simple conjugates, these 
nanoparticles can be coated with different ligands for different purposes. Typically, 
these nanoparticles are positively charged, which can interact electrostatically with 
the negatively charged dsRNA without the requirement of a chemical bond to hold 
them together (Jeong et al., 2009).  However, delivery systems can have unwanted 
aggregation with erythrocytes if a significant net positive charges are presented at the 
surface (Malek et al., 2009). Notably, the negative charge of the glomerulus basement 
can interact with the nanoparticles and cause some of the delivery systems that 
electrostatically bond to their cargo to disintegrate while being filtered (Naeye et al., 
2013; Zuckerman et al., 2012). This consequently leads to the loss of dsRNA in urine. 
However, this could advantageous if the target is proximal tubular cell, providing the 
dsRNA can be reabsorbed through endocytic mechanisms.  
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Encapsulating the cargo dsRNA to prevent nuclease degradation or activation of the  
immune system is a common design shared by many delivery systems, in addition to 
chemical modification (Wang et al., 2012a).  An additional common strategy to 
minimise the interaction with serum proteins is to shield the nanoparticles with short 
chains of stabilisers such as polyethylene glycol (PEG)(Alexis et al., 2008).  
Target searching motifs can also be conjugated on to the delivery systems. Aptamer, 
antibody, peptides and organic/inorganic ligands are all good conjugate partners, 
providing they bind specifically and efficiently with their targets.   
The exact pathways which NP-dsRNA is delivered remain largely undetermined. 
However it is generally accepted that the nanoparticles will bind to the cell membrane 
surface receptor, which triggers an internalisation mechanism. During endocytosis, 
the NP-sirna complex will be largely confined to the endosomes. However, some of 
the complex may escape the endocytic pathway and localise to the cytoplasm. The 
majority of the complex will proceed to the lysosome and be degraded. Thus in 
designing the NP-miR complex, maximising the surface functional groups is 
beneficial, providing the stability of the nanoparticle is not affected. This is due to two 
reasons. Firstly, this reduces the number of nanoparticles required for the desired gene 
regulation. This directly minimise the impact exerted by NP on cellular health. 
Simultaneously the number of shRNA cargo can be maximised (Yu et al., 2009).   
After endosome escape, the delivered dsRNA must be loaded onto the RISC protein 
complex to initiate the RNAi pathway (Chiu and Rana, 2002; Ma et al., 2005; 
Nykanen et al., 2001).  At this stage, the cargo needs to dissociate from the delivery 
system to be successfully loaded on the RISC complex. A degradable linker is likely 
be superior to an unstable one. One example of such a linker is a disulphide bridge, 
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which can be cleaved to asulfhydryl moiety under reducing conditions. This has 
biological applicability as the cell cytoplasm is always in a reduced state due to a 
substantially high ratio (greater than 100) of reduced glutathione to oxidised 
glutathione disulfide (Holmgren and Bjornstedt, 1995; Saito et al., 2003). Other 
degradable linkers include acid-labile and enzymatically cleavable linkers, which can 
useful depending on the target tissue.  
 
5.2.2 Ultrasound Microbubbles Mediated Gene Transfer 
Another method of non-viral gene delivery is ultrasound microbubble mediated gene 
transfer. This method utilises the acoustic power of ultrasound and microbubbles to 
transiently alter the permeability of cell membranes and thus facilitate gene delivery. 
Though ultrasound itself has been shown to change cell membrane permeability 
(Brayman et al., 1999; Fechheimer et al., 1987), the co-administration of 
microbubbles has been shown to reduce the acoustic pressure required to achieve 
comparable levels of gene transfer (Miller, 2000). Additionally, the membrane 
permeating ability can be greatly improved using microbubble preparations.(Nomikou 
and McHale, 2012). Microbubbles were originally designed and used clinically as  
agents to increase the contrast in ultrasound imaging, but soon their potential as 
energy deposition foci to enhance nucleic acid were exploited and studied (Blomley, 
2003).  
Microbubbles have been shown to oscillate in an ultrasound field resulting in acoustic 
pressure at any given frequency (Nomikou and McHale, 2012). Depending on the 
intensity of ultrasound, microbubbles can form either stable cavitation, where 
microbubbles vibrate continuously (at low intensity) or inertial cavitation, where 
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microbubbles rapidly compress, expand and collapse (at high intensity) (Husseini et 
al., 2005; Suslick, 1990). When this occurs in the micro-environment in close 
proximity to target cells, the integrity of the cell membrane can be compromised. 
Pores can form transiently, allowing free passage of material (such as nucleic acid) 
and thus sonoporation. However, high intensity can cause irreversible damage to the 
cell membrane which leads to cell death (Nomikou and McHale, 2012). Nucleic acid 
is thought to enter cells by diffusion after pore formation, but other mechanisms like 
caveolin- and clathrin- mediated endocytosis have also been suggested (Escoffre et al., 
2013).  
To induce ultrasound microbubble mediated gene transfer, nucleic acid is mixed with 
the microbubble preparation and co-administered into the circulation. Ultrasound 
waves in the MHz range are applied on the target organ for a short period of time, 
usually 2-5 minutes. Due to its easy operability and non-invasive nature, ultrasound 
microbubble mediated gene delivery is becoming more popular for gene delivery.  I 
was lucky enough to learn and harness this technique from Professor Lan’s lab in Li 
Ka Shing Institute of Health Science, where he used hexafluoride based microbubbles 
(SonoVue)  together with ultrasound to deliver plasmid DNA containing various 
miRNA to the kidneys (Li et al., 2013; Zhong et al., 2013; Zhong et al., 2011). 
However, due to the unavailability of SonoVue in Australia, delivery of miR-200b to 
mouse kidneys using this approach has not yet been attempted. 
 
5.3 Manufacturing and Testing of Nanoparticle-miRNA Conjugate 
In parallel with lentivirus induced gene delivery, a novel type of nanoparticles 
designed for targeted gene/drug delivery was also established in collaboration with 
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Department of Chemistry, University of Sydney. The desired properties of these 
nanoparticles were as follows: 
 Fully functional at a size smaller than 40nm (cut-off size for renal filtration) 
 High cellular penetration 
 Low cellular toxicity and low likelihood of inducing oxidative stress 
 Biologically naïve 
 High stability 
 Neutral charge 
 Ability to stabilise the “cargo” (RNA/DNA/Drug) 
 Options to add additional functional groups (chemical or physical) 
The following diagram demonstrates a schematic overview of the design of the 
nanoparticle. Aptamers are DNAs with tertiary structures that are able to recognise 
specific protein molecules such as antibodies. Fluorescent dye can also be attached to 
trace and study the bio-distribution of these nanoparticles.  
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Figure 5.2 A schematic diagram of the design of the nanoparticles. “Cargo” 
(microRNA) and different functional molecules are attached to the polymeric 
nanoparticles.  
 
5.3.1  Structure and Synthesis of Nanoparticles 
Based on the desired properties, nanoparticles were designed and manufactured by 
The Key Centre for Polymers and Colloids, School of Chemistry, University of 
Sydney.  
The basic building block of the nanoparticle consisted of a hydrophobic tail, 
polystyrene, polyacrylamide and a carboxyl group (Figure 5.3). The carboxyl group 
served as an electrostatic stabiliser as well as a surface modification group for the 
desired applications. 
 
Figure 5.3 Chemical structure of the basic building block of the nanoparticles. The 
different blocks are highlighted with the styrene ring in blue, acrylamide in yellow 
and carboxyl group in pink.  
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The polystyrene-polyacrylamide building blocks of the nanoparticles were allowed to 
self-assemble in water to form micelles. Due to the difference in polarity, the 
hydrophobic tail and polystyrene will form the inner core, while the hydrophilic 
polyacrylamide and carboxylic acid will form the outer layer of the micelle. Sodium 
hydroxide was added to deprotonate the carboxylic acid of the micelle, which was 
then converted to nanoparticles by emulsion polymerisation. The resulting 
nanoparticle was observed using Transmission Electron Microscopy (TEM) to verify 
the size and shape (Figure 5.4). These nanoparticles were spherical in shape and had a 
typical size of 25-30 nm in diameter. 
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Figure 5.4 Transmission Electron Microscopy (TEM) images of the nanoparticles. 
Synthesised nanoparticles were verified for size and shape using TEM. The 
nanoparticles were spherical in shape and typical size was between 25-30 nm in 
diameter.  
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5.3.2 Cellular uptake of Nanoparticles 
To determine the cellular uptake of the nanoparticles, 1x10
12
 rhodamine fused 
nanoparticles (1 mL) were added to HK-2 cells in a 6-well plate. The HK-2 cells were 
then incubated at 37
o
C for 48hr before trypsinisation and washed twice with ice cold 
PBS.  Flow cytometry was then used to determine the uptake of nanoparticles. 99.75% 
cells were positive for rhodamine after 48hr when compared to negative control 
(Figure 5.5), demonstrating robust cell membrane penetration ability of the 
nanoparticles. Furthermore, the similar pattern between the control and treated cells in 
the forward and side scatter plot (Figure 5.5 top panel) also indicated minimal 
biological impact on the cells. This result was also supported by the direct observation 
of normal cellular morphology indicating the non-toxic nature of these nanoparticles.  
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Figure 5.5 Cellular uptake of nanoparticles in HK-2 cells. Rhodamine fused 
nanoparticles (1x10
12
 nanoparticles) were added to HK-2 cells and incubated for 48 
hr. The cells were then subjected to flow cytometry to determine the percentage of 
rhodamine positive cells. Left panel: negative control. Right panel: HK-2 cells treated 
with Rhodamine fused nanoparticles. Top panel: forward and side scatter of cells 
measured with live cells gated (R1). Bottom panel: side scatter and intensity of 
emission light of the cells gated above. Rhodamine positive cells were gated again in 
R3.  
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5.3.3 Rate of Uptake of the Nanoparticles 
We next determined the rate of uptake of the nanoparticles by HK-2 cells as the 
kinetics may play an important role in “cargo” delivery in vivo. Again, HK-2 cells 
were treated with rhodamine fused nanoparticles for various amount of time ranging 
from 0 min to 24 hr before subjected to flow cytometry. HK-2 cells began to uptake 
the nanoparticles as early as 30 mins. Almost half of the cells were rhodamine 
positive after 6 hr and most cells uptake the nanoparticles by 24 hrs (Figure 5.6).   
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Figure 5.6 Uptake of nanoparticles by HK-2 cells over 24 hrs. HK-2 cells were 
treated with 500 μL nanoparticles (1x1012nanoparticles/mL) and incubated at 37oC 
for 0 min to 24 hrs. Cells were collected at 0 mins (negative control), 5 min, 30 min, 2 
hrs, 6 hrs and 24 hrs. Flow cytometry was used to detect the rhodamine presence and 
hence nanoparticle uptake. 
 
5.3.4 Cellular Distribution of Nanoparticles in HK-2 cells 
We next determined the cellular distribution of the nanoparticles using confocal 
microscopy. The distribution determines potential application of the nanoparticles and 
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may have implications for cytotoxicity. For therapeutic purposes, miRNAs are 
required to bind to mRNA and inhibit its translation in the cytoplasm. Thus, ideally, 
the nanoparticles should remain only in the cytoplasm and be absent from the nucleus.  
HK-2 cells were seeded onto a sterile piece of glass in the well of a 6 well plate and 
treated with 2 different amounts of the rhodamine fused nanoparticles, one with 250 
μL and one with 500 μL (1x1012  nano-partiles/mL). Cells were then incubated at 
37
0
C for 24 hrs before being washed with PBS 3 times. 4',6-diamidino-2-
phenylindole (DAPI)  was used to stain the nucleus. Nanoparticles were found to be 
confined to the cytoplasm of HK-2 cells when applied at low concentration (Figure 
5.7 B, E). HK-2 cells treated with higher concentrations of nanoparticles had, as 
expected, a greater accumulation of nanoparticles in the cytoplasm, but nanoparticles 
began to enter the nucleus, indicating their ability to traverse the nuclear membrane 
(Figure 5.7 C, F). This may be a desirable property depending on the purpose of the 
application. For our purposes nuclear accumulation is unnecessary.  
167 | P a g e  
 
  
Fi
g
u
re
 5
.7
 C
el
lu
a
lr
 d
is
tr
ib
u
ti
o
n
 o
f 
rh
o
d
a
m
in
e 
fu
se
d
 n
a
n
o
p
a
rt
ic
le
s.
 H
K
2
 c
el
ls
 w
er
e 
se
ed
ed
 o
n
to
 a
 p
ie
ce
 o
f 
g
la
ss
 in
 t
h
e 
w
el
l o
f 
a
 6
-w
el
l 
p
la
te
. 0
.2
5
 o
r 
0
.5
 t
ri
lli
o
n
 n
an
o
p
a
rt
ic
le
s 
w
er
e 
in
cu
b
a
te
d
 w
it
h
 H
K
2
 f
o
r 
2
4
 h
rs
. C
el
l n
u
cl
eu
se
s 
w
er
e 
st
a
in
ed
 w
it
h
 D
A
P
I a
n
d
 c
el
ls
 w
er
e 
ex
a
m
in
ed
 u
si
n
g
 c
o
n
fo
ca
l m
ic
ro
co
p
y.
 F
o
r 
ea
ch
 g
ra
p
h
, t
o
p
 le
ft
: t
h
e 
n
u
cl
eu
s 
st
a
in
, t
o
p
 r
ig
h
t:
 r
h
o
d
a
m
in
e 
em
is
si
o
n
, b
o
tt
o
m
 le
ft
: l
ig
h
t 
in
ve
rt
ed
 im
a
g
e,
 b
o
tt
o
m
 r
ig
h
t:
 m
er
g
ed
 im
a
g
e 
  A
: n
eg
at
iv
e 
co
n
tr
o
l (
b
ro
a
d
 v
ie
w
).
 B
: H
K
2
 c
el
ls
 t
re
a
te
d
 w
it
h
 0
.2
5
 t
ri
lli
o
n
 n
a
n
-p
a
rt
ic
le
s 
(b
ro
a
d
 v
ie
w
).
 C
: H
K
2
 c
el
ls
 t
re
a
te
d
 w
it
h 
0
.5
 t
ri
lli
o
n
 n
a
n
-p
a
rt
ic
le
s 
(z
o
om
ed
 v
ie
w
).
 D
: n
eg
a
ti
ve
 c
o
n
tr
o
l (
zo
o
m
ed
 v
ie
w
).
 E
: H
K
2
 c
el
ls
 t
re
a
te
d
 
w
it
h
 0
.2
5 
tr
ill
io
n
 n
a
n
-p
a
rt
ic
le
s 
(z
o
o
m
ed
 v
ie
w
).
 F
: H
K
2
 c
el
ls
 t
re
a
te
d
 w
it
h
 0
.5
 t
ri
lli
o
n
 n
a
n
-p
a
rt
ic
le
s 
(b
ro
a
d
 v
ie
w
).
 
168 | P a g e  
 
5.3.5  Bio-distribution of Nanoparticles in Mice. 
The nanoparticles were then tested for in vivo use in c57bl6 mice to study the bio-
distribution and adverse effects after intravenous administration. 400 μL nanoparticles 
fused with rhodamine (1x10
14
 nanoparticles/mL) were administered intravenously 
through the tail vein. The mouse was allowed to rest for 40 mins before being imaged 
using an In-Vivo FX PRO in vivo imaging machine (Carestream, NY, USA). 
Rhodamine was excited and the emission was detected and plotted. X-ray images of 
the mouse were also obtained and superimposed onto the rhodamine emission image 
to visualise the bio-distribution of these nanoparticles. Nanoparticles were found to be 
distributed throughout the body of the mouse with more intense emission in lungs and 
liver. No fluorescence was detected in the brain. Kidneys, did not demonstrate enough 
emission to be visualised in the whole body scan (Figure 5.8). The mouse was then 
culled and organs were harvested. The ex vivo organs including heart, lung, liver and 
kidney were immediately imaged using the in vivo imaging system. Among these 
organs, lung and liver demonstrated the strongest fluorescence, whilst the kidney and 
heart had reduced but significant amount of emission compared to the control mouse 
organs (Figure 5.9).  
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5.3.6 MiRNA Conjugation with Nanoparticles. 
5.3.6.1 Conjugation Chemistry 
To conjugate miRNA-200b to the nanoparticles, carboxyl groups on the surface of 
nanoparticles were covalently linked to the primary amine group on the 5’ end of the 
miRNA in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
and N-Hydroxysuccinimide (NHS).  
 miRNA-200b was synthesized with amine modification at the 5’ end of the sense 
strand (guide strand). Two proprietary designs by Sigma-Aldrich intended for 
increased binding efficiency and reduced potential sense strand off-target effects 
(http://www.sigmaaldrich.com/life-science/functional-genomics-and-
rnai/mirna/microrna-mimics.html) were incorporated. These designs include two 
oligo-dT attached to the 3’end of the sense strand via a phosphor-diester bond and 
insertion of uracil between the third last and fourth last bases (excluding the oligdT at 
the end) creating a bulge. A cy3 label was attached to the 3’ end of the sense strand in 
order to trace and quantitate the miRNA. 
 
5.3.6.2 First Attempt 
5.3.6.2.1 DEPC treatment of nanoparticles 
In order to minimize the possible degradation by RNAse activity in the conjugation, 
nanoparticles were treated with 0.1% (v/v) diethylpyrocarbonate (DEPC) by stirring 
under room temperature followed by autoclaving. The nanoparticles were then 
purified by centrifugation against a membrane with a molecular cut-off size of 
100kDa, followed by washing three times with RNAse free water. After the final 
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centrifugation, the nanoparticles that were retained on the membrane were 
resuspended in RNAse free water in its original volume. 
 
5.3.6.2.2 Conjugation 
5ml nanoparticles with 0.05% soluble content were used to conjugate to miR-200b.  5% 
of the surface carboxyl groups (theoretical calculation) were activated by the addition 
of 4.81x10
-7
 EDC and 2.89x10
-7
g NHS followed by stirring at room temperature for 1 
hr. 2.5 nmole of miR-200b was then added to the activated nanoparticles. The pH of 
the mixture was adjusted to 10 and stirred constantly at slow speed overnight at 4
o
C. 
After conjugation, the mixture was purified by ultracentrifugation against a membrane 
with a molecular size cut-0ff of 30 kDa to remove unbound miRNA-200b and 
coupling reagents. The retained NP-miR-200b conjugate was further purified by 
washing with RNAse free water. 
 
5.3.6.2.3 Result 
The volume ofNP-miR-200b conjugate was brought up to 5 mL with RNAse free 
water. The intensity of the fluorescence of the filtrate (free unbound miRNA-200b in 
around 5mL water) was compared to the one of the retained NP-miR-200b conjugate. 
It was apparent that the intensity of the free miRNA-200b was much higher than the 
conjugate. The conjugate was then used to transduce HK-2 cells to determine the 
percentage of cy3 positive cells. Various amounts of NP-miR-200b conjugate ranging 
from 50 µL to 1000 µL were used incubate with HK-2 cells, which were then 
subjected to flow-cytometry analysis. However, a maximum of 17% cy3 positive HK-
2 was achieved by 1mL NP-miR-200b conjugate (Figure 5.10). At this concentration, 
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NP induced significant cell toxicity, which was reflected in the increase of cell 
fragments captured by flow cytometry. It was concluded that the conjugation 
efficiency was too low and conjugation conditions had to be optimized to increase 
efficiency and reduce toxicity. 
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Figure 5.10 Flow cytometry analysis of cy3 positive after NP-miR-200 transduction.  
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HK-2 cells were transduced with various amount of NP-miR-200b conjugate and 
incubated for 48 hr before being subjected to flow cytometry analysis. G1= live cells. 
G2=cy3 positive cells. G2=R2. 
 
5.3.6.3 Further Attempts 
Various conditions were tried to optimize the conjugation efficiency, which are 
summarized in Table 5.1 below. 
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Number of 
Particles (% 
soluble content) 
Carboylic 
acid 
activation 
(%) 
EDC 
Amount (g) 
NHS 
Amount (g) 
pH 
miRNA 
Purificatioin 
Method 
Source of 
miRNA 
Activation 
Time 
(min) 
Yield * 
1 0.05 5 4.81E-07 2.89E-07 10 HPLC GenePharma 60 <20% 
2 0.05 5 4.81E-07 2.89E-07 8 HPLC GenePharma 60 <20% 
3 0.05 5 4.81E-07 2.89E-07 6 HPLC GenePharma 30 <20% 
4 0.05 5 4.81E-07 2.89E-07 6 HPLC GenePharma 60 <20% 
5 0.05 10 9.62E-07 5.78E-07 6 HPLC GenePharma 60 <20% 
6 0.05 20 1.92E-06 1.16E-06 6 HPLC GenePharma 60 <20% 
7 0.05 40 3.85E-06 2.31E-06 6 HPLC GenePharma 60 <20% 
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8 0.05 60 5.77E-06 3.47E-06 6 HPLC GenePharma 60 <20% 
9 0.05 80 7.70E-06 4.62E-06 6 HPLC GenePharma 60 <20% 
10 0.05 100 9.62E-06 5.78E-06 6 HPLC GenePharma 60 <20% 
11 0.5 100 9.62E-05 5.78E-05 6 HPLC GenePharma 60 <20% 
12 0.05 5 4.81E-07 2.89E-07 6 No 
Sigma-
Aldrich 
60 <20% 
13 0.05 80 7.70E-06 4.62E-06 6 No 
Sigma-
Aldrich 
60 <20% 
14 0.05 80 7.70E-05 4.62E-05 6 
Cold 
Ethanol 
Sigma-
Aldrich 
60 <30% 
 
Table 5.1: Summary of optimizations attempted to increase the NP-miRNA conjugation efficiency.  
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5.3.6.4 Attempt with 800% Activation of Carboxyl group 
5.3.6.4.1  Conjugation Condition 
It was hypothesised that the carboxylic acid on the surface of the nanoparticles was 
not efficiently and fully activated, which in turn may have hindered the conjugation 
process. Excess EDC and NHS (800% of the amount required theoretically to 
activated all carboxylic acid) was used to activate the nanoparticles. 5 ml 
nanoparticles (0.005% soluble content) were activated with EDC and NHS for 1 hr 
before the addition of 2.5 nmole miR-200b. The mixture was incubated overnight at 
4
o
C on a slow orbital shaker. The conjugation mixture was purified using an 
ultracentrifugation tube with a filter cut-off size of 30 kDa. The filtrate containing free 
miRNA was further purified, removing EDC and NHS, which interferes with 
photometric quantitation of RNA), using an ultracentrifugation tube with a filter cut-
off size of 3 kDa. Both free miRNA and conjugated miRNA were collected and 
quantitated using Nanodrop.  
 
Starting miRNA (ng) 38000 
Free miRNA (ng) 8230 
Conjugated miRNA (ng) 29770 
Conjugation Efficiency  78% 
Table 5.2 Calculation of the percentage of miRNA conjugated.  
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However, precipitation was noticed at the bottom of the tube. The likely cause of the 
precipitation was the destabilisation of nanoparticles due to excessive EDC and the 
NHS coupling reagent.  
 
5.3.6.4.2 In vitro transduction of NP-miR-200b of HK-2 Cells 
The conjugated NP-miRNA complex was used to transduce HK-2 cells regardless of 
the precipitation. 50 µL NP-miRNA conjugate was added to each well of HK-2 cells 
on a 6-well plate. The plate was then incubated for 72 hr before total RNA was 
extracted and analysed.  
miR-200b levels in the HK-2 cells transduced with NP-miR-200b were increased by 
58% (n=1) when compared to cells transduced with NP-NS-miR (Figure 5.11A). This 
level was considerably lower than the expected amount of miR-200b after 
transduction with NP-miR-200b. The obvious reason being, that although miR-200b 
was conjugated to nanoparticles, destabilisation of the nanoparticle structure affected 
their ability to enter the cell. Thus the miR-200b could not be effectively delivered 
into the cells. The lack of detection of overexpression of miR-200b could also be 
explained by the failure of amplification of miR-200b due to steric hindrance exerted 
by the nanoparticles during the reverse transcription step.  
The lack of changes in expression in E-cadherin (Figure 5.11B) and fibronectin 
(Figure 5.11C) also reflected that NP-miR-200b was not functional. Further 
optimisation was required.  
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C 
 
Figure 5.11 miR-200b level and marker gene expression after incubation of HK-2 
with NP-miRNA conjugate (n=1). 50 µL of NP-miRNA conjugate (0.05% soluble 
content) was added to HK-2 cells in one well of a 6-well plate and incubated at 37
o
C 
for 72 hr. Total RNA including miRNA was extracted, reverse transcribed and 
amplified using real-time PCR. miRNA level was normalised to U6 while the mRNA 
level was normalised to β-tubulin. A: miR-200b. B: E-cadherin. C: Fibronectin. 
 
5.3.6.5 Conjugation of Nanoparticles with miR-200b and no dye modification 
5.3.6.5.1 Conjugation Conditions 
To eliminate the possible destabilisation of nanoparticles caused by the hydrophobic 
dye attached at the 3’end of the sense of the miRNA, a new batch of miR-200b was 
synthesised with amine modification at 5’ end of the sense strand only. The miR-200b 
was purified using cold ethanol precipitation.  
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To conjugate, 500 µL (0.5% soluble content) freshly manufactured nanoparticles were 
activated by the addition of 4.81x10
-7
g EDC and 2.89x10
-7
g NHS (100% carboxylic 
acid activation), followed by stirring at room temperature for 1 hr. 10 nmole of miR-
200b was added to the activated nanoparticles, which were then incubated overnight 
at 4
o
C on a shaker. The conjugate mixture was then purified and washed using an 
ultracentrifugation tube with a molecular cut-off size of 100 kDa. The retained NP-
miR-200b conjugate (150 µL) was quantitated using Nanodrop. The concentration of 
miRNA in the NP-miR-200b conjugate was determined to be 241.57 ng/µL. This was 
equivalent to 5% of all surface carboxyl groups (about 260 on each nanoparticle) 
being conjugated to miR-200b. Noticeably, no precipitation was formed even after 
high speed centrifugation (20,800 G for 5 mins).  
 
5.3.6.5.2 In vitro transduction of HK-2 cells with NP-miR-200b 
With confidence in the stability of the NP-miR-200b conjugate, HK-2 cells were 
transduced with these newly conjugated nanoparticles. 50 µL and 20 µL of the NP-
miR-200b conjugate were added to each well of HK-2 cells on a 6-well plate 
separately. Cells were incubated for 72 hrs before total RNA was extracted and 
analysed. miR-200b level increased by 169% and 58% (n=1) in HK-2 cells incubated 
with 50 µL and 20 µL NP-miR-200b conjugate respectively, when compared to 
control (Figure 5.12A). However, the NP-miR-200b conjugate did not exert the 
expected effects on the expression of E-cadherin and fibronectin (Figure 5.12B, C). 
Hence it was concluded that the steric hindrance exerted by the nanoparticles 
significantly reduced the accessibility of miRNA to the miRNA processing protein 
complex, such as dicer, which is essential for functional miRNA gene regulation. 
Conversely, the same hindrance may also inhibit the reverse transcription of miRNA 
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by repelling the reverse transcription protein machinery. Thus, a cleavable bond 
between the nanoparticle and the miRNA, such as disulphide bond instead of an 
unbreakable bond, such as the amide bond used, may significantly increase the 
functional gene regulation by miR-200b once it is inside the cell. 
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Figure 5.12 miR-200b levels and marker gene expression after incubation of HK-2 
(n=1) with NP-miRNA conjugate. 50 µL or 20 µL of NP-miRNA conjugate (~1.67% 
soluble content) was added to HK-2 cells in one well of a 6-well plate and incubated 
at 37
o
C for 72 hr. Total RNA including miRNA was extracted, reverse transcribed and 
amplified using real-time PCR. miRNA level was normalised to U6 while mRNA level 
was normalised to β-tubulin. A: miR-200b. B: E-cadherin. C: Fibronectin. 
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5.4 Discussion  
In this chapter, the possibility of using a novel type of nanoparticles to deliver 
miRNA to the kidneys was examined. These nanoparticles were intentionally 
designed and manufactured to be approximately 25nm, so that, after functionalization, 
the final size would be less than 40nm. At this size, nanoparticles should be freely 
filtered by the kidney glomerulus. However, other factors such as charge and shape 
could also play key roles on the glomerular filtration of nanoparticles. In one study, a 
single-walled carbon nanotube with sizes ranging from 100nm to 500nm passed freely 
through the gl;omerular fenestration (Ruggiero et al., 2010). We have clearly 
demonstrated the efficient and rapid cellular incoporporation of these nanoparticles. 
This is of key importance for systemic in vivo applications to avoid degradation and 
clearance.  
The nanoparticles were designed to be negatively charged to reduce cell toxicity 
(Kanasty et al., 2013). Thus, the negatively charged miRNA cannot be 
electrostatically bound to the nanoparticles. A stronger bond has to be created to not 
only overcome the repulsion but also hold the cargo miRNA to the nanoparticles. 
Initially, a covalent amide bond was established by conjugating the carboxyl groups at 
end the surface of nanoparticles to the amine functional groups at the 5’ end of the 
passenger strand (sense strand) of modified miRNA. However, no silencing was 
observed even after high conjugation and delivery efficiency was achieved in HK-2 
cells treated with these nanoparticles. It has been reported that chemical modification 
can abolish the silencing effects of siRNA. This was mainly due to the fact that, in 
order to be recognised by the RISC protein complex, the 5’ terminus of the antisense 
strand has to be phosphorylated (Chiu and Rana, 2002; Ma et al., 2005; Nykanen et al., 
2001).  Blocking all four sites of the dsRNA significantly diminished the RNAi effect 
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while blocking both 5’ and 3’ of the sense strand or the 3’ of the antisense strand 
retained the silencing effects (Czauderna et al., 2003).  Thus, the chemical 
modification in this study should not be the reason for the lack of change in 
expression level of target genes. The size of nanoparticles was then considered. The 
double stranded miRNA has to be processed by Dicer and loaded onto RISC protein 
complex in order to function. The estimated size of the miRNA is 15kDa while the 
size of nanoparticles is ~700kDa. Furthermore, the amide bond is stable and cannot be 
broken inside the cell to release miRNA. Thus steric hindrance exerted by 
nanoparticles may prevent the miRNA from being processed. Unbreakable bonds 
such as amide bonds have been used in conjugation of dsRNA with functional motifs 
while maintaining silencing effects. However, they are usually small molecules that 
have comparable size to the delivered dsRNA (Jeong et al., 2009).  It was then 
decided to incorporate a degradable linker into the delivery system so that the miRNA 
cargo can be release inside the cytoplasm under reduced condition. It is proposed that 
a pyridyl disulfide cystreamine linker will be conjugated to the nanoparticles before 
linking the thiol modified miRNA to the linker. This project is in progress.  
The bio-distribution demonstrated that liver retained the highest level of nanoparticles 
while kidney had less but significant amount of nanoparticles. However, these 
nanoparticles have not been functionalised to bind specifically to kidneys yet. Since 
the sodium glucose co-transporter 2 (SGLT2) is expressed only in the proximal 
tubular cells (Komala et al., 2013), it naturally becomes a good target for nanoparticle 
binding. Antibodies against SGLT2 are be a good candidate to conjugate to 
nanoparticles for proximal tubular cell targeted delivery. However, antibody is 
expensive and it is generally difficult to conjugate peptides to other molecules. 
Aptamers are single stranded DNA or RNA sequences that are usually 60-80 bases in 
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length and possess certain 3D structures which allow them to have high affinities to 
other molecules including proteins (Cox et al., 2002).  Many aptamer have been 
developed and the first aptamer based drug Macugen was approved in 2006 for 
treating age-related macular degeneration (http://en.wikipedia.org/wiki/Pegaptanib).  
By attaching an aptamer which has high affinity with SGLT2, it is believed that the 
internalisation of nanoparticles by proximal tubular cells will greatly increase. The 
same chemical reaction used to conjugate miRNA to the nanoparticles can be applied 
to attach the aptamer. Furthermore the direct link between miRNA and aptamer, thus 
a DNA-RNA chimera, could also be developed for targeted delivery of miR-200b to 
proximal tubular cells. A DNA based aptamer against SGLT2 is currently being 
developed by selecting the aptamer pool against the proximal tubular cells (Sefah et 
al., 2010). Once developed and conjugated, these nanoparticles will be tested for the 
targeted delivery of miRNA and later be used for delivery any cargos to proximal 
tubular cells.  
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6 Chapter 6 Role of PMEPA1 in Renal Fibrosis 
6.1 Specific background and objectives 
As described in Chapter 1, TGFβ1 plays a key role in the pathogenesis and 
progression of nephropathy. Central to TGFβ1 mediated cellular modification is the 
SMAD signalling pathway, whose importance has been extensively established. 
Subsequent targeting of SMAD signalling in various models of renal fibrosis to 
achieve reno-protective effects has demonstrated positive results, which confirmed the 
SMAD pathway as a promising therapeutic target. Recently, a natural biological 
molecule called Prostate Transmembrane Protein, Androgen Induced (PMEPA1) has 
been shown to be able to antagonise the TGFβ-SMAD signalling pathway by 
preventing SMAD phosphorylation and translocation into the nucleus (Watanabe et 
al., 2010). Interestingly, PMEPA1 itself is induced by TGFβ1 and hence forms a 
negative feedback loop to TGFβ signalling. As outlined in the previous chapter, miR-
200b can further elevate PMEPA1 levels in addition to the auto induction of TGFβ, 
indicating a further mechanism whereby miR-200b mediates its anti-fibrosic 
properties.  Furthermore, PMEPA1 can selectively target R-SMAD (SMAD2, 3), 
providing a highly specific target for inhibiting the profibrotic SMAD signalling 
pathway, whilst leaving the antifibrotic ‘reno-protective’ SMAD7 signalling intact 
(Liu et al., 2011). Thus the efficacy of using PMEPA1 as a therapeutic agent in 
preventing renal fibrosis was examined in this study. Additionally, the roles of 
PMEPA1 in several signalling pathways, independent of SMAD signalling were 
studied in the context of renal fibrosis. 
Immortalised human proximal tubular epithelial cells (HK-2) were used in this study 
and TGFβ1 was used to induce cellular fibrotic responses and EMT. Gain and loss of 
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function methodology were used to study the role of PMEPA1 in preventing TGFβ1 
induced cellular fibrotic responses and EMT.  
The specific aims of this study were to determine the effect of PMEPA1: 
1. on the expression of renal tubular cell E-Cadherin  
2. in preventing TGFβ1 induced renal tubular cell profibrogenic responses  
3. in preventing EMT       
4. in TGFβ signalling, both SMAD dependent and SMAD pathways independent 
in the context of renal fibrosis. 
 
  
191 | P a g e  
 
6.2 Materials and Methods 
6.2.1 Cell culture of HK-2 cells and TGFβ1 exposure 
Immortalised human proximal tubular epithelial cells (HK-2) from American Type 
Cell Collection (ATCC, USA) were used in this study. HK-2 cells were grown in 
KSFM (Life Technologies, USA) supplemented with 5ng/mL recombinant EGF and 
0.05mg/mL bovine pituitary extract in 6-well plates (Thermo Fisher Scientific, USA) 
and incubated in 5% CO2 and 95% air at 37
o
C. Cells were passaged constantly at a 
sub-confluent stage to maintain a healthy epithelial cell phenotype.  
6.2.2 Transient knockdown of PMEPA1  
PMEPA1 specific siRNAs were designed using siRNAWizard 
(http://www.sirnawizard.com/) and obtained from GenePharma (Shanghai, China). 
siRNAs were synthesized as a double stranded RNA duplex and delivered in powder 
form  for increased stability. siRNAs were then reconstituted into 25μM stock 
solution with RNAse-free water (Life Technologies, USA) and aliquoted before being 
stored at -80
o
C.  
HK-2 cells were seeded at 50% confluence in 6-well plates 16 hr prior to transfection. 
On the day of transfection, the cells were washed with 500μL Opti-MEM medium 
(Life Technologies, USA) and incubated with a further 500μL Opi-MEM until the 
addition of the transfection complex. 5μL of Lipofectamine2000 (Life Technologies, 
USA) was diluted in 250μL Opi-MEM, while PMEPA1 siRNA was mixed with 
250μL Opi-MEM. Diluted Lipofectamine2000 and siRNA was incubated for 5 min at 
room temperature before being mixed and incubated for a further 15 min for complex 
formation. 500μL fresh medium was applied followed by the addition of the PMEPA1 
siRNA transfection complex.  
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The transfected cells were incubated for 6 hrs at 37
 o
C, in 5% CO2 and 95% air before 
2mL of complete KSFM medium was added and incubated overnight. On the next day, 
the experimental conditions were applied for 48 hrs at which time mRNA and protein 
lysate were collected for further studies. 
 
6.2.3 Transient over-expression of PMEPA1 
6.2.3.1 Generating the PMEPA1 gene insert 
The PMEPA1 coding sequence with 5’ and 3’ overhang was produced for insertion 
into the plasmid construct. This was achieved by the following 3 steps:  
1. Amplification of the PMEPA1 coding region from either genomic DNA or  
the cDNA library 
2. Adding restriction enzyme recognition sites at both ends of the PMEPA1 gene 
3. Restriction enzyme endonuclease digestion to ensure annealing 
6.2.3.1.1 Amplification of the PMEPA1 coding region from either genomic DNA 
or the cDNA library 
Primers that amplify the coding region of the PMEPA1 gene with/without restriction 
enzyme recognition sites were designed. The sequences designed are shown below 
with restriction enzyme recognition sites in bold (Table 6.1). A NheI recognition site 
was added to the forward primer while a BamHI recognition site was added to the 
reverse primer. 4bp random nucleotides were added to the 5’ of the sequence for 
improved restriction digestion efficiency.  
PMEPA1 F ATGCACCGCT TGATGGGGGT 
PMEPA1 R CTAGAGAGGG TGTCCTTTCTGTTTATCCTT CTCT 
193 | P a g e  
 
PMEPA1 F -
NheI 
TATGGCTAGCATGCACCGCT TGATGGGGGT 
PMEPA1 R-
BamHI 
CAGTGGATCCCTAGAGAGGGTGTCCTTTCTGTTTATCCTT 
CTCT 
 
Table 6.1: Table summarising the sequences of primers used to amplify PMEPA1 
cDNA. 
1μL of genomic DNA (100 ng/μL) or cDNA (reverse transcribed from 1 μg HK-2 
mRNA) was used as the template to amplify the coding sequence of PMEPA1 gene 
using PfuUltra II Fusion HS DNA Polymerase (Agilent, USA). The template DNA 
was mixed with 1 μL of each of the forward and reverse primers, 1.2 5μL of 10mM 
dNTP mix, 5 μL of 10x reaction buffer, 1μL of PfuUltra II Fusion HS DNA 
Polymerase and made up to 50 μL with RNAse free water.  
The PMEPA1 gene was PCR amplified using the following protocol: 
3. Initial denaturation:   95 oC  2 min for genomic DNA  
1 min for cDNA 
4. 3 step cycling for 30 cycles 
a. Denaturation  95
 o
C  20 s 
b.Annealing   55
 o
C  20 s 
c.Extension   72
 o
C  45 s 
5. Final extension  72 oC  3 min 
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The resulting PCR product was resolved on an agarose gel to check the correct size of 
the PCR product.  22.5 μL of the PCR product was mixed with 2.5 μL 10x BlueJuice 
Gel Loading Buffer (Life Technologies, USA) before being loaded onto a 1% agarose 
gel and resolved at 90V. The digitised image of the agarose gel is shown in Figure 6.1. 
The expected size of PMEPA1 coding sequence without restriction sites is 864bp, and 
884bp inclusive of restriction sites. The PCR product amplified from cDNA had the 
correct size, while no product was observed following amplification of genomic DNA.   
 
Figure 6.1 Amplification of PMEPA1. Lane 1: PMEPA1 from genomic DNA with both 
restriction enzyme recognition sites. Lane 2:  PMEPA1 from cDNA with both 
restriction enzyme recognition sites. Lane 3:  PMEPA1 from genomic DNA with no 
restriction enzyme recognition sites. Lane 4:  PMEPA1 from cDNA with no restriction 
enzyme recognition sites.  
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6.2.3.1.2 Adding restriction enzyme recognition sites at either end of the 
PMEPA1 gene 
Since the PMEPA1 coding region with restriction recognition sites was successfully 
directly amplified from cDNA, a secondary PCR round to add restriction recognition 
sites was deemed unnecessary.  
6.2.3.1.3 Restriction enzyme endonuclease digestion of amplified cDNA  
The amplified PCR product was purified to remove proteins and salts that may 
interfere with the restriction enzyme digestion using the MinElute PCR cleanup Kit 
(Qiagen, USA) according to manufacturer’s instruction outlined in Chapter 2. NheI 
and BamHI restriction endonucleases digestion were used to create “sticky ends” of 
the PMEPAI1 gene insert. The digestion was performed in a sequential order. 2μg of 
purified PCR product was mixed with 2μL 10x Buffer, 1 μL NheI restriction enzyme 
(NEB, USA) and made up to 20μL with water. The mixture was incubated at 37oC for 
2 hr followed by purification again to remove protein, salts and cleaved DNA 
fragments. The eluted DNA was mixed with 2μL 10x buffer, 2μL BamHI restriction 
enzyme (NEB, USA) and made up to 20μL with water. The mixture was incubated at 
37
o
C for 1 hr and purified.  
 
6.2.3.2 Plasmid vector preparation for cloning 
The plasmid vector used in this experiment was pCDNA3.1 (Life Technologies, 
USA). PMEPA1 was cloned into the multiple cloning site downstream of the CMV 
promoter. Preparation included the following steps: 
1. Transformation of competent cells 
2. Selection and growing of bacterial cells containing the desired plasmid 
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3. Linearization of the plasmid vector using restriction enzymes. 
 
6.2.3.2.1 Transformation of competent cells 
The original pCDNA3.1 plasmid was diluted to 2ng/μL and 1μL of the diluted 
plasmids was used to transform 50μL One ShotStbl3 chemically competent E. coli 
cells (Life Technologies, USA). Briefly, 1μL diluted plasmid was added to one tube 
of competent cells and mixed gently followed by incubation on ice for 30 min. The 
competent cells were heat-shocked at 42
o
C for 45 s followed by another 2 min 
incubation on ice. 250 μL S.O.C medium was added into the cells, which were then 
incubated at 37
 oC for 1 hr at 225rpm in a shaking incubator. After incubation, 100 μL 
of the mixture was plated onto an agar plate containing 100 μg/mL ampicillin (Sigma-
Aldrich, USA). The plate was incubated at 37
 o
C overnight for colony formation. 
 
6.2.3.2.2 Selection and growing bacterial cells containing desired plasmid 
Colonies incorporating the plasmid were picked and grown in 5mL LB medium at 37
 
o
C for 12-16 hr. A Plasmid miniprep was then performed using Qiagen Miniprep Kit 
(Qiagen, USA). Extracted plasmid was then resolved on a 1% agarose gel to ensure 
the correct size. 
 
6.2.3.2.3 Linearization of plasmid vector using restriction enzyme 
2μg of vector plasmid was mixed with 2μL 10x Buffer, 1 μL NheI restriction enzyme 
(NEB, USA) and made up to 20μL with water. The mixture was incubated at 37oC for 
2 hr followed purification again to remove protein, salts and cleaved DNA fragments. 
197 | P a g e  
 
The eluted DNA was mixed with 2μL 10x buffer, 2μL BamHI restriction enzyme 
(NEB, USA) and made up to 20μL with water. The mixture was incubated at 37oC for 
1 hr and purified. The linearised plasmid with both 5’ and 3’ sticky ends was then 
exposed to shrimp alkaline phosphatase (Promega, USA) to remove the 5  ´phosphate 
groups on the DNA backbone to prevent auto-ligation of the linearized DNA, using 
the method outlined in Chapter 2. The resulting DNA was purified and eluted in water 
and was then ready for cloning. 
 
6.2.3.3 Molecular cloning and selection 
The PMEPA1 cDNA and pCDNA3.1 plasmid vector, both with sticky ends were then 
ligated. 1:3 molar ratio of vector to insert DNA was used. 100 ng linearised 
pCDNA3.1 plasmid was mixed with 35 ng PMEPA1 cDNA in the presence of 1 μL 
10x ligation buffer, 1 μL of T4 DNA ligase (NEB, USA) and water to 10 μL. The 
mixture was then incubated at 4
o
C overnight. A negative control was also examined 
using identical experimental conditions but without the addition of the insert DNA.  
2 μL of the ligation mix was the used to transform 50 μL One ShotStbl3 chemically 
competent E. coli cells (Life Technologies, USA) using the method described in 
section 5.2.3.2.1. The transformed E.coli from both positive and negative tubes were 
plated onto agar plates containing 100μg/mL ampicillin and incubated at 37oC 
overnight. The number of colonies on each plate were counted. Transformation was 
considered successful (more than 50% colonies contain the inserted gene) only when 
positive plates had significantly more (at least ≥2 times more) colonies than negative 
plates. 5 colonies from positive plates were inoculated into 5 mL LB medium and 
incubated at 37
 o
C for overnight at 225rpm in a shaking incubator. Plasmid was 
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extracted and sequenced at The Australian Genome Research Facility (AGRF). For 
sequencing, 1 μg plasmid DNA was mixed with 1 μL sequencing primer (10 μM 
stock) and made up to 12 μL with water. Sequencing primers used were:  
Forward: CACGCTGTTTTGACCTCCATAGA,  
Reverse: GCACCGGAGCGATCGCAGATC.  
Clones with the correct sequence were then grown in 25 mL LB medium at 37
o
C for 
16 hr followed by plasmid midiprep as outlined in Chapter 2. 
 
6.2.4 PMEPA1 siRNA  
Three different designs of PMEPA1 siRNA targeting different locations of the mRNA 
were tested to determine the optimal siRNA to be used in subsequent experiments. 
The sequences of these siRNA were as follows (Table 6.2): 
PMEPA1-2 sense GAGCAAAGAGAAGGAUAAACAUU 
PMEPA1-1 anti-sense UGUUUAUCCUUCUCUUUGCUCUU 
PMEPA1-2 sense GUCCCUAUGAAUUGUACGUUUUU 
PMEPA1-2 anti-sense AAACGUACAAUUCAUAGGGACUU 
PMEPA1-3 sense GCAUCAGCGCCACGUGCUAUU 
PMEPA1-3 anti-sense UAGCACGUGGCGCUGAUGCUU 
Table 6.2: Table summarising the sequences of siRNAs used to knock down 
PMEPA1 mRNA. 
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6.2.5 Establishing human proximal tubular epithelial cell line overexpressing 
PMEPA1 
In order to study the effects of PMEPA1 over-expression without the adverse effects 
of transfection, lentivirus was used to transduce HK-2 cells to produce a human 
kidney proximal tubular cell line that consistently over-expresses PMEPA1. Upon 
infection, the replication inactivated lentivirus will insert the “cargos” which are 
PMEPA1 driven by CMV promoter and GFP driven by EF1 promoter into the 
genome of the host cell. The co-transduction of GFP gene with PMEPA1 provided a 
simple but useful selection marker for identifying the positively transduced cells. The 
stably transduced cells could then be used for experiment or stored in liquid nitrogen 
until needed.  
 
6.2.5.1 Cloning  
PMEPA1 coding region was amplified using the methods outlined in section 5.2.3. 
However, instead of pCDNA3.1, the insert was cloned into pCDH-CMV-MCS-EF1-
GFP plasmid (SBI, USA). The full sequence of this plasmid can be found at 
http://www.systembio.com/support/resources/lentiviral-tech/vector-sequences.  
 
6.2.5.2 Lentivirus packaging 
HKE293T cells were seeded on to T75 tissue culture flask with 20mL complete 
medium (DMEM, high glucose, GlutaMax, Pyruvate supplemented with 10% FBS) at 
the density of 5 million cells per flask 24hr before the transfection.  Mixtures of 4 
plasmids carrying the “cargo” gene (pCDH-CMV-PMEPA1-EF1-GFP) as well as all 
the necessary proteins (REV, GAG-POL, VSV-G) to assemble the lentivirus were co-
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transfected into HEK293T cells.  In details, 2.25μg pCDH-CMV-PMEPA1-EF1-GFP 
and 22.5μL (11.25μg) pPack packaging plasmid mix (SBI, USA) were diluted in 
1.35mL Opti-MEM medium before the addition of 13.5μL of X-tremeGENE HP 
(Roche, USA) transfection reagent. The solution was gently mixed and incubated at 
room temperature for 20mins before added to the HEK293T cells in a drop wise 
manner. The flask was then gently swirled to evenly spread the transfection complex 
and then incubated at 37
0
C for 48hr.  
 
6.2.5.3 Lentivirus collection, purification and concentrating 
48hr post transfection, cell supernatant containing mature lentivirus (replication 
inactivated) was collected and filtered using a 0.45μm low protein binding filter 
(Millipore, USA). The volume of filtered supernatant was measured and then mixed 
with ¼ volume of 5x PEG-IT Virus Precipitation Solution (SBI, USA). The 
supernatant/PEG-IT solution was stored at 4
0
C for 24hr to allow lentivirus to 
precipitate to the bottom of the tube followed by centrifugation at 1500g for 30min. 
The supernatant was then removed and the lentivirus pellet was resuspended in 1/50 
original volume in PBS solution. The resuspended lentivirus was either used straight 
away or stored at -80
0
C for future use.  
 
6.2.5.4 Lentiviral Transduction of HK-2 cells 
HK-2 cells were seeded onto 6-well plate in 2mL complete medium at the density of 
0.2 million cells per well 24hr before the addition of lentivirus. Various amounts of 
lentivirus were added toeach well of HK-2 cells in order to find the optimal 
transduction concentration and the plate was then incubated at 37
0
C. To verify 
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successful transduction, cells were observed under a fluorescent microscope 48hr post 
addition of the lentivirus for GFP expression. Wells demonstrating about 80-90% 
positive cells indicate ideal transduction efficiency and were used for colony selection. 
 
6.2.5.5 Positive Colony Selection 
HK-2 cells demonstrating the ideal transduction efficiency were passaged every 2 
days for 10 passages and GFP expression was closely monitored to ensure stable 
integration of the inserted gene. In order to get a colony originating from a single cell, 
transduced HK-2 cells were trypsinised from  the plate, washed, diluted and seeded 
onto 96-well plates in 100μL complete medium at the density of 1 cell per well. The 
96-well plate was then incubated at 37
0
C for 7 days allowing the colonies to grow. 
Positive colonies with a majority of cells expressing GFP were picked and sub-
cultured. 
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6.3 Results 
6.3.1 Selection of the optimal siRNA for PMEPA1 knockdown 
Three PMEPA1 siRNA constructs were designed to target different locations of the 
PMEPA1 mRNA and tested to determine the optimal siRNA for use in subsequent 
experiments. siRNA was transfected into HK-2 cells, with or without TGFβ1 
exposure 24 hr post transfection. PMEPA1 mRNA level was measured using real-
time PCR. PMEPA1 siRNA-1 reduced PMEPA1 mRNA by 61% in the absence of 
TGFβ1 and 64% in the presence of TGFβ, compared to non-specific siRNA (Figure 
6.2). Thus PMEPA1 siRNA -1 was used in the subsequent experiments to determine 
the effects of silencing PMEPA1 gene expression. 
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PMEPA1 Knockdown (Presence of TGF-beta)
N
S
 S
iR
N
A
 +
 T
G
F
β
P
M
E
P
A
1
 K
D
 s
iR
N
A
 1
 +
 T
G
F
β
P
M
E
P
A
1
 K
D
 s
iR
N
A
 2
 +
 T
G
F
β
P
M
E
P
A
1
 K
D
 s
iR
N
A
 3
 +
 T
G
F
β
0
1
2
3
4
5
*
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
/ 
T
u
b
u
li
n
 
Figure 6.2 Selection of the siRNA with optimal silencing of PMEPA1 gene expression.  
HK-2 cells were transfected with three different PMEPA1 siRNA followed by either 
control or 0.5ng/mL TGFβ1 exposure for 48 hr. RNA was collected and PMEPA1 
mRNA levels were measured using real-time PCR and normalised to β-Tubulin. NS 
siRNA=non-specific siRNA, Values are Means ± SEM, n=3 for siRNA 1, *P<0.05  
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6.3.2 Effects of PMEPA1 silencing on E-Cadherin, Fibronectin 
The effects of loss of function of PMEPA1 were then studied in HK-2 cells exposed 
to TGFβ. HK-2 cells were transfected with PMEPA1 siRNA or non-specific siRNA 
and then exposed to control +/- TGFβ1 for 48hr. mRNA was collected and PMEPA1, 
E-Cadherin and fibronectin expression were measured by real-time PCR. PMEPA1 
siRNA efficiently silenced PMEPA1 expression by at least 65% (65% in the absence 
of TGFβ1, 70% in the presence of TGFβ1 (Figure 6.3A).  
However, silencing PMEPA1 did not yield a statistically significant difference in the 
in the expression of E-Cadherin in the presence or absence of TGFβ1, though a trend 
for reduction was observed when compared to non-specific siRNA group (Figure 
6.3B). The expression of the extracellular matrix protein fibronectin, was elevated 
when PMEPA1 was silenced in the absence of TGFβ1 whilst not altered in the 
presence of TGFβ1 compared to non-specific siRNA group (Figure 6.3C). This 
observation could be possibly due to the complete phosphorylation of SMAD proteins 
(SMAD2/3) by TGFβ1 signalling and thus maximum fibronectin expression. In the 
absence of TGFβ1, silencing of PMEPA1 was able to increase the phosphorylation of 
SMAD proteins which in turn activates fibronectin mRNA production.  
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Figure 6.3 Effects of PMEPA1 gene silencing.   
HK-2 cells were transfected with 100nM PMEPA1 siRNA followed by either control 
medium or 0.5ng/mL TGFβ1  for 48 hr. RNA was collected and  PMEPA1, E-
cadherin and fibronectin mRNA level were measured using real-time PCR and 
normalised to β-Tubulin. PMEPA1 silencing was expected to further reduce the 
expression of E-Cadherin from that observed with TGFβ1. Although a trend for 
reduction was observed, results did not reach statistical significance. Fibronectin 
mRNA appeared to be increased by PMEPA1 silencing in the absence of TGFβ. 
However, the result is not statistically significant. Values are Means ± SEM, n=3, 
*P<0.05, **P<0.01, ***P<0.001 
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6.3.3 Effects of PMEPA1 over-expression on HK-2 cells  
The effects of overexpression of PMEPA1 in human proximal tubular cells were then 
determined. pCDNA3.1-PMEPA1 was transfected into HK-2 cells and cultured for 48 
hrs in the presence or absence of  0.5ng/ml TGFβ1. mRNA was collected and 
profibrogenic and EMT markers were examined.  
 
6.3.3.1 Over-expression of PMEPA1  
PMEPA1 mRNA expression was determined first to confirm successful transfection 
and positive over-expression of PMEPA1 gene in HK-2 cells. The PMEPA1 mRNA 
level that was increased by TGFβ1 (a 3.7 fold increase compared to control), was 
further elevated 7.9 fold by transfection of pCDNA3.1-PMEPA1 plasmid when 
compared to empty vector (Figure 6.4).  
P M E P A 1
C
O
N
T
R
O
L
 
T
G
F

 
V
.C
O
N
T
R
O
L
 +
 T
G
F

E
V
 +
 T
G
F

P
M
E
P
A
1
 +
 T
G
F

0
2 0
4 0
6 0
8 0
R
e
la
ti
v
e
 E
x
p
r
e
s
s
io
n
/R
P
L
1
1
***
***
 
Figure 6.4 Confirmation of PMEPA1 over-expression in HK-2 cells of. pCDNA3.1 
was transfected into HK-2 cells which were then exposed to 0.5ng/mL TGFβ1 for 48 
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hr. RNA was collected and the PMEPA1 expression level was measured using real-
time PCR. V.Control = vehicle control, EV= empty vector. Values are Means ± SEM, 
n=3. ***P<0.001 
 
6.3.3.2 The effects of PMEPA1 over-expression on extracellular matrix protein 
expression in HK-2 cells  
Extracellular matrix proteins such as collagens and fibronectin were examined. 
Unexpectedly, PMEPA1 over-expression did not alter the expression of COL1A1 and 
fibronectin (Figure 6.5A,B)  that was increased in the presence of TGFβ1.  
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Figure 6.5 Effects of PMEPA1 over-expression on extracellular matrix proteins in 
HK-2 cells. pCDNA3.1-PMEPA1 was transfected into HK-2 cells before treatment 
with 0.5ng/mL TGFβ1 for 48 hr. RNA was collected and expression levels of genes of 
interest were measured using real-time PCR. V. Control = vehicle control, EV= 
empty vector. Values are Means ± SEM, n=3. ***P<0.001 
 
6.3.3.3 Impact of PMEPA1 over-expression on other genes of interest in HK-2 
cells 
Other genes of interest including EMT makers such as ZEB proteins, matrix 
metalloproteinase and profibrogenic maker PAI-1 were also examined. Again MMP 
expression demonstrated limited regulation by the significantly increased level of 
PMEPA1, with the exception of MMP13, which was reduced 2 fold compared to 
empty vector (Figure 6.6 A, B, C, D). These results cannot be explained by the known 
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mechanism of PMEPA1, which is competition for the SMAD binding protein and 
thus disruption of the SMAD signalling pathway.  
PAI-1 is a potent inhibitor of the urokinase/tissue type plasminogen activator 
(uPA/tPA), which regulates the activity of matrix metalloproteinases (MMPs). Since 
MMPs are involved in the proteolytic degradation of matrix proteins such as collagen 
and fibronectin, a reduction in PAI-1 expression will up-regulate MMPs and thus 
down-regulate the level of fibronectin, which could be renoprotective (Ghosh and 
Vaughan, 2012; Nagase and Woessner, 1999; Visse and Nagase, 2003). However, 
PAI-1 expression was not changed with PMEPA1 over-expression (Figure 6.6E).  
To understand the effect of PMEPA1 on transcription factors ZEB1 and SIP1 which 
are heavily regulated by TGFβ1 and miR-200b, the expression level of ZEB1, and 
SIP1were also measured. Consistently, PMEPA1 over-expression did not change their 
expression levels in the presence of TGFβ1 (Figure 6.6F, G).  
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Figure 6.6 Effects of PMEPA1 over-expression on MMPS, ZEB proteins and PAI-1 in 
HK-2 cells. pCDNA3.1-PMEPA1 was transfected into HK-2 cells before exposure to 
0.5ng/mL TGFβ1 for 48 hr. RNA was collected and expression levels of genes of 
interest were measured using real-time PCR. V.Control = vehicle control, EV= empty 
vector. Values are Means ± SEM, n=3. ***P<0.001, **P<0.01, *P<0.05 
 
6.3.3.4 Effects of PMEPA1 over-expression on protein expression in HK-2 cells 
Western blotting was subsequently used to study the effects of PMEPA1 over-
expression on protein changes in HK-2 cells. PMEPA1 was expected to reduce the 
phosphorylation status of SMAD2 and SMAD3, which in turn modify the TGFβ1 
induced profibrogenic responses (Watanabe et al., 2010). However, the lack of change 
in the expression of mRNA of target genes suggested exogenous PMEPA1 over-
expression may only have restricted impact on the signalling pathways and 
downstream targets. 
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In order to minimise the variability between experiments and to reduce the impact of 
variable transfection in cells, a stable cell line that consistently over-expresses 
PMEPA1 was produced using lentiviral induced gene transfer from HK-2 cells.  Two 
HK-2 cell lines were constructed; one consistently over-expressing GFP, while the 
other one over-expressing both GFP and PMEPA1. The detailed methods used to 
construct these cell lines were outlined in the material and methods section of this 
chapter.  
The successfully transformed HK-2 cells were then exposed to 0.5ng/mL TGFβ1 to 
study the differential phosphorylation status of signalling molecules as well as the 
production of extracellular matrix protein. SMAD2 (Figure 6.7A) and SMAD3 
(Figure 6.7B) were activated by TGFβ1 as expected (5.9 fold and 2.1 fold 
respectively). However, over-expression of PMEPA1 did not substantially decrease 
the phosphorylation of these signalling molecules. On the contrary, exogenous 
PMEPA1 trended to further increase the phosphorylation of SMAD2 (Figure 6.7A) 
and SMAD3 (Figure 6.7B), though no statistical significance was reached. p38 and 
p42 phosphorylation were also measured. PMEPA1 over-expression increased p38 
phosphorylation by 65% compared to empty vector (Figure 6.7C), but p42 
phosphorylation remained unchanged (Figure 6.7D). These results were consistent 
with the mRNA findings suggesting insufficient blockade of SMAD protein 
phosphorylation induced by TGFβ1 in HK-2 cells.  
E-Cadherin (Figure 6.7E) and fibronectin (Figure 6.7F) expression levels were 
subsequently examined. PMEPA1 over-expression did not demonstrate any protective 
effects when cells were exposed to TGFβ1. These result further demonstrated that, in 
HK-2 cells, PMEPA1 over-expression alone could not effectively alleviate the 
profibrogenic effects induced by TGFβ1. 
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Figure 6.7 Effects of PMEPA1 over-expression on phosphorylation status of SMAD3, 
SMAD2, p38, p42 and production of E-Cadherin and fibronectin. HK-2 cells 
constantly over-expressing PMEPA1 were exposed to 0.5ng/mL TGFβ1 for 48 hr. 
Lysate was collected and western blotting was used to study the changes in 
phosphorylation status and production level. EV= empty vector. Values are Mean ± 
SEM, n=3. ***P<0.001,*P<0.05 
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6.4 Discussion 
PMEPA1 was first characterised in 2000 as a novel androgen regulated gene in 
LNCaP cells (Xu et al., 2000) and later it was found to be up-regulated in renal cell 
carcinoma and other solid tumours (Giannini et al., 2003; Rae et al., 2001). The 
positive regulation of PMEPA1 by TGFβ signalling was also established (Brunschwig 
et al., 2003). However it was not until 2010 when Watanabe et al. successfully 
demonstrated that PMEPA1 could sequester SMAD activity and thus attenuating 
TGFβ signalling (Watanabe et al., 2010), PMEPA1 became a popular target, 
anticipated to rectify TGFβ induced adverse effects. In this chapter, both PMEPA1 
knockdown and over-expression were examined in HK-2 cells that were treated with 
or without TGFβ1. This is the first time that the potential therapeutic effects of 
PMEPA1 were studied in the renal context with a focus on proximal tubular cells. 
TGFβ and its downstream signalling pathways had been long recognised as a main 
driving factor for the pathogenesis of progressive kidney fibrosis. Central to this, the 
R-SMAD proteins (SMAD2 and SMAD3) and their activation by phosphorylation 
play a key role in the transduction and amplification of the signalling process (Lan 
and Chung, 2012). Thus, targeting SMAD became popular as therapeutics to halt 
renal fibrosis, whilst avoiding the unwanted side effects of direct TGFβ targeting. We 
firstly knocked down the expression of PMEPA1 using siRNA mediated gene 
silencing to identify any exacerbation of renal fibrosis. PMEPA1 siRNA successfully 
silenced PMEPA1 mRNA expression in HK-2 cells, both in the absence and the 
presence of exogenous TGFβ1. As expected, fibronectin mRNA was significantly up-
regulated in PMEPA1 silenced HK-2 cells in the absence of TGFβ1 while E-Cadherin 
demonstrated a trend for reduction. Interestingly, the corresponding result was not 
observed when silenced cells were exposed to TGFβ1, possibly due to the complete 
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phosphorylation of SMAD2/3 by potent TGFβ1 activation. These result suggest a 
limited role for PMEPA1 in TGFβ/SMAD signalling in kidney proximal tubular cells.  
To study the potential protective effects of PMEPA1 gene over-expression on HK-2 
cells mRNA expression profile, transfection of PMEPA1 carrying plasmid was used 
and over-expression was confirmed with real-time PCR. PMEPA1 over-expression 
did not alter the expression of TGFβ signaling target molecules in HK-2 cells exposed 
to TGFβ1.  It is now well established that interruption of SMAD activity can abolish 
TGFβ signaling and thus the downstream target effects. The lack of change suggested 
a minimal interruption of SMAD signaling activated by exogenous TGFβ1 in 
PMEPA1 over-expressing HK-2 cells. This was confirmed by the western blot data. 
TGFβ1 activated SMAD2 and -3 phosphorylation were further increased when 
PMEPA1 was over-expressed. The lack of renoprotection when PMEPA1 expression 
was modified was unexpected This is thought to be due to several reasons. Firstly, this 
is the first study that has investigated the effects of PMEPA1 in renal proximal tubular 
cells. The studies that identified the SMAD signaling blockade used either prostate 
cancer cells or colon cancer cells. The difference between the cell types may account 
for the differential impact of PMEPA1 over-expression. The different expression 
profile of genes including cell surface receptors, signaling molecules and even cellular 
matrix proteins may also contribute to the results observed. Secondly, PMEPA1 
competes for the SMAD binding proteins with SMAD 2/3 and thus interrupts SMAD 
signaling. The possible differential expression of SMAD binding protein with lower 
levels in HK-2 cells may render PMEPA1 targeting non-ideal. Comparison between 
the SMAD binding protein levels could be compared with the cancer cells in the 
future.. Furthermore, other kidney cell lines including podocytes, mesangial cells and 
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endothelial cells could be investigated to study the potential protective effects of 
PMEPA1 in the kidney.  
Nonetheless, this study demonstrated that PMEPA1 over-expression does not 
effectively reverse TGFβ induced fibrosis in proximal tubular cells, despite the 
positive results shown in cancer cells. Furthermore, the creation of HK-2 cells 
consistently over-expressing PMEPA1 provides an excellent tool for future studies 
relevant to PMEPA1 in HK-2 cells.  
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7 Chapter 7 Future Studies and Clinical Applications 
7.1 Future Experiments 
 
In this thesis, several dsRNA delivery methods were exploited for their abilities to 
transfer genes of interest in in vivo and in vitro systems.  However, due to method 
development involved, two projects were not fully completed. A table was created to 
summarise the two methods tried.  
Method Mode of Delivery Genome Incorporation  Kidney Accumulation Mode of Action 
Lentivirus Mediated  Systemic Yes Medium to Low Biological 
Nanoparticle Mediated Systemic No Medium Physical 
 
Table 7.1 Table summarises the two in vivo delivery systems carried out during the 
study. 
 
In the rest of this chapter, the future work and their clinical applications will be 
discussed. 
7.2  Nanoparticle Mediated Gene Transfer 
In this thesis, we have successfully demonstrated in in vitro experiments that the 
novel nanoparticles, manufactured as part of this thesis, can effectively penetrate 
tubular cell membranes and concentrate in the cytoplasm.  The in vivo delivery of 
nanoparticles through intravenous injection showed clear uptake in organs such as 
liver, kidney and heart. However, in the initial gene transfer experiment, the potential 
steric hindrance that prevented the processing of miRNA by DICER may well be 
caused by nanoparticles themselves due to an unbreakable amide bond. A breakable 
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disulphide bridge that will cleave under the reduced cytoplasmic environment is 
proposed and will be carried out. Aptamers that will bind specifically to SGLT2 in the 
apical membrane of the proximal tubule once the nanoparticle is filtered are also 
being developed and will be subjected to testing once selected. A new type of 
selection method called CELL-SELEX that selects aptamer against a particular cell 
type rather than a single protein will also be utilised for aptamers that bind to 
proximal tubular cells at high affinity. Meanwhile the positively selected aptamers 
will be negatively selected against liver cells to reduce non-specific uptake by liver. In 
effect, this will result in an increased proportion of aptamer tagged nanoparticles that 
will be taken by the kidney proximal tubular cells. As part of this selection, the 
aptamer does not necessarily recognise a particular surface protein, but could be two 
or multiple proteins in close proximity- a pattern specific to the cell type. This 
selection also ensures that the aptamer selected will be against the extracellular 
portion of the surface receptors and avoids the candidates that bind only to the 
intracellular amino acid sequences that could happen if the traditional SELEX 
methodology is used. Once selected, the aptamer will be attached to the nanoparticles 
via the formation of amide bond using already established protocols.  However, this 
conjugation may be challenging due to the length of the aptamer as it is approximately 
80 bases (comparing to 23bps for dsRNA) and the intended tertiary structure could 
have a negative impact on the conjugation. Nevertheless, the final nanoparticles, 
stabilised, conjugated with miRNA and proximal tubular cells recognising aptamer 
will be delivered intravenously and over-expression of miRNA levels in different 
organs including kidneys will be examined to confirm positive transduction in mice. 
At the same time, toxicology testing will be performed and the number of copies of 
miRNA per nanoparticle e determined to achieve maximum delivery with minimal 
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impact on cellular health. The ability to cross the blood brain barrier will also be 
examined to prevent undesired nanoparticle accumulation and over-expression of 
miRNA in the brain. A full evaluation of adverse effects of systemic injection of 
nanoparticles will be obtained before initiation of any large animal trials.  
If optimised, this method provides a mean of silencing target gene(s) specifically in 
the kidney proximal tubular cells with high efficiency and low toxicity. However, the 
intravenous administration of these nanoparticles could be one of the potential issues 
in their use as therapeutic agents, particularly in outpatient settings. Chemical 
modification or shielding of miRNA may be applied to protect the conjugate so that 
they can be orally administered. Ultrasound and microbubble technologies can be 
used in conjunction with nanoparticles to enhance cellular uptake and achieve added 
specificity with localised sonoporation.   Different molecules including drugs can be 
attached to the nanoparticles and be delivered to the cytoplasm of the target cells. 
Thus the potential of these novel nanoparticles are broad.   
 
7.3 Lentiviral Mediated Gene Transfer 
Although the transduction of miR-200b using lentivirus in mice failed to show 
satisfactory efficiency in this PhD project, the lentivirus carrying empty plasmid 
successfully integrated the cargo genes into the genome of kidney cells at a detectable 
level. This could be due to the tertiary structure of delivered miR-200b gene 
preventing efficient integration. Future work to improve the efficiency of lentiviral 
transduction may include the optimisation of packaging system to produce more 
lentiviral particles, optimisatioin of miR-200b containing plasmid, alternative delivery 
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methods, such as localised injection to renal parenchyma rather than systemic delivery 
and an increased  number of injections with more lentiviral particles.  
One of the advantages of using lentiviral mediated gene transfer is that a stable 
insertion of transgene into the genome of the target cells is able to be carried out. 
Thus the expression of desired gene can be sustained for a long period of time. 
Meanwhile the disadvantage of this method is stable integration, because the insertion 
site is random. The transgene can be integrated within another functional gene which 
will be disrupted and rendered non-functional. It can also land in the promoter or 
enhancer sequences of other important genes, causing significant adverse effects to 
the normal cell metabolism. Despite these drawbacks, successful pre-clinical and 
clinical trials have demonstrated positive outcome of lentivirus based gene therapy. 
 
7.4 Ultrasound Microbubble Mediated Gene Transfer 
Ultrasound microbubble mediated gene transfers have been demonstrated to be a 
promising new gene delivery strategy. It has minimal invasiveness with relatively 
high gene transfer efficacy. These microbubbles have already been approved for use 
in clinical settings as contrast enhancers.  Furthermore, the first clinical trial using 
ultrasound microbubble mediated gemcitabine delivery in patients with inoperable 
pancreatic cancer showed reduced tumour size/growth rate when compared to control 
patients who were treated with the drug alone.  The utilisation of ultrasound 
microbubble is rapidly entering clinical trial phase and more studies are expected to 
be reported in the near future. 
Due to lack of availability of SonoVue in Australia, a sulphur hexafluoride based 
substitute was obtained from Bracco Imaging. Plasmid containing miR-200b will be 
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delivered to the kidneys of c57bl6 mice followed by UUO. Furthermore, ultrasound 
microbubble can be combined with nanoparticles and lentivirus to achieve higher 
gene transfer efficiency compared to using those methods alone. Once optimised, the 
same technique can be applied to gene/drug delivery to other organs by simply 
redirecting the ultrasound waves. Local administration of microbubble and gene/drug 
preparation may increase the transfer efficiency by several orders of magnitudes. Thus, 
ultrasound microbubble mediated gene transfer will be further investigated in the 
context of combating renal fibrosis. 
 
7.5 Overview 
All the gene delivery methods discussed have a sound scientific basis as well as future 
applicability in gene therapies. Each method has its pros and cons. The choice of  the 
delivery method depends on the target of the cell and the size of the cargo delivered. 
However, with rapidly expanding knowledge pertaining to the different methods, 
more sophisticated optimisation can be tailored to suit the purpose of individual 
applications. All these delivery systems discussed will be tested and optimised in the 
future as part of the future studies that arise from this PhD.  
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